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Ipratropium bromide is a short-acting, non-selective, muscarinic antagonist frequently 
prescribed for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and as 
an emergency adjunct therapy for acute asthma. Within the past decade, there has 
been an accumulating wealth of clinical evidence which indicates that anti-muscarinic 
drugs, such as ipratropium, are responsible for an increased risk of stroke or, an 
adverse cardiovascular outcome (including increasing the risk and severity of 
myocardial infarction (MI)). 
 MI remains the highest risk factor of death for COPD patients due to the systemic co-
morbidities associated with COPD, which includes ischaemic heart disease (IHD). 
Despite the knowledge that approximately 22% of COPD patients also suffer from 
underlying IHD, the cardiovascular safety of muscarinic antagonists, such as 
ipratropium, has not been tested in a non-clinical setting of IHD or MI. In order to 
address this, the current project was designed to investigate, for the first time, the 
effects of ipratropium on the myocardium in a non-clinical setting. 
It was identified that under normoxic conditions, ipratropium did not have a significant 
effect on cardiac myocyte viability or infarction, from 3 month Sprague Dawley rats. In 
addition to this, following simulated ischaemia, ipratropium also did not appear to 
exacerbate myocardial injury. However, when ipratropium was administered in the 
context of simulated ischaemia followed by reperfusion, there was a significant 
exacerbation in myocardial injury which was characterised by increases in infarction, 
apoptosis, necrosis and a loss of resilience of oxidative stress. 
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In order to characterise the mechanism by which ipratropium exerts the observed 
cardio-toxic effects, it was investigated whether acetylcholine (ACh) or cyclosporin A 
(CsA) were capable of attenuating the ipratropium induced cardiotoxicity. Both agents 
showed significant limitation of injury when co-administered with ipratropium 
indicating that ipratropium exerts its cardio-toxic effect through a mechanism which 
links muscarinic signalling to the mitochondrial permeability transition pore (mPTP). 
This supports previously published work where the protective signalling of ACh has 
been shown to promote the phosphorylation of pro-survival kinases, such as Akt and 
Erk1/2 and that this provides inhibition of the mPTP.  
Western blotting was employed to identify whether there was an involvement of the 
pro-survival kinases Akt and Erk1/2, as well as the stress induced kinase JNK. 
Ipratropium significantly increased levels of phospho-Akt and phospho-Erk1/2. 
However, JNK levels appeared to be insignificantly altered in comparison with the 
control groups. Both ACh and CsA were capable of limiting these increases. 
Further to this, an aged study was carried out, which showed that, within the aged 
myocardium, ipratropium is capable of eliciting further injury in comparison with the 3 
month age groups. The effect of ipratropium on tolerance of oxidative stress was not 
significant, but, also, ACh and CsA were shown as unable to protect. Significant levels 
of JNK were also observed in the aged animals in comparison with the 3 month groups. 
In combination, the results presented here demonstrate, for the first time, that 
ipratropium is capable of exacerbating ischaemia/reperfusion injury in in vitro models 
of myocardial ischaemia/reperfusion. In addition, ACh and CsA are capable of limiting 
this injury, implying a role for pro-survival kinases and the mPTP in ipratropium 
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induced myocardial injury. In the aged study, ipratropium still exacerbated injury, 
however, ACh and CsA appeared unable to protect, therefore promoting previous 
work that cellular signalling is altered in the senescent myocardium. In conclusion, 
further studies must be carried out in order to fully characterise the cardio-vascular 
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Chapter 1  Literature review 
1.0  Introduction 
 
The clinical manifestation of ischaemia/reperfusion is more commonly known as acute 
myocardial infarction (MI). Within the UK, approximately 80,000 individuals suffer 
from MI annually, of which many are predisposed to the condition due to underlying, 
diagnosed or un-diagnosed, ischaemic heart disease (IHD) (Dorsch et al. 2008). Chronic 
obstructive pulmonary disease (COPD) represents a significant, and increasing cause of 
morbidity and mortality across the globe, accounting for the fourth highest cause of 
deaths, globally, every year (Singh, Loke and Furberg 2008). In addition to this, the 
pathology of COPD is associated with approximately a 52% increased risk in mortality 
due to cardiovascular events (Singh et al. 2011), with many COPD patients also 
suffering from underlying IHD. It is estimated that around 22% of COPD patients will 
die from complications following a myocardial ischaemic event and, in particular, from 
MI (Lofdahl et al. 2007). 
In 2008, a meta-analysis of COPD patients was released by Singh et al. which indicated 
that the administration of anti-cholinergic (muscarinic acetylcholine receptor 
antagonist) drugs to COPD patients increased the risk and severity of a stroke or 
cardiovascular event (Singh, Loke and Furberg 2008). Anti-cholinergic compounds are 
the most commonly prescribed treatment for COPD, due to their ability to antagonise 
the M3 muscarinic receptors within the respiratory system, thereby alleviating 
bronchial spasm, symptomatic of COPD exacerbations, facilitating bronchodilation, due 
to their bronchodilatory effect (the specific mechanism of action is discussed in section 
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1.9.4). However, despite the known co-morbidities between COPD and IHD, there have 
been no pre-clinical investigations to assess the effects of anti-cholinergic compounds, 
such as ipratropium bromide (a non-selective muscarinic receptor antagonist), in the 
setting of IHD or MI.  
 
1.1  Chronic Obstructive Pulmonary Disease (COPD) 
 
COPD, as defined by the Global initiative for Chronic Obstructive Lung Disease (GOLD), 
is a lung pathology associated with airflow obstruction that is not fully reversible (Singh 
et al. 2008). According to the World Health Organisation, COPD affects approximately 
64 million people and constitutes the most common chronic respiratory disease 
globally (Berndt, Leme and Shapiro 2012). By 2020, it is estimated that COPD will be 
responsible for the 3rd highest number of deaths due to disease, annually, throughout 
the world (Mannino and Kiriz 2006). COPD is an umbrella term which includes 
emphysema and chronic bronchitis and accounts for around 5% of all deaths within the 
UK annually (Feary et al. 2010). The primary diagnostic criterion is a spirometry result 
showing an irreversible, decreased, ratio of forced expiratory volume in one second to 
forced vital capacity (FEV1/FVC ratio) (Berndt, Leme and Shapiro 2012). The major 
pathophysiology of COPD is chronic inflammation of the respiratory system, including 
the bronchi, lung tissue and pulmonary vasculature (Asano et al. 2010). The primary 
causes of COPD are due to environmental irritants, which may be occupational but the 
major cause is tobacco smoke (Baur, Bakehe and Vellguth 2012). 
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Despite this, the involvement of genetic factors also plays a fundamental role in 
determining COPD development (Almansa et al. 2012). As with many complex disease 
states the pathogenic mechanisms of COPD, due to genetic predispositions, are 
challenging to unravel. This is, partially, due to the associated systemic pathologies 
which accompany COPD as well as the heterogeneous nature of the disease 
(Nakamura 2011). For example, the irreversible airflow obstruction necessary for a 
diagnosis of COPD may result from the loss of elastic recoil of the alveoli, symptomatic 
of emphysema, or due to obstruction throughout the bronchi and bronchioles 
(bronchitis) (Almansa et al. 2012). Alternatively, COPD may be a consequence of both 
pathologies (Berndt, Leme and Shapiro 2012). Despite both disorders occurring as a 
consequence of cigarette smoking they are not actually mechanistically related, 
therefore the elucidation of genetic determinants for either pathology is not 
necessarily sufficient to determine the concurrence of both in COPD patients (Berndt, 
Leme and Shapiro 2012). 
Despite these difficulties, however, COPD development has been strongly linked to a 
genetic disorder known as alpha-1 antitrypsin (AAT) deficiency (Foreman, Campos and 
Celedon 2012). AAT is encoded by the SERPINA1 gene and primarily synthesised in the 
liver (Thun et al. 2013). The primary role of ATT is as an endogenous inhibitor of 
neutrophil elastase (a serine protease secreted by neutrophils and macrophages 
which, during inflammatory immune responses, destroy both bacteria and host tissue) 
(Stoller and Aboussouan 2012). 
In the context of COPD, AAT deficiency was first identified in 1964 where two patients 
with severe emphysema, which progressed to loss of lung compliancy due to the 
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subsequent development of chronic bronchitis, were reported (Eriksson 1964). The 
loss of AAT exacerbates COPD development (even in patients who have never smoked) 
by mimicking the features of smoking-related COPD via production of alveolar lesions, 
characteristic of emphysema (Stockley 1999). Interestingly, in COPD patients without 
AAT deficiency, disease development has also been linked to an imbalance between 
anti-protease activity and increased transcriptional activity of neutrophil protease 
genes (Stockley 1999, Almansa et al. 2012). This indicates mechanistic similarity of 
COPD development despite whether the initial impetus is due to environmental or 
genetic factors. 
Irrespective of the cause, COPD causes partially reversible airflow obstruction, which is 
characterised by shortness of breath, coughing and wheezing. The primary cellular 
response is an inflammatory immune response comprising of neutrophils, CD8+ 
cytotoxic T-lymphocytes and macrophages (Almansa et al. 2012). Despite the 
anatomical differences of bronchitis and emphysema, both pathologies predominantly 
result from a destructive, neutrophil driven, immune response (Barnes and Celli 2009). 
Following inflammatory stimuli, such as cigarette smoke and environmental pollutants, 
neutrophils are recruited to the lungs, primarily via the actions of alveolar 
macrophages (Stockley 1999). This permits the release of pro-inflammatory cytokines, 
for example Il-1 and TNF-α, leading to a downstream immunologic inflammatory 
signalling cascade and hyper-secretion of mucus (Barnes and Celli 2009). The excess 
mucus secretion exacerbates the inflammatory response and promotes bronchitis due 





Figure 1.1: Schematic to show the inflammatory immune cells and mechanisms involved in 
COPD development, including the mucus hyper-secretion symptomatic of chronic bronchitis 
and alveolar wall destruction as is typical of emphysema (adapted from Barnes and Celli 2009). 
 
In addition to airflow obstruction, there is increasing evidence that COPD is also 
responsible for wider systemic pathologies, including diabetes mellitus, stroke and 
cardiovascular disease (Macnee, Maclay and McAllister 2008). This indicates that the 
morbidity and mortality rate from death associated with COPD may be much higher 
than death directly due to COPD. In particular, IHD is a well known co-morbidity 
associated with COPD (Huiart, Ernst and Suissa 2005, Maclay, McAllister and Macnee 
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can be 
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2007, Macnee, Maclay and McAllister 2008). Underlying IHD also represents the 
highest risk factor for death by myocardial infarction (MI) in COPD sufferers (Zielinski 
et al. 1997). It is estimated that approximately 22% of patients with COPD suffer from 
underlying IHD (Lofdahl et al. 2007). Currently, the association between COPD and IHD 
is attributed to underlying systemic inflammation associated with both pathologies 
(Barnes and Celli 2009). However, despite the recent association with anti-cholinergic 
treatments and CVD, patients with COPD and underlying IHD have not been tested in 
pre-clinical trials for bronchodilator drugs, including anti-cholinergics such as 
ipratropium. 
As presented in table 1.1, whether anti-cholinergic treatment is associated with an 
increase in adverse cardiovascular outcomes remains as a matter of some contention. 
There is approximately an equal split between studies which show a positive 
association versus those which show a negative association of anti-cholinergics with 
regards to adverse cardiovascular outcomes (Hilleman et al. 2009). The potential 
difference in conclusions from these studies could be explained by a difference in the 
end points which were investigated. Also, for some studies, underlying heart 
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1.2  Ischaemic heart disease (IHD) 
 
Globally there are approximately 16.7 million deaths due to cardiovascular disease 
(CVD) every year, of which around 7.2 million deaths are attributed to ischaemic heart 
disease (IHD) (Mendis et al. 2004). With respect to COPD patients, IHD is a common co-
morbidity, with approximately 22% of COPD patients also have a diagnosis of IHD, 
however, in reality, it is likely that many COPD patients, with underlying IHD, have not 
received a diagnosis for both pathologies (Barnes and Celli 2009). 
IHD is characterised by myocardial ischaemia, whereby blood supply to myocardial 
tissue is reduced. This is most commonly due to the build up of atherosclerotic plaques 
in the coronary arteries (Ross 1999). This leads to occlusion of the coronary arteries, 
although even a 50% reduction in the diameter of the coronary arteries is sufficient for 
an ischaemic event to occur (Hoffman et al. 2004). Within the UK, IHD is responsible 
for approximately 82,000 deaths per year and affects approximately one fifth and one 
eighth of men and women, respectively. As such, IHD constitutes both the leading 
cause of death globally and within the UK (Brayton et al. 2012). In addition, IHD also 
has been established as the leading cause of global burden as well as substantially 
reducing quality of life, as well as life expectation, for patients (Allender et al. 2007).  
The incidence and risk of IHD is primarily associated with increased age accompanied 
by hypercholesterolemia and hypertension (Brayton et al. 2012). Especially within 
Western society, smoking, inactivity, diabetes and diet have been shown to majorly 
influence the development of atherosclerosis and subsequent IHD (Baur, Bakehe and 
Vellguth 2012).  
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From a clinical perspective, IHD frequently manifests in a multitude of symptoms such 
as arrhythmias, angina, heart failure and myocardial infarction (MI), although 
frequently patients do not present with symptoms until after they have experienced a 
severe ischaemic insult or MI (Misra et al. 2009). MI remains the most serious and 
often fatal consequence of IHD (Lofdahl et al. 2007), with myocardial infarct size as a 
determining factor for long term prognosis (Ferreira 2010). The primary therapeutic 
option is myocardial revascularisation (a method which restores blood flow to the 
myocardium) in order to salvage myocardial tissue, thereby limiting infarct size and 
optimise clinical outcome (Lee et al. 2008). Currently, thrombolytic therapy, for 
example streptokinase, first administered in 1974 by Braunwald et al. (Ferreira 2010), 
and primary percutaneous coronary artery angioplasty are the most commonly used 
interventions (Hausenloy, Tsang and Yellon 2005). 
 
1.3  Pathogenesis of myocardial infarction 
 
Myocardial infarction develops as a clinical manifestation of IHD and frequently 
presents as myocardial ischaemia, whereby blood, and thus oxygen, flow is limited to 
areas of the myocardium with resultant cardiac myocyte loss due to cessation of 
oxidative phosphorylation (Hausenloy and Yellon 2013). Paradoxically, upon 
restoration of blood flow to the ischaemic tissue (reperfusion), further, irreversible 
damage is caused (Hausenloy et al. 2005). The exact mechanism by which 
ischaemia/reperfusion (I/R) injury occurs as a consequence of diverse cellular signalling 
cascades remains elusive, however it is known that myocyte death occurs via both 
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apoptosis and necrosis (Kung, Konstantinidis and Kitsis 2011), with a fundamental role 
for the mitochondrial permeability transition pore (mPTP). Figure 1.2 represents a 
simple overview of the major pathways which lead to myocyte loss following I/R 
(Brookes and Darley-Usmar 2004).  
In the neonatal heart, cardiac myocytes become terminally differentiated, and 
therefore lose the ability to proliferate (Kuwahara et al. 2000). It is therefore essential 
that functional myocytes are salvaged following I/R in order to ensure the myocardium 
can adequately function following this injury (Hausenloy and Yellon 2004). 
Figure 1.2: Schematic to represent the basic mechanisms leading to myocyte loss following I/R. 
I/R induces increases in Ca2+ and reactive oxygen species (ROS), which therefore permits 
opening of the mPTP. Primary necrosis occurs as a result of depleted ATP levels. The release of 
mitochondrial pro-apoptotic proteins into the cytosol also initiates apoptotic mechanisms. 
However, these pathways are interlinked as, if ATP levels are too low, apoptosis is unable to 
occur, and thus myocyte fate will be determined by necrosis, rather than apoptosis (Adapted 
from (Brookes and Darley-Usmar 2004)). 
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1.3.1   Ischaemia 
 
Despite having been one of the most extensively studied topics in cardiovascular 
research, the exact definition of myocardial ischaemia remains as a matter of some 
debate (Hearse 1994). Rudolf Virchow first proposed the term “ischaemia” in 1858, 
which translates as: “... I propose the new term ischaemia in order to describe the 
hindrance of blood supply and the increase in the resistance of influx” (Letterer 1958). 
Throughout this work, the definition is determined as the conditions by which the 
oxygen and nutrient supply to the myocardium are insufficient to meet myocardial 
demand (Asano et al. 2010). Physiologically, myocardial ischaemia occurs as a 
consequence of a reduction, or entire cessation, of blood flow to the heart. This causes 
a reduction in oxidative phosphorylation (Figure 1.3) and, consequently, reduced ATP 
formation (Murphy and Steenbergen 2008). Cardiac myocytes, the contractile cells 
within the myocardium, rely heavily on adequate ATP supply, produced via oxidative 
phosphorylation, primarily in the electron transport chain, within the mitochondria 
(Hausenloy and Yellon 2004). As a result, following ischaemia, myocytes resort to 
anaerobic respiration (the conversion of glucose to lactic acid) to meet the energy 
demands of the heart. However, this process leads to an accumulation of lactic acid 
within the ischaemic region of the heart (Solaini and Harris 2005).  
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Figure 1.3: Schematic to represent the electron transport chain (ETC) which occurs on the 
mitochondrial membrane. Per each ETC cycle, ten NADH+, a consequence of glycolysis, the 
conversion of pyruvate to acetyl-coenzyme A and from the citric acid cycle, enter the ETC. Two 
molecules of FADH2 are also required and originate from the citric acid cycle. The ETC is 
comprised of five protein complexes, the first two of which systematically oxidise NADH 
(complex I) and FADH2 (complex II), thereby providing electrons for the chain. At complex IV, 
the electrons are transferred to oxygen molecules, therefore reducing the oxygen to H2O. 
Concomitantly, protons are pumped out of the mitochondrial intermembrane space and into 
the cytosol, therefore causing a net negative charge in the mitochondrial matrix and net 
positive charge in the intermembrane space. It is this electrochemical gradient which then 
permits the synthesis of ATP in complex V (adapted from Chaban, Boekema and Dudkina 
2014).  
 
The severity and length of ischaemia are primarily the factors on which myocyte loss 
are dependent (DeBoer et al. 1983). For example, an ischaemic event of less than 20 
minutes results in reversible myocardial injury whereby, despite initial depression of 
contractile function, the myocardium may eventually completely recover (Davis et al. 
2012). Following an ischaemic attack of 15 minutes, ATP levels are depleted by 
approximately 65%. This is further increased to a reduction of 90% if ischaemia occurs 
for 40 minutes (Reimer and Jennings 1986). The ability of the myocardium to maintain 
ion homeostasis and generate sufficient force is therefore lost, leading to myocyte 
necrosis, characterised by acidosis, organelle disorganisation and swelling of the 
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can be 
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myocytes prior to subsequent cellular death (Maxwell and Lip 1997). Necrotic cardiac 
myocyte death due to ischaemia is referred to as myocardial infarction (Braunwald and 
Kloner 1985). 
The inability of cardiac myocytes to meet ATP demand also causes cessation of 
function of ATP dependent Ca2+ and Na+/K+ ion pumps and ion exchangers and 
transporters (Schafer et al. 2001). This promotes K+ accumulation in the extracellular 
matrix and an inability for cardiac myocytes to maintain healthy, physiological 
intracellular concentrations of Na+ and Ca2+ (Wang et al. 2012). The majority of Ca2+ 
removal from the intracellular space is via the Na+/Ca2+ exchanger (NCX), with a very 
minor contribution from SERCA (Sarcoplasmic reticulum/Endoplasmic Reticulum Ca2+ 
ATPase) (Murphy and Steenbergen 2008). The NCX is an antiporter membrane protein 
responsible for the removal of intracellular Ca2+ (Lee, Dhalla and Hryshko 2005). For 
over twenty-five years, it has been indicated that a rise in cytosolic Ca2+ precedes 
irreversible myocardial injury following an ischaemic insult (Murphy and Steenbergen 
2008). Under conditions of ischaemia, the NCX essentially functions in reverse, such 
that it serves to increase intracellular Ca2+ as opposed to maintaining Ca2+ homeostasis 
(Inserte et al. 2009). Although the increase in Ca2+ has been shown to precede 
irreversible myocyte injury rather than generate injury alone, the ability to attenuate 
Ca2+ homeostatic de-regulation is sufficient to delay the onset of irreversible 
myocardial injury (Murphy and Steenbergen 2008).  
During ischaemia, ATP is degraded to adenosine monophosphate (AMP), which, 
consequently is further broken down thereby leading to the formation of free radicals 
(Glantzounis et al. 2005) (Figure 1.4). 
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Figure 1.4: Schematic representation of ROS formation following I/R. The mechanism involved 
shows that degradation of ATP to AMP subsequently leads to the formation of superoxide free 
radicals (O2
.-) which occurs during reperfusion/re-oxygenation. Xanthine oxidase produces uric 
acid from hypoxanthine and xanthine. This process is further involved in the formation of ROS 
via production of hydroxyl radicals (adapted from Glantzounis et al. 2005). 
 
A plethora of work has been conducted to ascertain the role of reactive oxygen species 
(ROS) and their role in infarct development following myocardial ischaemia (Bolli et al. 
1989) (described more fully in section 1.3.5). It has since been elucidated that, 
although following ischaemia, myocardial oxygen levels within the ischaemic zone do 
not immediately fall to zero and so, initially at least, oxygen is available to generate 
ROS (Davis et al. 2012). The quantities of ROS produced during ischaemia alone, are 
not sufficient to cause injury but contribute to the pathological outcome of I/R injury 
(Murphy and Steenbergen 2008). 
 
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can be 
viewed in the Lanchester Library Coventry University.
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1.3.2  Reperfusion injury 
 
In order to prevent further irreversible, and potentially fatal, myocardial injury, it is 
necessary to reperfuse the myocardium following ischaemia. This is in order to salvage 
reversibly damaged myocytes, which is critical in order to maintain the integrity of as 
much of the myocardium as possible. This was first proposed by Herrick in 1912: “The 
hope for the damaged myocardium lies in the direction of securing a supply of blood 
through friendly neighbouring vessels so as to restore as far as possible its functional 
integrity” (Muller 1977). However, it was not until 1971 that Maroko et al proposed 
experimental studies designed to investigate the factors associated with infarct size 
(Maroko et al. 1972). Conversely, it has since been demonstrated that reperfusion 
itself is capable of eliciting further, irreversible, damage to the myocardium (Yellon and 
Hausenloy 2007b). The potentially detrimental aspect of myocardial reperfusion injury, 
termed “lethal reperfusion injury,” has been defined as: as “myocardial injury caused 
by the restoration of coronary blood flow after an ischaemic episode (Yellon and 
Hausenloy 2007b). Therefore, the process of reperfusion causes further damage to the 
heart by inducing contractile dysfunction, microvascular impairment, lethal 
arrhythmias and also further myocyte death (Xiong et al. 2009, Hearse 2001). There 
have since been considerable efforts in the field to elucidate both the cellular 
mechanisms by which reperfusion injury is caused as well as measures with the 
potential to limit damage after a myocardial ischaemic insult.   
The key determinant for the initiation of intrinsic apoptosis during reperfusion is 
mitochondrial outer membrane permeabilisation (MOMP), thereby initiating a 
caspase-dependent apoptotic cascade (Dewson and Kluck 2009). Increases of 
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intracellular Ca2+ and oxidative stress lead to rapid ATP depletion, thereby causing 
rupture of the outer mitochondrial membrane (Halestrap 2010). This facilitates the 
influx of toxic mitochondrial proteins into the cytosol, thus initiating apoptosis 
(Halestrap 2009, Halestrap and Pasdois 2009, Hausenloy et al. 2002). Myocyte death 
by necrosis also occurs (Yellon and Hausenloy 2007), via the resultant collapse of 
mitochondrial function after disturbance of mitochondrial membrane potential due to 
sustained increases in Ca2+ and the absence of adenine nucleotides (Crompton 1999). 
Ultimately, this leads to opening of the mitochondrial permeability transition pore 
(mPTP, described in further detail in section 1.7), which promotes primary necrosis due 
to depletion of ATP as well as apoptosis following outer mitochondrial membrane 
rupture (Miura and Tanno 2011).  
The re-introduction of oxygen to the ischaemic myocardium has been consistently 
shown to cause a rapid increase in ROS (Murphy and Steenbergen 2008) (Figure 1.4). 
During reperfusion, in particular, this increase is associated with superoxide formation 
which then elicits myocyte damage via extensive oxidative stress (Pasdois et al. 2011). 
This is evidenced by the ability of antioxidants to reduce ROS levels and myocardial 
stunning (as described in section 1.3.3) (Buja and Weerasinghe 2010), however, 
whether the reduction in ROS can promote salvage of tissue, thereby reducing infarct 
size, remains as a matter of some controversy (Murphy and Steenbergen 2008). This is 
primarily due to the difficulties in translating experimental, animal models into clinical 
practice in humans as the contribution of ambient oxygen to ROS burst (as observed 
experimentally) is likely to be different from the oxygen levels inside the heart 
following ischaemia (Cascio et al 1992). As such, the pathological significance of ROS 
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and, hence potential benefits of reducing levels of ROS, in humans is still uncertain 
(Murphy and Steenbergen 2008). However, ROS scavengers have been shown as 
effective in the reduction of infarct size (Hayashida et al. 2008). 
 
1.3.3  Stunned myocardium and hibernating myocardium 
 
In the 1980s, two additional pathophysiological states due to I/R emerged, showing 
discrepancy between post-ischaemic myocardial contractile dysfunction and the other 
symptoms of ischaemia (Ferreira 2010). These were termed the stunned myocardium 
and hibernating myocardium, respectively. The principle is that, following reperfusion, 
there are regions of the myocardium which consist of viable myocytes, but with 
impaired function (Braunwald and Kloner 1985, Redwood, Ferrari and Marber 1998). 
First suggested by Heyndrickx et al in 1975, myocardial stunning is thought to occur 
due to the generation of oxygen free radicals or Ca2+ overload, both of which cause 
disruption of contractile proteins, thereby limiting contractility of the heart (Bolli et al. 
1989, Ferreira 2010). 
However, the hibernating myocardium is different from this as it relates to persistent 
left ventricular dysfunction (Bolli 1990). This was first described by Diamond, in 1978, 
“…ischaemic non-infarcted myocardium can exist in a state of functional hibernation” 
(Rahimtoola 1985). Both stunned and hibernating myocardium are characterised by 
dysfunctional, but still viable, cardiac myocytes, in contrast to infarction where 
myocytes are no longer viable (Bolli 1990). However, in a clinical context, contractile 
43 
 
dysfunction, as shown by ECG changes, may be sufficient injury to cause death, even in 
the absence of extensive infarction, or myocyte loss (Buja and Weerasinghe 2010). 
 
1.3.4  No-reflow phenomenon 
 
The no-reflow phenomenon occurs when blood flow to the ischaemic tissue is still 
impeded to regions of the myocardium despite relief of the cause of ischaemia 
(Rezkalla and Kloner 2002). Reperfusion is frequently initiated via the dissolution of an 
atherosclerotic plaque or the removal of the coronary artery occlusion (Kloner 2011). 
However, microvascular obstruction sometimes means that there is an inability for 
blood supply to be returned to areas of the ischaemic myocardium (Braunwald and 
Kloner 1985). It has been observed that endothelial swelling results in membrane 
bound blebs within the lumen which can plug the lumen, thereby hindering 
reperfusion (Kloner 2011). 
 
1.3.5   Oxygen derived free radicals 
 
Free radicals or reactive oxygen species (ROS) are a consequence of healthy, 
physiological processes, such as oxidative phosphorylation, and in the context of a 
healthy cell are usually generated by the mitochondria (Munday 2001). This free 
radical production is balanced by endogenous cellular anti-oxidant mechanisms, such 
as ROS catalysis by free radical scavengers, for example superoxide dismutase (Tsutsui, 
Kinugawa and Matsushima 2011). This is necessary, as a property of free radicals is the 
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presence of an unpaired electron, therefore enabling oxidative damage of other 
cellular components (Gustafsson and Gottlieb 2008). In particular, alterations and 
peroxidation of the proteins and phospholipids which comprise cell membranes, due 
to increases in free radical formation, leads to loss of membrane integrity and 
subsequent cell death (Dominguez-Rodriguez, Abreu-Gonzalez and Reiter 2014).  
However, in the context of the ischaemic myocardium, anti-oxidant enzymes are 
insufficient to limit free radical induced injury as reperfusion with oxygenated blood 
causes an influx of oxygen derived free radicals to the ischaemic myocardium (Seddon, 
Shah and Casadei 2007). Upon introduction to the ischaemic myocardium, oxygen is 
rapidly reduced which leads to high levels of free radicals in the ischaemic myocardium 
within the first few minutes of reperfusion (Figure 1.4, Zweier 1988). The concept of 
oxygen derived free radicals as contributing to reperfusion injury was originally 
proposed by Hearse in 1973 (Hearse, Humphrey and Chain 1973) and, subsequently in 
1987, free radical levels were shown to peak during reperfusion (Zweier, Flaherty and 
Weisfeldt 1987). Further to this, the activation and accumulation of neutrophils within 
the reperfused myocardium further stimulates free radical formation following I/R 
(Glantzounis et al. 2005, Jordan, Zhao and Vinten-Johansen 1999). In conjunction with 
this, ROS levels following muscarinic agonism by CDP-choline have been shown to be 
significantly reduced, with an associated reduction in apoptosis, following oxidative 
stress in cardiac myocytes (Gonzáles-Pacheco et al. 2014). 
The production of ROS has also been shown to reduce endogenous levels of nitric 
oxide (Brown and Borutaite 2007). This may exacerbate endothelial injury and 
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influence the severity of microvascular dysfunction, contributing to contractile 
dysfunction as observed during myocardial stunning (Chen and Zweier 2014).  
 
1.3.6   Polymorphonuclear leukocytes (PMNs) 
 
Following I/R, an inflammatory immune response is elicited whereby chemotaxis 
recruits polymorphonuclear leukocytes (PMNs) to the ischaemic myocardium (Mehta, 
Nichols and Mehta 1988, Zhao et al. 2003). PMNs were initially associated with the 
inflammatory response observed following myocardial iscahemia/reperfusion injury in 
1939 (Kenneth Mallory, White and Salcedo-Salgar 1939). It was presumed that the 
influx of PMNs to the ischaemic region of the myocardium represented an endogenous 
healing mechanism, activated as a pathophysiological response (Stangl et al. 2002). 
This notion was clinically demonstrated in the 1970s where the administration of the 
anti-inflammatory prednisone, in patients with acute myocardial infarction, resulted in 
ventricular aneurysm and rupture (Roberts, Kelliher and Lathers 1976). However, 
further to this, histological studies were conducted which showed a direct association 
between infarct development and the length of an ischaemic insult and the levels of 
PMN accumulation (Romson et al. 1983). This is primarily due to PMNs contributing as 
a major source of oxygen derived free radicals (Metha, Advani and Nadkarni 1988), 
therefore promoting oxidative stress and myocardial damage (Kaminski et al. 2002). 
 In addition to this, de-granulation of PMNs following immunogenic activation leads to 
release of potent enzymes which serve to hydrolyse and systematically breakdown the 
extracellular matrix. This has the consequence that myocardial tissue integrity cannot 
46 
 
be maintained with resultant myocyte death due to anoikis following loss of anchorage 
of myocytes from the extracellular matrix (Ikeda et al. 1998). 
Despite controversy in this field, the majority of accumulating evidence supports that 
PMN accumulation in the ischaemic myocardium promotes injury. Most recently, pre-
conditioning has been shown to reduce PMN accumulation, which is instrumental in 
reducing infarct size (Granfeldt et al. 2012). This was attributed to involvement of a 
reduction in superoxide (Granfeldt et al. 2012). Further to this, the inhibition of PMN 
adhesion and degranulation, as well as in the context of neutropaenia, has been shown 
to elicit a cardioprotective effect following I/R (Simpson et al. 1990). 
 
1.3.7   Alteration of Ca2+ homeostasis 
 
It was first described by Shen and Jennings in 1972 that myocardial reperfusion was 
accompanied by Ca2+ overload (Shen and Jennings 1972). Changes in intracellular Ca2+ 
homeostasis have since been shown to play an important role in the pathogenic 
outcome of reperfusion injury (Chen et al. 2006, Chen et al. 2011). Primarily, this 
appears to be due to increased entry of Ca2+ into the cytosol via specific calcium 
channels in the sarcoplasmic reticulum (Gao, Korthuis and Benoit 1996, Wier et al. 
1997). Further to this, activation of Ca2+ dependent proteases, such as calpain I and 
troponin I, result in myofibril proteolysis and the resultant activation of signalling 
pathways, leading to reperfusion injury, inevitably follow (Verma et al. 2002). 
Following I/R injury, there is an alteration in Ca2+ homeostasis which is observed as 
excessive levels of intracellular Ca2+ concentrations. This is primarily attributed to 
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dysfunction of the sarcoplasmic reticulum and NCX which, in the context of healthy 
cells, hold crucial roles in maintenance of Ca2+ regulation (Chen et al. 2006). The 
endoplasmic reticulum has been demonstrated as holding an integral role in mediating 
cellular Ca2+ levels in the context of cellular stresses such as oxidative stress as those 
associated with I/R (Flesch et al. 1996). Primarily these mechanisms are thought to 
involve the NCX (Motegi et al. 2007) (described in section 1.3.1). 
Historically, increases in cytosolic Ca2+ as a determinant for myocardial injury following 
I/R were considered unimportant (Cobbold and Bourne 1984, Kim, Jin and Lemasters 
2006). However, within the past two decades, the majority of studies have provided 
evidence that deregulation of Ca2+ homeostasis, thus leading to an increase in cytosolic 
Ca2+ levels, precedes irreversible myocardial injury as a consequence of I/R  (Imahashi 
et al. 2005, Koretsune and Marban 1989). 
The endoplasmic reticulum is important in the maintenance of Ca2+ mediated intrinsic 
apoptosis, through mechanisms which have originated from either an extra- or intra-
cellular context (Scorrano et al. 2003). This is partially due to the activation of BH-3 
only domain members of the Bcl-2 family of proteins, such as Bim and BAD (Morishima 
et al. 2004). Following this, upstream pro-apoptotic signalling is relayed to the 
endoplasmic reticulum, which produces pro-apoptotic stimuli via the mitochondria. 
The intracellular increases in Ca2+ promote opening of the mPTP due to associated 
mitochondrial Ca2+ overload, therefore leading to depolarisation and permeabilisation 
of the inner mitochondrial membrane and subsequently myocyte death via necrosis 
(due to outer mitochondrial membrane rupture) and apoptosis (due to release of pro-
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apoptotic factors into the cytosol) (Kim, Jin and Lemasters 2006, Miura and Tanno 
2011).  
Although necrotic and apoptotic pathways following I/R injury are fully described in 
section 1.4, there is also potential that endoplasmic reticulum mediated increases in 
Ca2+ lead to apoptosis via a caspase-12 dependent mechanism. This occurs as caspase-
12 is activated either through the intrinsic machinery of the endoplasmic reticulum, 
but also via calpain cleavage (as observed via increases in Ca2+).  Following the 
activation of pro-caspase-12, caspase-12 is then capable of initiating apoptosis via 
cleavage of caspase-9 through a mechanism which is independent from both 
mitochondrial apoptogen release (specifically APAF-1 and cytochrome c) and 
heptodimeric apoptosome formation (McIlwain, Berger and Mak 2013). 
 
1.3.8  Altered myocardial metabolism 
 
Despite reperfusion being a necessary process in order to permit recovery of the 
ischaemic myocardium, the alteration of normal metabolism following ischaemia may 
potently contribute to a delay in functional, myocardial recovery (Verma et al. 2002). 
In particular, the limitation of oxygen availability to the heart during ischaemia 
prevents oxidative phosphorylation and, as such, cardiac myocytes resort to anaerobic 
respiration in order to fulfil their high ATP demands (Weinberg et al. 2000). However, 
persistent lactate production, as a result of anaerobic metabolism, frequently still 
occurs following reperfusion due to an inability of the heart to immediately recover 
and revert back to aerobic respiration. This is evidenced by a 40% reduction in normal 
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mitochondrial pyruvate dehydrogenase activity following reperfusion, which may 
persist for up to 30 minutes.  
Clinically, the implication of prolonged lactate production under these conditions is an 
increase in contractile dysfunction of the ventricles, in particular left ventricular 
function (Davis et al. 2012), as well as represented by an increase in infarct size 
(Ferreira 2010). This was demonstrated experimentally in mice as tolerance to 
myocardial I/R injury has been associated with a decrease in lactate dehydrogenase. 
The observed decrease was associated with both a reduction in infarct size and 
improved contractile function following reperfusion (Xiang et al. 2011). Further to this, 
these associations have been linked with Rho kinase (ROCK) activity (Xiang et al. 2011). 
Rho is a member of a small sub-family of monomeric G-proteins and can be activated 
by various GPCRs, including muscarinic acetylcholine receptors (mAChRs) (Lanzafame, 
Christopoulos and Mitchelson 2003).  
In the context of the myocardium, acetylcholine has been shown to promote 
cardioprotective signalling, including following I/R injury, via activation of ROCK (De 
Sarno et al. 2005). It is therefore possible that muscarinic receptor activation by 
acetylcholine promotes the restoration of aerobic metabolism, which can decrease the 
injurious effects of anaerobic metabolism following the onset of reperfusion.  
 
1.3.9  Gap junctional remodelling 
 
Gap junctions are transmembrane conduits which allow direct intercellular 
communication between neighbour cells via linkage of their cytoplasmic 
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compartments (Minamino 2009). Gap junctions are primarily comprised of hexamers 
of connexin proteins which are, in general, preferentially and specifically expressed in 
various cell types and tissues, respectively (Bruce et al. 2008). Within the myocardium, 
gap junctions serve to assist in myocardial contraction by facilitating propagation of 
action potentials between cardiac myocytes (Ando et al. 2005, Yue et al. 2006). 
Connexin43 (Cx43) is the predominant gap junction protein in the heart, both by 
abundance and functional importance (Ando et al. 2005). However, there are also 
roles for connexin40 (Cx40) and connexin45 (Cx45) (Minamino 2009). In particular, 
Cx40 plays a major role in the atria by permitting myocyte-to-myocyte propagation of 
the action potential during atrial depolarisation (Benes et al. 2014). Genetic ablation or 
mutation of Cx40 proteins have shown to cause an inherited predisposition of atrial 
fibrillation (Chaldoupi et al. 2009). Cx45 has an indispensible function within the 
atrioventricular node and bundles of His (Frank et al. 2012). Cx40 and Cx43 are 
generally co-expressed and it is considered that the expression of Cx45 may insulate 
the conductive tissues from the contractile cells and fibres within the myocardium (Lo 
2000). Despite the full role of Cx45 remaining elusive, it has been observed that over 
expression of Cx45 serves to improve pacemaker function iv vitro, with a possible 
clinical application as a synthetic biological pacemaker in the future (Tong et al. 2010).  
Following I/R, loss and hypercontracture of cardiac myocytes through necrosis 
produces a pathophysiology, unique to the heart, known as contraction band necrosis 
(CBN), which, ultimately leads to sarcolemmal rupture (Shintani-Ishida, Unuma and 
Yoshida 2009). Evidence from studies shows that induction of hypercontracture via 
micro-injection of Na+ spreads to neighbouring myocytes via gap junctional proteins 
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(Ruiz-Meana et al. 1999). Further to this, the chemical uncoupling of gap junctions 
under conditions of I/R limits CBN as myocyte-to-myocyte gap junctional 
communication cannot occur (Garcia-Dorado et al. 1997), however this can result in 
contractile dysfunction and lethal arrhythmias (Garcia-Dorado, Rodriguez-Sinovas and 
Ruiz-Meana 2004). More recently, ischaemia and hypoxia have been shown to 
promote the intracellular translocation of Cx43 to the plasma membrane at 
intercalated discs, thereby enhancing myocyte-to-myocyte communication, associated 
with increases of CBN (Shintani-Ishida, Unuma and Yoshida 2009, Zeevi-Levin et al. 
2005). However, following ischaemia, total levels of Cx43 protein have been observed 
to decrease (Zhang et al. 2006).  
It has been well documented that the quantity of gap junctions within the heart can be 
regulated by acetylcholine (Murray, Nickel and Gay 2009). Following hypoxia, 
muscarinic acetylcholine activation is also capable of restoring suppressed Cx43 levels, 
therefore promoting gap junctional integrity, and inhibiting lethal arrhythmias (Yue et 
al. 2006, Zhang et al. 2006).  
Despite the evidence appearing paradoxical, acetylcholine is also capable of eliciting 
cardiac myocyte preservation following I/R due to its ability to activate pro-survival 
kinases (as described in section 1.5). In particular, the association of Cx43 with the M3 
mAChR subtype has been shown as being impaired following ischaemia (Yue et al. 
2006). However, the effect of reperfusion signalling pathways on gap junctional 




1.4  Cell death during ischaemia/reperfusion injury 
 
It was previously considered that myocyte death following both myocardial ischaemia 
and reperfusion was a uniform, necrotic, process. The necrotic pathology of cardiac 
myocytes was considered to involve cellular swelling, denaturation of intracellular 
proteins, membrane damage and subsequent membrane rupture (Buja and 
Weerasinghe 2010). In particular, cardiac myocyte loss by necrosis can propagate 
across the intercalated discs via the CBN phenomenon (Minamino 2009). However, 
within the past two decades, it has become apparent that following I/R injury 
myocytes are subjected, as with other nucleated cells, to apoptosis as well (Dewson 
and Kluck 2009, Kim and Kang 2010). In contrast to classical apoptosis mechanisms, 
which avoid inflammatory immune responses, following I/R, cardiac myocytes do not 
immediately fragment to apoptotic bodies for removal by phagocytes, but elicit 
exudative inflammation as cardiac myocytes release small quantities of chemo-
attractants upon initiation of apoptosis (Buja and Weerasinghe 2010). This indicates 
that the mechanism of apoptosis, in the myocardium, can further contribute to 
myocyte loss by necrosis as well. There is now a multitude of evidence which promotes 
that, following myocardial I/R, myocytes are permitted to die by apoptosis, necrosis 
(more specifically oncosis following ischaemia) and autophagy (Buja and Weerasinghe 
2010). All death processes which occur in the infarcted and reperfused myocardium 





1.4.1  Necrosis 
 
Necrosis is the mechanism by which the majority of cells within an organ will 
prematurely die following disease, injury or conditions of hypoxia/ischaemia (Wang et 
al. 2008) and has been described as a “destructive, irreversible death process” (Searle, 
Kerr and Bishop 1982). Morphologically, cells and organelles swell leading to 
mitochondrial dysfunction which is inevitably accompanied by the depletion of ATP. 
Subsequent rupture of the cell leads to intracellular components leaking into the 
extracellular matrix and, consequently, initiating an inflammatory immune response, 
thereby causing further damage to cells in the immediate periphery (Majno and Joris 
1995). It was previously considered that necrosis was entirely responsible for cardiac 
myocyte loss following I/R (Majno and Joris 1995). However, it has since been 
elucidated that apoptosis and autophagy also play important roles in the fate of 
cardiac myocytes following an ischaemic insult (Kim and Kang 2010, Zeng et al. 2014). 
It is currently postulated that necrosis is responsible for approximately 35-50% of 
myocyte loss following I/R (Buja and Weerasinghe 2010). The major cause of necrosis 
in the reperfused myocardium is through opening of the mPTP which initiates primary 
myocyte necrosis (Hausenloy, Boston-Griffiths and Yellon 2011), further described in 
section 1.7. 
 
1.4.2  Apoptosis 
 
The word apoptosis, coined by Wyllie et al. (Wyllie, Kerr and Currie 1980), is derived 
from Greek meaning “falling off”. In the context of autumnal leaves from a tree, or 
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petals from a flower, this was related morphologically to programmed cell death. 
However, now there is a clearer understanding of apoptosis, to define on functional 
criteria appears more appropriate: “A stepwise, tightly regulated mechanism for 
eliminating damaged or superfluous cells without harming their healthy neighbours” 
(Bishopric et al. 2001). Apoptosis is regulated by complex cellular mechanisms (Figure 
1.5) and tightly regulated by a myriad of receptors, organelles and proteins, including 
caspases (cysteine aspartate specific proteases) which represent the most important 
initiators, effectors and executioners in the apoptotic machinery (Cryns and Yuan 
1998).  
The elimination of cells via apoptosis is fundamental in the development and 
maintenance of tissue integrity in multicellular organisms (Twomey and McCarthy 
2005). However, apoptosis is also central to a cornucopia of disease states including 
degenerative processes, cancer and I/R (Kroemer and Martin 2005).  
In relation to the myocardium, cardiac myocytes are activated to die by apoptosis in 
response to a range of cellular stresses including work overload, free radical stress and 
I/R injury (Bishopric et al. 2001). There is evidence that, following I/R, approximately 
50-65% of myocyte death occurs via apoptosis (Buja and Weerasinghe 2010), this 
includes both caspase dependent and caspase independent components, of which the 
apoptotic cascade may be mediated by the mitochondria (intrinsic pathway) or 
activation of cell surface death receptors (extrinsic pathway). The full extent of 
apoptotic pathways in the myocardium is beyond the scope of this thesis, however, 
the review conducted by Orogo and Gustafsson provides an excellent overview of 
apoptosis within the cardiovascular system (Orogo and Gustafsson 2013).  
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Figure 1.5: Intrinsic and extrinsic apoptosis pathways. Intrinsic (or mitochondrial dependent) 
apoptosis is initiated via cellular stresses (a), for example DNA damage or conditions of I/R. 
apoptosis (b) occurs as a consequence of ligand binding to death receptors or the action of 
CD8+ cytotoxic T-cells. (Adapted from Twomey and McCarthy 2005, Kroemer and Martin 2005, 
Orogo and Gustafsson 2013) All abbreviations within the list of abbreviations.  
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can be 
viewed in the Lanchester Library Coventry University.
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1.4.2.1 Caspase dependent apoptosis (intrinsic pathway) 
 
Mitochondria, frequently known as the “power house” of a cell, are present in the 
majority of present day eukaryotic species (Saelens et al. 2004), and are primarily 
responsible for providing cells with ATP through oxidative phosphorylation (Hüttemann 
et al. 2007). However, following apoptotic stimuli, such as increases in ROS, as observed 
under conditions of I/R, the mitochondria becomes a target for the initiation of 
apoptosis and subsequent destruction of the cell (Dewson and Kluck 2009). This 
pathway is regulated by downstream G-protein coupled receptor (GPCR) signalling 
following environmental stresses such as those during I/R (Sun et al. 2010b). Pro-
apoptotic signalling converges on the mitochondrial membrane bound Bcl-2 proteins, 
Bak and Bax, thus resulting in their activation and oligomerisation, to form pores 
within the outer mitochondrial membrane (Scorrano et al. 2003). This permits the 
release of apoptogenic factors (such as cytochrome c, second mitochondria-derived 
activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) and 
apoptosis inducing factor (AIF)) into the cytosol, thereby initiating caspase-dependent 
and caspase-independent apoptotic cascades (Dewson and Kluck 2009).  
The release of cytochrome c and apoptosis protease activating factor-1 (APAF-1) into 
the cytosol, promotes the formation of the heptodimeric apoptosome whereby 
cleavage of pro-caspase-9 is enabled following subsequential dimerisation of 
cytochrome c and APAF-1. Activation of caspase-9 then promotes downstream 
proteolytic pro-caspase cleavage causing a caspase dependent apoptotic cascade 
(Dewson and Kluck 2009). This ultimately leads to DNA fragmentation, condensation of 
organelles, membrane blebbing and reorganisation of the cellular constituents into 
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apoptotic bodies which are then removed via phagocytosis, in the absence of an 
inflammatory immune response (as shown in Figure 1.5).  
In order to alert circulating phagocytes to their presence, and hence prevent 
secondary necrosis, apoptotic cells secrete specific “find me” signals such as 
lysophosphatidylcholine, sphingosine 1-phosphate, and the nucleotides ATP and UTP 
during the early stages of apoptosis (Chekeni et al. 2010). These signals recruit 
monocytes and macrophages to the region of apoptotic cells. In order for recruited 
phagocytes to identify the apoptotic cells amongst the multitude of viable cells, 
apoptotic bodies also present “eat me” flags. This is most commonly observed as 
exposure of phosphatidylserine as well as alteration of glycosylation patterns on the 
surface of apoptotic cells as serves to advertise the presence of apoptotic cells to the 
macrophages in the proximity of the dying cells (Ravichandran 2011). Interestingly, 
despite both “find me” and “eat me” signals being non-specific for monocytes or 
macrophages, during phagocytosis of apoptotic bodies there is minimal neutrophil 
recruitment (and hence minimisation of an inflammatory response), this has been 
attributed to the co-release of “keep out” signals in the supernatant of apoptotic cells, 
in particular lactoferrin, which act as a potent cellular deterrent for neutrophil 
migration (Bournazou et al. 2009). 
A role for p53 has also been elucidated in the context of I/R injury. p53 is a critical 
regulator of the cell cycle and is best known for its tumour suppressor actions whereby 
p53 arrests the cell cycle at the G1/S checkpoint. This provides a mechanism where 
incorrect DNA sequences in proliferating cells are identified and then either repaired, 
or removed through apoptosis. p53 is also capable of sensing cellular stresses, such as 
oxidative stress and conditions of I/R and can then couple to the apoptotic cascade. 
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Upon such cellular stresses, cytoplasmic p53 rapidly translocates to the cytoplasmic 
surface of the outer mitochondrial membrane (Vaseva et al. 2012). This primarily 
involves recruitment of Bcl-2 proteins (such as Bak and Bax), thereby directly 
promoting MOMP (Green and Kroemer 2009, Vaseva and Moll 2009). However, p53 
also appears capable of preventing the repressor activity of Bcl-xL, which then 
indirectly promotes apoptosis, as previously described (Vaseva et al. 2012). There is 
also recent evidence that p53 may be a critical regulator in necrosis via interaction 
with cyclophilin D, a key component of the mPTP (Vaseva et al. 2012). 
Despite significant evidence that intrinsic and extrinsic apoptosis pathways play an 
instrumental role in myocyte loss following I/R injury, there has been conflicting 
evidence as to whether apoptosis is initiated during ischaemia, reperfusion or plays an 
active role in both (Foo, Mani and Kitsis 2005, Gustafsson and Gottlieb 2007). 
However, further to this, both broad spectrum caspase inhibitors (eg, ZVAD-fmk) (Buja 
and Weerasinghe 2010) as well as capsase-3 specific (DEVD-fmk) (AL-Rajaibi et al. 
2008, Mocanu, Baxter and Yellon 2000) have been shown to limit infarct size by 21-
31% and 25-39% respectively. This implies an instrumental role for caspase dependent 
apoptosis in myocardial I/R injury. 
Further to this, the Bcl-2 proteins exhibit apoptosis regulation and, depending on the 
protein domains present, may be pro- or anti-apoptotic. Many of the Bcl-2 proteins are 
thought to associate with components of the mPTP, for example the voltage 
dependent anion channel (VDAC), thereby not only regulating apoptosis but also 
playing a role in necrotic myocyte loss (Bishopric et al. 2001).  
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1.4.2.2 Caspase dependent apoptosis (extrinsic pathway) 
 
In contrast to the intrinsic apoptotic pathway, the extrinsic pathway (schematically 
represented in Figure 1.5) is initiated by ligand binding to cell surface members of the 
tumour necrosis factor receptor family, known as death receptors (Lavrik, Golks and 
Krammer 2005), for example Fas (also known as CD95 or Apo1) and tumour necrosis 
factor-α receptor-1 (TNFR1, also known as p55 or CD120a) (Crow et al. 2004).  
 Within the cytosolic component of death receptors, there are specific death domains 
(DD) (Buja and Vela 2008). Upon association of ligands (for example TNF-α, Fas ligand 
(FasL) and TNF-related apoptosis-inducing ligand (TRAIL)) with a death receptor, the 
ligand-receptor complex trimerises with DR4 (TNF receptor superfamily 10a). This 
leads to respective recruitment of cytosolic DD-containing adapter proteins (eg. Fas 
associated via death domain (FADD) and TNFR1 associated via death domain (TRADD)). 
This causes subsequent formation of a death inducing signalling complex (DISC), which 
permits the oligomerisation and self-cleavage of pro-caspase 8 (Foo, Mani and Kitsis 
2005). This activation of the initiator caspase, caspase-8, allows downstream activation 
of other caspases, Bcl-2 family members and pro-apoptotic regulators, converging on 
cellular death by apoptosis. Caspase-8 can directly elicit a caspase-dependent 
apoptotic cascade via cleavage of pro-caspase-3, such that apoptosis proceeds as with 
the intrinsic pathway, following caspase-3 activation. However, caspase-8 is also 
capable of associating with the pro-apoptotic Bcl-2 family member Bid. The protease 
activity of caspase-8 cleaves Bid allowing a truncated fragment (t-Bid) to translocate to 
the mitochondria. This permits activation of the mitochondrial (intrinsic) apoptotic 
machinery as t-Bid interacts with Bak and Bax, enabling MOMP, therefore forming a 
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bridge and cross-talk between the extrinsic and intrinsic apoptotic pathways (Crow et 
al. 2004). 
I/R has been shown to elicit activation of both the intrinsic and extrinsic apoptotic 
pathways (Foo, Mani and Kitsis 2005, Gustafsson and Gottlieb 2007). In particular, 
mutant knock-out mice studies have shown an instrumental role for both intrinsic and 
extrinsic apoptotic pathways in the absence of the other (Buja and Vela 2008). 
However the contribution of both to overall loss of myocytes by apoptosis remains as a 
matter of some debate.  
 
1.4.3  Other death pathways 
 
Autophagy is defined as a process by which lysosomes degrade proteins and 
organelles, such that they can be used as substrates by other cells (Crow et al. 2004), 
although there has been considerable discussion as to whether autophagy can be 
considered as a cellular death process (Yuan, Lipinski and Degterev 2003). In contrast 
with other cellular death processes (necrosis and apoptosis) autophagy is a mechanism 
by which cellular constituents are utilised to produce energy, rather than a process 
which is energy expensive (Glick, Barth and Macleod 2010). In the context of cellular 
stress (for example pathological increases in ROS following I/R), autophagy may be 
initiated in order to scavenge nutrients necessary for the continuation of cellular 
metabolism (Klionsky 2007).  
However, autophagy cannot proceed indefinitely, and excessive autophagy will 
ultimately lead to cellular death by apoptosis (Eisenberg-Lerner et al. 2009). However, 
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in the context of the ischaemic myocardium, autophagy can serve to scavenge 
damaged organelles via mechanisms which actually serve to prevent apoptosis and 
protect against myocyte loss (Eisenberg-Lerner et al. 2009). Studies have also provided 
evidence that autophagic stimuli are enhanced during ischaemia (Calise and Powell 
2013). Further to this, agents which enhance autophagy have been shown 
instrumental in cardioprotection and reduction of infarct size (Przyklenk et al. 2011, 
Sala-Mercado et al. 2010). In particular, rapamycin (which inhibits the mammalian 
target of rapamycin (mTOR) pathway, and consequently phosphoinositol 3-kinase and 
Akt activation through this mechanism) induced autophagy has been shown to 
promote myocyte viability following I/R by a reduction in ROS and improvement of 
mitochondrial function (Yang, Wang and Peng 2010). 
A further cell death pathway is the contemporary notion of necroptosis, a morphology 
of cell death which resembles programmed necrosis (Galluzzi and Kroemer 2008), 
where apoptotic and necrotic pathways interact (Kung, Konstantinidis and Kitsis 2011). 
In the context of the cardiovascular system, myocyte loss from I/R injury was 
previously attributed to apoptosis and necrosis. However, the identification of 
programmed necrosis initiated studies which identified that myocyte death through 
regulated necrosis also plays an important role in I/R injury (Kung, Konstantinidis and 
Kitsis 2011). Primarily by the suggestion that Bax has the ability to regulate 
mitochondrial swelling and mPTP opening and that in Bax/Bak knockout mice, the 
mPTP is unable to function (discussed in more detail in section 1.7, Whelan et al. 
2012).  
Although this remains as a matter of some controversy, it is a novel explanation for the 
unique pattern of myocyte loss observed during I/R. This is especially poignant when it 
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is taken into consideration that, in contrast to other cell types, cardiac myocyte 
apoptosis often also initiates necrosis although generally apoptosis does not elicit an 
inflammatory response and clears dying cells and the resultant debris in the absence of 
necrosis. 
 
1.5  Signalling Kinase Pathways 
 
Within the context of myocardial I/R injury, it has been shown that the activation of 
protective signalling pathways is paramount to salvage functional myocytes, in the 
reversibly damaged myocardium, and prevent fatal myocardial injury. In particular, 
cascades of pro-survival kinases have been identified as instrumental in cellular 
protection and proliferation both within the context of healthy cells, as well as I/R. In a 
general sense, the cellular mechanisms which underlie normal cardiac development, 
differentiation and growth have been shown to be up-regulated under conditions of 
I/R, following endogenous administration of growth factors, which elicits cardio-
protection from acute I/R injury due to recruitment of pro-survival signalling pathways, 
which are now referred to as the RISK pathway (Hausenloy and Yellon 2004). In 
particular, RISK signalling is comprised of pro-survival kinases (and their associated 
pathways) (Davidson et al. 2006). This includes the phosphoinositide 3-kinase 
(PI3K)/protein kinase B (Akt) pathway, despite not comprising all pro-survival signalling 
cascades, the extracellular signal-regulated kinase 1/2 (Erk1/2) pathway and c-Jun N-
terminal kinase (JNK) pathway. Interestingly both these pathways are of particular 




1.5.1  Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) 
pathway 
 
Participation of the PI3K/Akt pathway in cellular growth, proliferation and survival has 
been frequently documented, including the importance in cellular survival of cardiac 
myocytes (Kuwahara et al. 2000).  The activation of PI3K, by appropriate ligand or 
cytokine binding to cell surface receptors (frequently GPCRs), leads to downstream 
phosphorylation of phosphatidylinositol 4,5 biphosphate (PIP2), which ultimately leads 
to the formation of phosphatidylinositol 3,4,5-triphosphate (PIP3). A proportion of this 
is hydrolysed by inositol phosphatase, therefore producing phosphatidylinositol 3,4 
biphosphate. PIP3 and PIP2 then recruit Akt to the plasma membrane and fully 
phosphorylate Akt at Thr-308 (within Akt’s catalytic domain) and Ser-473 (at the C 
terminus), leading to its activation (Mullonkal and Toledo-Pereyra 2007). 
Akt is one of the best described survival kinases and, as such, a multitude of cellular 
effects have been reported following Akt activation. In particular, cardiac myocytes are 
terminally differentiated and do not proliferate, therefore loss of myocytes via any 
cellular death mechanism, plays a crucial role in the functional outcome of the 
myocardium following injury, such as I/R (Miyamoto, Murphy and Brown 2009). 
Despite Akt substrates being distributed throughout the cell, and translocation of Akt 
to the plasma membrane for full activation, once phosphorylated, Akt frequently 
accumulates in the nucleus (Tsujita et al. 2006). This nuclear proportion of active Akt is 
then well situated to antagonise apoptosis via the activation p38-MAPK (mitogen-
activated protein kinase) as well as regulating gene transcription (Abel and Doenst 
2011). Akt can also directly promote cellular survival by ameliorating pro-apoptotic 
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stimuli such as apoptosis signal regulated kinase (ASK-1) and glycogen synthase kinase-
3β (GSK-3β).  
Within the context of the endoplasmic reticulum (ER), following ER stress and the 
accompanying increases in Ca2+, Akt activation is sufficient to down-regulate GSK3β, 
thereby promoting restoration of cardiac contractile function, as well as suppression of 
mPTP opening (Zhang et al. 2011). Further to this, at the mitochondrial level, Akt has 
roles in protecting myocytes from apoptosis via promotion of Bcl-2 inhibition of Bak as 
well as inhibition of BH3 only domain, pro-apoptotic proteins, such as BAD, Bim and 
Bax (Li and Sato 2001). This prevents MOMP, therefore preventing cytochrome c and 
AIF release into the cytosol. Consequently, Akt is also capable of indirectly inhibiting 
apoptosis by the suppression of caspase activation due to the limitation on 
apoptosome formation. However, Akt is also able to reduce caspase-3 activation, 
which has been shown experimentally to limit the number of apoptotic myocytes 
following I/R (Su et al. 2012). Following increased cytosolic Ca2+ as observed during I/R, 
Akt can also elicit cardio-protection through the mitochondria via inhibition of mPTP 
opening (Miyamoto, Murphy and Brown 2009).  
Despite the well documented protective effects of Akt, following myocardial 
ischaemia, constitutive over expression of Akt is actually capable of increasing infarct 
size, an observation which has been attributed to an increase in necrosis, rather than 




1.5.2  Extracellular signal-regulated kinase 1/2 (Erk 1/2) pathway 
 
MAPKs are serine and threonine kinases which regulate a variety of cellular processes, 
including those related to proliferation and survival. There are three main families of 
MAPKs, which include p38-MAPK, extracellular signal-regulated kinase (Erk1/2) and 
the c-Jun N-terminal kinase (JNK). Primarily, MAPKs are activated by extracellular 
ligand binding to receptor tyrosine kinases or G-protein coupled receptors (GPCRs) 
(Chen et al. 2001).  
Erk1/2, mediates cell proliferation and apoptosis, in particular through the Ras-Raf-
Mek-Erk signalling pathway via GPCR or RTK activation (Mebratu and Tesfaigzi 2009). 
Activation of Erk1/2 has been shown to promote cellular proliferation and survival and 
inhibit apoptosis, due to rapid phosphorylation, in response to a variety of stimuli and 
cellular stresses, including hypoxia (Buckley et al. 1999) and I/R in cellular models 
including cardiac myocytes, (Brar et al. 2000, Liu et al. 2008). The proposed mechanism 
for action is that Erk1/2 activation is able to prevent dephosphorylation of BAD and, 
subsequently, restrict caspase activation due to inhibition of MOMP and apoptosome 
formation (Bullard, Govewalla and Yellon 2005).  
In particular, in the context of I/R and ACh, Erk1/2 has been shown as an instrumental 
in promoting cardio-protection due to the ability of muscarinic signalling to activate 
Erk1/2 and elicit, at least in part, cardio-protective properties via Erk1/2 downstream 




1.5.3   c-Jun N-terminal kinase (JNK) 
 
c-Jun N-terminal kinase (JNK) is one of the three main subfamilies of the mitogen 
activated protein kinases (MAPKs). JNK is stress activated and known to play an 
integral role in the initiation of apoptosis in various disease states, including I/R, 
following its phosphorylation and subsequent activation (Zhao and Herdegen 2009). 
The activation of JNK includes both intrinsic and extrinsic apoptotic pathways, whereas 
inhibition of JNK permits the attenuation of apoptosis in several cell types and under 
various cellular contexts (Son, Rhee and Pyo 2006, Venugopal et al. 2007). This 
includes cardiac myocytes following I/R (Ferrandi et al. 2004). Further to this, more 
recently, JNK activation has been demonstrated to trigger both apoptosis as well as 
autophagy, with the consequential exacerbation of myocardial I/R injury (Xu et al. 
2014).  
Following activation, the cellular re-localisation of JNK to the nucleus initiates 
transcription of pro-apoptotic genes (Dhanasekaran and Reddy 2008). It was previously 
considered that this was the primary process by which JNK permits a change in cellular 
stability, leading to an apoptotic cascade. However, it has since been elucidated that 
following cellular stresses, including myocardial I/R, there is also sub-cellular re-
location of JNK to the mitochondria (Wiltshire, Gillespie and May 2004). The 
mitochondrial localisation of JNK is advantageous for the interaction of JNK with 
proteins which permit MOMP and therefore, subsequent activation of intrinsic 
apoptotic pathways (Kim et al. 2008a, Kim et al. 2008b, Wiltshire, Gillespie and May 
2004).  Prevention of JNK activation, either by genetic ablation, or chemical inhibition 
has provided evidence, in vivo and in vitro, for protection of cardiac myocytes 
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following I/R injury (Chambers and LoGrasso 2011, Ferrandi et al. 2004). The activation 
of muscarinic receptors, in particular the M3 subtype, following innervation by 
endogenous ACh, has also been shown to inhibit JNK activation (Wang et al. 2003). 
 
1.5  RISK pathway – pro-survival kinase signalling cascade 
 
Activation of the reperfusion injury salvage kinase (RISK) pathway has been implicated 
as instrumental in limiting reperfusion induced injury (Hausenloy and Yellon 2004, 
Hausenloy, Tsang and Yellon 2005). This pathway consists of a cascade of pro-survival 
kinases and included phosphatidyl-3-OH kinase (PI3K)-Akt and p42/p44 extracellular 
signal-regulated kinases (Erk1/2) (Hausenloy and Yellon 2004). During the early 
minutes of reperfusion, activation of either Akt or Erk1/2, promotes activation of 
downstream effectors which ultimately promoted cellular survival (Hausenloy and 
Yellon 2004). It is well documented that Akt and Erk1/2 activation exert an anti-
apoptotic action, and the RISK pathway was elucidated in view that reperfusion injury 
has been shown to have both apoptotic and necrotic components (Hausenloy, Tsang 
and Yellon 2005).  
The RISK pathway has since become a target for ischaemic and pharmacological pre- 
and post-conditioning (Hausenloy, Tsang and Yellon 2005). In particular, 
pharmacological activation of this cascade, with acetylcholine as well as many other 
agents and growth factors, throughout the first few minutes of reperfusion have been 
shown as pivotal for maintenance of tissue integrity and protection against lethal 
reperfusion injury, via a reduction in apoptosis (Hausenloy and Yellon 2004). Further to 
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this, there is evidence which supports that activation of the RISK pathway is closely 
associated with inhibition of opening of the mitochondrial permeability transition pore 
(mPTP, addressed in more detail in section 1.7) (Smart et al. 2006, Davidson et al. 
2006). This provides strong evidence that the RISK pathway affords protection by both 
a reduction in both apoptosis as well as necrosis, shown experimentally by a decrease 
in infarct size (Hausenloy and Yellon 2004). 
 
1.6  Pre-conditioning and post-conditioning 
 
Pre-conditioning was first characterised by Murry et al. in 1986 where brief periods of 
non-lethal ischaemia followed by reperfusion were shown to have a potent 
cardioprotective effect against a subsequent, prolonged and more severe ischaemic 
insult (Murry, Jennings and Reimer 1986). This notion has since evolved to encompass 
pharmacological pre-conditioning, as well as post-conditioning, whereby a cardio-
protective stimulus is administered after ischaemia, but prior to reperfusion. 
Post-conditioning, for myocardial syndromes, at least, represents a far more attractive 
strategy for tissue salvage. This is because, although pre- and post-conditioning have 
mechanistic similarities and share degrees of tissue salvage (Okorie et al. 2011), it is 
almost impossible to predict a cardiovascular event, making pre-conditioning 
inconceivable; whereas, due to the surgical ability to regulate reperfusion, post-
conditioning is a clinically viable option (Hausenloy et al. 2004). 
The cellular pathways responsible for both pre- and post-conditioning have not been 
fully elucidated, but  shared mechanistic properties have been identified, these include 
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the up-regulation of signalling cascades which link to the RISK pathway (Frohlich et al. 
2013) (described in section 1.5). This promotes cellular survival by inhibition of the 
mPTP opening and activation of the mitochondrial ATP sensitive potassium channel 
(mitoKATP). 
 
The activation of muscarinic receptors by acetylcholine has been shown as effective in 
both myocardial pre-conditioning (Critz, Cohen and Downey 2005, Qin, Downey and 
Cohen 2003) and post-conditioning (Xiong et al. 2009, Zang, Sun and Yu 2007). 
Acetylcholine has been shown to be protective against I/R when used in both pre- and 
post-conditioning due to its ability to activate the RISK pathway (Liu et al. 2011a, Mioni 
et al. 2005, Yang et al. 2005, Zhao et al. 2010). 
 
 
1.7  Mitochondrial permeability transition pore (mPTP) 
 
Within recent years, the mechanisms by which I/R injury occurs have been more fully 
elucidated, and there is increasing evidence for the involvement of the permeability of 
the inner mitochondrial membrane, which results in loss of mitochondrial membrane 
integrity, mitochondrial swelling and ultimate rupture of the outer mitochondrial 
membrane (Halestrap 2009). The structure within the inner mitochondrial membrane 
responsible for the phenomenon is known as the mitochondrial permeability transition 
pore (mPTP).  
First reported in 1987 (Crompton, Costi and Hayat 1987), there is now a large body of 
evidence to suggest the mPTP, a non-specific pore located on the inner mitochondrial 
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membrane, remains closed throughout ischaemia but opens at the onset of 
reperfusion due to increases of intracellular of Ca2+ and oxidative stress (Griffiths and 
Halestrap 1995) and represents a major determinant in myocyte fate following I/R 
(Shanmuganathan et al. 2005). Upon opening, within the first few minutes of 
reperfusion, the mPTP allows free passage of molecules (≤1.5 KDa) and solutes 
between the mitochondria and cytosol. The build up of osmotic pressure within the 
mitochondria, due to the influx of solutes, causes the subsequent rupture of the outer 
mitochondrial membrane.  
It has been almost 30 years since the mPTP was first identified and, since then, 
considerable efforts have been made to fully elucidate the structure and functional 
mechanism which leads to opening of the mPTP. Despite considerable work, primarily 
with the use of knock-out animals, the exact structure of the mPTP remains elusive. 
The mPTP was previously considered to comprise of VDAC (voltage dependent anion 
channel), ANT (adenine nucleotide transferase) and cyclophilin-D, located in the outer 
membrane, inner membrane and matrix, respectively. It has also been suggested that 
there is a role for the mitochondrial phosphate carrier. However, it has since been 
elucidated that ANT and VDAC do not appear to be critically involved in forming the 
channel of the mPTP (Baines 2009) as genetic ablation of both ANT and VDAC do not 
prevent mPTP opening (Miura and Tanno 2011).  
Despite this, the role of the ANT was suggested as integral in mPTP structure with use 
of ANT modulators, such as atractyloside, which induced mPTP opening, as well as 
bonkrekic acid, which permitted its closure (Schultheiss and Klingenberg 1984). This 
evidence implies that the ANT may contribute to the mPTP in a regulatory capacity, 
rather than being structurally essential in pore formation, however there is sufficient 
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evidence to provide a molecular link between the ANT and mPTP formation (Halestrap 
and Brenner 2003). The involvement of the VDAC as a structural component has also 
presented difficulties. In modified mitochondria which lack the outer mitochondrial 
membrane, mitochondrial swelling and subsequent rupture of the mitochondrial 
membranes does not occur, this implies an integral role of the outer mitochondrial 
membrane in the structure of the mPTP (Le-Quoc and Le-Quoc 1985). As the VDAC is 
capable of forming electrophysiological channels (which mimic and resemble the 
structure and function of the mPTP), it was presumed to be the outer mitochondrial 
membrane component of the mPTP. However, as with ANT knock-out studies, the 
mPTP has been shown to adequately function in the absence of VDAC (Javadov, 
Karmazyn and Escobales 2009). 
The majority of research to elucidate the mPTP’s structure has been concentrated on 
cyclophilin D since the observation that the association of cyclosporin A with 
cyclophilin D was capable of significantly inhibiting mPTP opening – even under 
conditions of moderate oxidative stress and Ca2+ overload. With use of cyclophilin D 
knock-out studies, it was described that cyclophilin D null liver mitochondria required 
significantly higher levels of Ca2+ to induce mitochondrial swelling and were resilient to 
CsA inhibition. However, as cyclophilin D is endogenously situated within the 
mitochondrial matrix, it appears unlikely that it plays a structure role in pore formation 
(Hausenloy et al. 2010). This gives rise to the hypothesis that although cyclophilin D is 
involved as a critical regulatory component of the mPTP, it is not structurally involved 
(Baines 2009, Elrod et al. 2010). Also, as cyclophilin D is a small, soluble matrix protein, 
it further rules out any structural involvement in the mPTP (Baines 2009).  Further to 
this, mPTP opening has shown to be potently inhibited by sanglifehrin A binding to 
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cyclophilin D (Clarke, McStay and Halestrap 2002). This provides further evidence for 
cyclophilin D involvement in the mPTP as, unlike CsA, sanglifehrin A does not inhibit 
calcineurin activity (Shanmuganathan et al. 2005). 
Upon opening, the mPTP, as shown in Figure 1.6, allows free passage of molecules ≤1.5 
kDa, resulting in outer mitochondrial membrane rupture. This causes primary necrosis 
due to ATP depletion (Yellon and Hausenloy 2007b) which occurs via the resultant 
collapse of mitochondrial function after disturbance of the mitochondrial membrane 
potential (Crompton 1999). Increase of intracellular Ca2+ and oxidative stress, due to 
rapid pH change and increases in ROS, leads to rapid ATP depletion, thereby causing 
rupture of the outer mitochondrial membrane. This facilitates the influx of toxic 
mitochondrial proteins, e.g. cytochrome-c, into the cytosol (Halestrap 2009, Halestrap 
and Pasdois 2009, Hausenloy et al. 2002). Thus, myocyte death via apoptosis can also 
occur due to outer mitochondrial membrane rupture following mPTP opening 
(Halestrap 2009, Halestrap and Pasdois 2009, Hausenloy et al. 2002). However, the key 
determinant for initiation of intrinsic apoptosis is mitochondrial outer membrane 
permeabilisation (MOMP). The principle components responsible for MOMP are the 
multi-domain Bcl-2 family members Bak and Bax (Whelan et al. 2012). Previously, the 
mPTP and MOMP were considered distinct components responsible for separate cell 
death mechanisms (Siu et al. 2008), however, it has recently been elucidated that 
Bak/Bax channels play an integral role in regulation of the mPTP as the absence of Bak 
and Bax renders cells immune from mPTP opening (Whelan et al. 2012). This further 
supports the contemporary notion of necroptosis, a form of programmed, regulated 
necrosis (section 1.3.3), and its potential involvement in I/R injury (Galluzzi and 
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Kroemer 2008, Kung, Konstantinidis and Kitsis 2011). Also, many of the Bcl-2 family 
proteins are thought to associate with the VDAC, thereby this further indicates that the 
regulation of apoptosis is able to interact with the mPTP and, potentially, play a role in 
regulating mPTP opening (Bishopric et al. 2001). 
 
Figure 1.6: Schematic to show the proposed structure and mechanism of the mitochondrial 
permeability transition pore (adapted from (Bishopric et al. 2001, Miura and Tanno 2011). 
 
 
1.8  Cyclosporin A 
 
In 1988, it was first discovered that Cyclosporin A (CsA), previously used as an 
immunosuppressive agent, was capable of potently inhibiting the opening of the mPTP 
(Crompton, Ellinger and Costi 1988). The ability for CsA to bind to cyclophilin A enables 
immunosuppression by the action of CsA to inhibit calcineurin. Cyclophilin D is a 
mitochondrial isoform of cyclophilin A (Schultheiss and Klingenberg 1984). It has since 
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can 
be viewed in the Lanchester Library Coventry University.
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been confirmed that CsA binds with high affinity to cyclophilin D, a key component of 
the mPTP, thus inhibiting binding of cyclophilin D to adenine nucleotide translocase 
and preventing subsequent opening of the mPTP (Basso et al. 2005). Extensive work 
has been carried out to characterise the cellular mechanisms by which CsA exerts this 
effect and the potential for its use as a cardioprotective agent (Cohen, Yang and 
Downey 2008, Crompton 1999, Halestrap 2009, Halestrap and Pasdois 2009, 
Hausenloy, Boston-Griffiths and Yellon 2011, Hausenloy et al. 2002) as it targets the 
mPTP (Shanmuganathan et al. 2005). One of the first reported studies was from 
Nazareth et al., who demonstrated that CsA administration was capable of reducing 
I/R injury in rat ventricular myocytes via a reduction in overall necrosis (Nazareth, Yafei 
and Crompton 1991). This provides evidence that mPTP opening primarily contributes 
to myocyte loss by necrotic pathways rather than apoptosis following I/R injury.  
 
1.9  Muscarinic acetylcholine receptors (mAChRs) 
 
Muscarinic receptors fall into the remit of the family of G-protein coupled receptors 
(GPCRs). GPCRs, also called seven-transmembrane receptors, represent the most 
abundant and diverse family of membrane bound receptors in eukaryotic cells. GPCRs 
are involved in a multitude of cellular and physiological processes and represent one of 
the major targets for the development of new pharmacological interventions for 
diverse pathologies (Shultz et al. 2008), including the exploitation of mAChRs for the 
development of new bronchodilator therapies for conditions such as COPD.  
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Despite the variation of ligands, all GPCRs share a distinct, evolutionarily conserved, 
structure. This consists of a single polypeptide which is embedded into the plasma 
membrane and folded, such that, seven segments transverse the entire width of the 
plasma membrane (Gilchrist, Li and Hamm 2002). The extracellular portions comprise 
the clefts to which ligand binding occurs. Ligand binding to a GPCR induces a 
conformational change, which initiates downstream signalling via involvement of G-
proteins (Figure 1.7). More specifically, G-proteins, also known as guanosine 
nucleotide-binding proteins, consist of α, β and ɣ subunits. Following ligand binding to 
a GPCR, dissociation of the β and ɣ subunits initiates downstream signalling (specific to 
the α subunit subtype). This is due to the dimeric complexes which are formed by the β 
and ɣ subunits (Torrecilla et al. 2007).  
 
Figure 1.7: Activation of a generic GPCR following agonist binding. Dissociation of the β and ɣ 
subunits following GPCR activation confers downstream signalling pathways (adapted from Li 
et al., 2002).  
 
This item has been removed due to 3rd Party Copyright. The unabridged version of the 
thesis can be viewed in the Lanchester Library Coventry University.
76 
 
In 1914, Sir Henry Hallett Dale published his seminal paper which identified the ability 
of acetylcholine to elicit two types of responses, simulated by either nicotine or 
muscarine (Fishman 1972). Further work differentiated acetylcholine receptors, on the 
basis of this observation, and they were subsequently termed nictonic or muscarinic 
acetylcholine receptors (nAChRs and mAChRs, respectively). It has since been 
elucidated that both types of acetylcholine receptors are GPCRs. In particular, mAChRs 
are coupled to either Gi/o or Gq/11, depending on the subtype. 
There are five known subtypes of mAChRs (Caulfield and Birdsall 1998), distributed 
throughout the body and across a plethora of tissues (Abrams et al. 2006) responsible 
for a multitude of neuronal and non-neuronal actions (Caulfield and Birdsall 1998, 
Caulfield and Birdsall 1998, Resende and Adhikari 2009). The M1, M3 and M5 subtypes 
are coupled to Gq/11 and the M2 and M4 subtypes are coupled to Gi/o.  
 
1.9.1  Muscarinic receptor signalling 
 
The immediate downstream signalling of the Gq/11 subtype mAChRs is the activation of 
Phospholipase C (PLC) which subsequently couples to PI3K activation. This signalling 
converges on the endoplasmic reticulum and leads to regulation of calcium via the IP3R 
located on the membrane of the endoplasmic reticulum. PLC is also able to activate 
PKC which leads to MAPK activation, in particular Erk1/2, and therefore promotes cell 




The M2 and M4 subtypes are coupled to Gi/o, this primarily couples to downstream 
signalling which causes down regulation of adenyl cyclase (AC) and therefore inhibition 
of cAMP production. However, despite these differences, Gi/o activation can also 
converge on diacylglycerol (DAG) and PKC signalling to elicit protection from apoptosis 
via Erk1/2, but also MAPK driven DNA synthesis and translation, therefore promoting 
cellular proliferation (an overview of muscarinic signalling cascades is outlined in 
Figure 1.8).  
Within mammalian pulmonary systems, the M1, M2, M3 and M4 subtypes are all 
differentially expressed (Haddad et al. 1999, Wessler and Kirkpatrick 2008). It is the 
agonist action of acetylcholine on the M3 subtype present on airway smooth muscle 
which is responsible for contraction in the lungs, despite approximately 80% of the 





Table 1.2: Localisation and differences in mAChR receptor subtypes and the signalling cascades 
to which they are coupled PLC = phospholipase C, IP3 = inositol tri-phosphate, DAG = 
diacylglycerol, PKC = protein kinase C, AC = adenyl cyclase. In particular, M2 and M3 receptors 
are expressed within the myocardium (adapted from Caulfield and Birdsall 1998). 
 
In human airways, the M3 receptors are coupled to the pertussis-toxin insensitive G-
protein α-subunit (Gq/11), leading to downstream activation of PLC. In turn, this initiates 
the formation of DAG and inositol tri-phosphate (IP3) from the phosphorylation of 
phosphatidylinositol 4,5-biphosphate. In patients with COPD, there is increased 
parasympathetic nervous system activity. Due to the environmental irritants, such as 
cigarette smoke, this induces bronchoconstriction (Costello et al. 1997). The action of 
ACh at the M3 receptors in the respiratory system initiates smooth muscle contraction, 
however over stimulation, as observed during COPD exacerbations, leads to a 
limitation in airflow due to excessive contraction and spasm of the smooth muscle in 
This item has been removed due to 3rd Party Copyright. The unabridged version of the thesis can be 
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the bronchi and bronchioles (Coulson and Fryer 2003). The over stimulation of 
muscarinic innervations at the M3 receptors also mediate mucus and water secretion 
and are, therefore, in part, accountable for the hyper-secretion of mucus in the 
respiratory systems of COPD patients (Mullol et al. 1992). 
In comparison with this, the function of the M2 receptors within the airways is still 
relatively unclear. In 1984, it was first demonstrated that functional M2 receptors were 
present in the pulmonary system (Fryer and Jacoby 1998). The M2 mAChR subtype is 
coupled to the pertussis toxin-sensitive G-protein (Gi/o) which, upon muscarinic 
activation, inhibits adenyl cyclase. However, there does not appear to be a direct role 
for the M2 receptors in smooth muscle contraction. It is, instead, postulated that M2 
receptors play a regulatory role by preventing adenylate cyclase-dependent smooth 
muscle relaxation. For example, relaxation induced by β-adrenergic agonists (Jacoby et 
al. 1998).  
Although M2 receptors constitute the majority of mAChRs in the myocardium by 
concentration, it has been shown that M1 and M3 receptors are also present (Abrams 
et al. 2006). Subsequently, it has also been identified that acetylcholine is the 
neurotransmitter responsible for negative chronotropic and inotropic cardiac 
responses via the activation of all three cardiac muscarinic receptor subtypes present 
(Nathanson 2008).  
In particular, it has been shown that M3 receptors may be involved in pro-survival 
signalling cascades following I/R injury. It has also been demonstrated that, following 
ischaemia, after 60 minutes reperfusion, the expression of M3 receptors is significantly 
increased, whereas the expression of M2 is, statistically unchanged, but slightly 
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depressed and M1 levels are indifferent from non-ischaemic controls (Yue et al. 2006). 
However, the clinical implications for this change in expression are yet to be fully 
elucidated. It is a short, but conserved, poly-basic region within the M3 receptor C-
terminal tail which appears to be responsible for the anti-apoptotic properties of 
muscarinic activation due to ACh binding (Budd et al. 2003).  
Following I/R, Gq/11 activation, in response to serum and glucose deprivation and redox 
stress, initiates extrinsic, mitochondrial dependent apoptosis. Interestingly, this is 
specific to the myocardium, and may attest to why cardio-myocyte apoptosis exhibits 
differently from other cells. But also this is restricted to cardiac muscle as striated, 
skeletal muscle lacks APAF-1, and therefore cannot support cytochrome-c mediated, 


























Figure 1.8: Cellular muscarinic signalling cascades. M1, M3 and M5 subtypes are coupled to Gq/11 
which permits downstream signalling via PLC, whereas M2 and M4 are coupled to Gi/o which 
induces downstream signalling which leads to a reduction in cAMP. However, all receptors are 
able to contribute to downstream signalling which activates ERk1/2 and, therefore promote 
cellular proliferation and survival via prevention of apoptosis. (Adapted from Borroto-Escuela 
et al. 2010, Ogoda et al. 2011, Sun et al. 2011) All abbreviations within the list of abbreviations. 
This item has been removed due to 3rd Party Copyright. The unabridged version of the 
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1.9.2  Acetylcholine 
 
Acetylcholine (ACh) is an ancient signalling molecule expressed and synthesised in 
vertebrates, invertebrates, prokaryotes, plants and fungi (Resende and Adhikari 2009). 
There is evolutionary evidence to promote the concept that acetylcholine has been 
instrumental in modulating cell function since the origin of life in non-neuronal 
(Horiuchi et al. 2003) and, more recently in evolutionary terms, neuronal cells (Wessler 
et al. 2001). 
ACh was the first neurotransmitter to be identified, by Sir Henry Hallett Dale in 1915, 
due to observations of its function in the heart following release from the vagus nerve. 
However, it was not until 1921 that Otto Loewi isolated and confirmed ACh as a 
neurotransmitter, although he originally named it “Vagusstoff” (which directly 
translates from the German as “stuff from the vagus nerve”) (Dani and Balfour 2011). 
ACh is now one of the best characterised neurotransmitters and the role of ACh in 
neurotransmission has been extensively studied (overview in Figure 1.9).  
Although acetylcholine is primarily considered as a neurotransmitter, non-neuronal 
cholinergic signalling in peripheral organs has now also been clearly defined (Caulfield 
and Birdsall 1998). From the context of the myocardium, endogenous acetylcholine 
has been observed to be readily synthesised, in both in vivo and in vitro experimental 
models. In particular, muscarinic innveration mediates smooth muscle contraction, 




Figure 1.9: Muscarinic receptor neurotransmission on airway smooth muscle and nerves 
(adapted from Bargmann 2005, Coulson and Fryer 2003).   
 
1.9.3  Acetylcholine and cardioprotection 
 
It has been well documented that muscarinic activation by acetylcholine (ACh), the 
endogenous agonist of mAChRs, promotes cell proliferation and is cytoprotective in a 
number of experimental models, cell types (Budd et al. 2003, Buys et al. 2003, Critz, 
Cohen and Downey 2005, De Sarno et al. 2003, Krieg et al. 2002, Li et al. 2011, 
Resende and Adhikari 2009) and against various cellular insults (De Sarno et al. 2003, 
Resende and Adhikari 2009). This includes Chinese-hamster ovary, P19 cardiac 
myocyte cell line, neuronal cells as well as within the myocardium including conditions 
of I/R (Buys et al. 2003, De Sarno et al. 2003, De Sarno et al. 2005, Styles, Zhu and Li 
2005). This protection is facilitated by the inhibition of apoptosis via activation of 
Phosphatidylinositol-3-OH Kinase (PI3K), leading to the activation of downstream 
targets such as protein kinase B/Akt and MAPK/Erk1/2 (overview of pathways in figure 
This item has been removed due to 3rd Party Copyright. The unabridged version of 
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1.10, Krieg et al. 2004). These pathways prevent activation of pro-apoptotic stimuli, eg. 
BH-3 only domain Bcl-2 proteins and caspase activation, and promote DNA synthesis 
thereby protecting the cell from apoptotic death (Budd et al. 2003, Li et al. 2011, 
Resende and Adhikari 2009). Acetylcholine has also been shown effective in protecting 
the myocardium against hypoxia induced apoptosis (Kim et al. 2008a, Liu et al. 2011a) 
by regulation of Bak, Bax and caspase-3. ACh has also been shown, specifically in the 
myocardium due to agonism of cardiac M3 receptors by decreasing the activity of pro-
apoptotic mediators Fas and p38 (Liu et al. 2013). 
More recently, acetylcholine induced cardioprotection has been shown to be abolished 
by atractyloside, a known opener of the mitochondrial Permeability Transition Pore 
(mPTP). This indicates an integral role of the mPTP in acetylcholine mediated 
cardioprotection (Sun et al. 2010a). Further to this, it provides evidence for the 
involvement of RISK signalling as both Gi or Gq signalling link with downstream Erk1/2 
activation. As previously described (section 1.7), there have been strong links 
demonstrated between the RISK pathway and mPTP opening (Davidson et al. 2006) 
which, have also been shown to have an association with non-neuronal ACh signalling. 
Although conjecture, it is possible that inhibition of muscarinic signalling by a 
muscarinic antagonist under conditions of I/R, for example in a COPD patient suffering 
MI, could have opposing effects and lead to a reduction of cell survival in the 
reperfused myocardium when myocyte death is executed (Freude et al. 2000). Indeed 
the M2 selective antagonist, methoctramine, has been shown to attenuate the 
cardioprotective effects of adenosine in in vitro models of I/R (Sun et al. 2011). It has 
also been observed that administration of 4-diphenylacetoxy-N-methylpiperidine 
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methiodide (4-DAMP), an M3 muscarinic antagonist, is capable of abrogating ACh 
induced cardio-protection, due to loss of activation of Erk1/2 and Bcl-2. As a 
consequence, mPTP opening is not inhibited, which initiates cellular death via 
apoptosis and necrosis (Lim et al. 2007, Yellon and Hausenloy 2007a) 
 
Figure 1.10: Schematic diagram to represent the convergence of muscarinic signalling 
pathways. Following innervations by endogenous, or exogenous, ACh, both Gi/o (M2 and M4) 
and Gq/11 (M1, M3 and M5) coupled receptors to activate ERk1/2 which, in the context of I/R, 
limits myocyte loss via regulation of apoptosis (through activation of Bcl-2 and inhibition of 
Bak) as well as necrosis via inhibition of the mPTP. The schematic clearly illustrates the 
involvement of components of the RISK signalling pathway and how ACh can link closure of the 
mPTP to RISK signalling. 
 
1.9.4   Muscarinic Antagonists 
 
Muscarinic antagonists are compounds which inhibit the action of acetylcholine at 
muscarinic receptors. Within the context of the pulmonary and cardiovascular 
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systems, there is an emerging, integral role for muscarinic signalling, in both the 
context of endogenous signalling and pharmacological interventions for disease states 
(as described in section 1.9.3).  
Within the respiratory system, muscarinic antagonists have been instrumental in the 
alleviation of symptoms of bronchoconstriction, in disease states such as COPD and 
asthma. In the context of COPD, this occurs, primarily via antagonism of the M3 mAChR 
subtype within the bronchi (Restrepo 2007). 
 
1.9.5  Atropine 
 
Atropine is a naturally occurring tropane alkaloid which may be extracted from 
members of plants from the solanaceae family (Gaire and Subedi 2013). In particular, it 
is known as a derivative from Atropa belladonna (Deadly nightshade) and Madragora 
officinarum (Mandrake). Atropine is a competitive antagonist for all 5 muscarinic 
receptor subtypes and was previously used as a bronchodilator for pulmonary 
pathologies due to its parasympatholytic actions in the bronchi, therefore leading to 
bronchodilation. This is primarily due to antagonism of the M3 subtype located on 
smooth muscle within the airways.  
However, due to the ability of atropine to cross lipid membranes, as well as its high 
absorbance rate, atropine administration is responsible for many adverse side-effects 
including hallucinations, ventricular fibrillation, tachycardia and nausea (Szajewski, 
1995). In addition to this, cumulative doses of atropine can lead to widespread 
paralysis which, in severe cases may lead to coma and death, due to off-target 
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inhibition of parasympathetically innervated organs. For these reasons, synthetic 
atropine derivatives, which also possess the potent anti-muscarinic action, have been 
developed in order to limit the systemic, adverse side effects from atropine inhalation. 
1.9.6  Ipratropium 
 
Ipratropium bromide ([8-methyl-8-(1-methylethyl)- 8-azoniabicyclo[3.2.1] oct-3-yl] 3-
hydroxy-2-phenyl-propanoate, ipratropium), a non-selective, short-acting, muscarinic 
receptor antagonist and synthetic atropine derivative (Wood et al. 1995), has been 
widely prescribed for management of pulmonary conditions, primarily Chronic 
Obstructive Pulmonary Disease (COPD) and as adjunctive therapy for acute asthma 
since 1987 (Restrepo 2007). The low absorbance rate of ipratropium, especially when 
administered by inhalation, coupled with its poor distribution across lipid-membranes 
made it a preferential treatment in comparison with atropine as the numerous adverse 
effects due to systemic atropine absorbance were essentially eliminated (Restrepo 
2007). Ipratropium is non-selective for M1, M2 and M3 muscarinic receptor subtypes 
(Restrepo 2007). The antagonist action of ipratropium at the muscarinic receptors in 
the lungs (primarily M3 subtype) inhibits acetylcholine induced vagus nerve-mediated 
reflexes, leading to smooth muscle relaxation and bronchodilation. This facilitates 
airflow by improving pulmonary function and alleviating the bronchospasm 




1.10  Link between ipratropium and ischaemia/reperfusion 
injury 
 
Within the past decade, despite much controversy, numerous studies have indicated 
cardiovascular risks associated with COPD patients receiving anti-cholinergics 
(Anthonisen et al. 2002, Guite, Dundas and Burney 1999, Lee et al. 2008, Macie et al. 
2008, Ringbaek and Viskum 2003, Singh, Loke and Furberg 2008, Wedzicha et al. 2008). 
In particular, since 2008, various analyses of clinical trials have associated an increased 
risk in occurrence and severity of adverse cardiovascular outcomes in COPD patients, 
including MI, with long-term use of anti-cholinergic drugs (Ogale et al. 2010, Rabe 
2010, Singh, Loke and Furberg 2008, Singh et al. 2011), indicating an increased risk of 
up to 52% mortality due to cardiovascular events in COPD (Singh et al. 2011). It is 
known that mortality by cardiovascular events in COPD patients is higher than all other 
causes of death and, in particular, 22% die from complications following an ischaemic 
event. However, despite the known co-morbidities, there have been no known pre-
clinical investigations to assess the effects of anti-cholinergic compounds, such as 
ipratropium, in the setting of IHD or MI.  
Ipratropium represents just one of the non-selective muscarinic receptor antagonists 
which have been indicated as instrumental in adverse cardiovascular outcomes 
(Dmochowski and Staskin 2005, Montuschi et al. 2013). Despite this study primarily 
assessing the adverse affects following I/R, with the focus on myocyte loss through 
either apoptosis or necrosis, there is also evidence to suggest that antagonism of 
cardiac mAChRs, in particular the M2 subtype, is capable of eliciting disease through 
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modulation of ventricular contraction force, atrio-ventricular conduction and QT 
interval prolongation (Andersson, Campeau and Olshansky 2011).  
Further to this, tiotropium (an M1, M3 selective anti-cholinergic) has been shown to 
limit fibroblast proliferation in the pulmonary system (Pieper, Chaudhary and Park 
2007). Whilst therapeutically beneficial, this implies that muscarinic antagonism has 
the potential to limit proliferative processes, which, depending on cellular context, 
may be detrimental to tissue integrity. More recently, Shaik et al have demonstrated 
that ipratropium is capable of eliciting suicidal erythrocyte death (eryptosis) via a 
mechanism dependent on the stimulation of increased cytosolic Ca2+ activity (Shaik et 
al. 2012). Despite differences between eryptosis and apoptosis, which only occurs in 
nucleated cells, both processes can be initiated by increases in Ca2+ concentration, 
indicating that ipratropium may have the ability to also trigger apoptosis. In addition, 
increases in intracellular Ca2+ concentration are associated with conditions of I/R and 
the resultant, corresponding myocardial injury. This further indicates that muscarinic 
antagonism potentially plays a role in the exacerbation of ischaemic injury. 
From an intracellular signalling perspective, muscarinic activation by endogenous and 
exogenous acetylcholine has shown to promote cellular survival through activation of 
pro-survival signalling cascades (including the RISK pathway and via clsure of the 
mPTP). In a clinical context, it may be the case that anti-cholinergics have the converse 
effect and limit these protective processes which, under conditions of IHD or I/R, may 




1.11  Studies in Aging  
 
The elderly (>60 years old) represent the fastest growing human age group globally. It 
is postulated that by 2020, approximately 20% of the world’s population will fall into 
this category (Cencioni et al. 2013). The average age for a COPD diagnosis is 67 years 
and, in addition to this, more than 80% of patients with ischaemic heart disease are 65 
years or older (Goff et al. 2007). In combination, approximately 22% of COPD and IHD 
patients share both morbidities (Resende et al. 2007). However, despite an increase in 
frequency in myocardial infarction in the elderly, as well as age as a contributor for 
COPD and IHD development, the cellular mechanisms and physicological differences 
which occur in the aged myocardium have not been fully explored. 
Despite still being a matter of some contention, there is mounting evidence supporting 
that myocardial I/R injury is not only more common, but also, more severe in both 
elderly patients and experimental models using aged animals (Boengler, Schulz and 
Heusch 2009, Kajstura et al. 1996, Lesnefsky et al. 1994, Ramani et al. 1996). Also, 
despite conflicting evidence, the efficacy of ischaemic pre-conditioning does not 
appear to be preserved in the aged heart, as shown in in vivo rabbit models (Przyklenk, 
Li and Whittaker 2001). However, the cellular mechanisms underpinning this remain 
unclear. 
It has also been reported that the inflammatory response, associated with I/R, is 
exacerbated in the aged rat heart. This is associated with significant increases in 
arrhythmias in comparison with young rats, and therefore poorer clinical outcomes 
(Liu et al. 2002, Nejima et al. 1989). During reperfusion, the timely restoration of blood 
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flow to the heart is imperative in avoiding fatal injury, within the senescent 
cardiovascular system, endothelial dysfunction has been described. This causes an 
exacerbation in the alteration of the restoration of coronary flow following I/R 
therefore leading to myocyte death (Besse et al. 2001). 
Mitochondrial metabolism and oxidative phosphorylation have been shown to 
decrease in the aged rat heart (6 months vs. 24 months, using Fischer 344 rats), which 
has been attributed to a decrease in complex III and IV activity (Paradies et al. 1993) 
during the electron transport chain. However, the activity of complex I and II appear 
resilient to the aging process (Lesnefsky et al. 2001). Also, within the mitochondria, 
aging increases oxidative stress, even at baseline levels, prior to myocardial injury 
(Boengler, Schulz and Heusch 2009), this is attributed to dysfunction of the 
cytochrome c binding site of complex III. However, within the context of the healthy 
myocardium, aging does not appear to influence ROS generation (Lesnefsky et al. 
2001). Furthermore, myocardial senescence, alone, appears to have a limited effect on 
haemodynamic function or baseline apoptosis in comparison with younger rats. 
However, following an ischaemic insult, there are significant increases in 
haemodynamic dysfunction and apoptosis activation (Kajstura et al. 1996). This is 
further associated with a loss of endogenous adenosine receptor signalling in the aged 
heart (Willems, Ashton and Headrick 2005).  
Following conditions of myocardial I/R, increased severity of injury in the aged 
myocardium is associated with prolonged accumulation of Ca2+ and oxidative mediated 
damage (Boengler, Schulz and Heusch 2009). Previous work has provided evidence 
that complex III becomes damaged following I/R in the young heart (Lesnefsky and 
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Hoppel 2003). Also, complex III is implicated as instrumental in ROS generation during 
reperfusion in the adult heart, it is postulated that the dysfunction of complex III in the 
aged heart, contributes to enhanced oxidative stress and, consequently, myocardial 
injury (Lesnefsky et al. 2001).  
In general, the mechanistic pathways of I/R injury have been predominantly identified, 
however the relative contributions of necrosis and apoptosis remain as a matter of 
some debate. However, despite evidence that levels of necrosis are indifferent 
between 16 month and 24 month old rats (Kajstura et al. 1996), it was demonstrated 
that left ventricular apoptosis increased by over 200% in the same age groups (Kajstura 
et al. 1996). Age-associated increases in Bcl-2, Bax and cytochrome c (all major 
components of the instrinsic apoptotic cascade) have been observed to have 
involvement (Liu et al. 2002, Phaneuf and Leeuwenburgh 2002). In particular, the ratio 
between mRNA levels of Bax and Bcl-2 is augmented, which may contribute to the 
observed increases in apoptosis in the aged myocardium following the challenge of I/R 
(Liu et al. 2002). More recently, increased levels of caspase-3 and TUNEL staining, with 
use of 8 week and 24 month Sprague-Dawley rats, were demonstrated and used, in 
conjunction with clinical trials, to confirm a correlation between increases in apoptosis 
and aging (Liu et al. 2011b). These studies support the hypothesis that apoptosis plays 
a major role in the exacerbation of I/R injury in the aged myocardium. This notion is 
indirectly supported by Guo et al. who indicated an integral role for apoptosis in post-
ischaemic heart failure (Guo et al. 2008). 
Under conditions of myocardial I/R, a major determinant for myocyte fate is the 
opening of the mPTP, which occurs within the first few minutes of reperfusion 
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(Hausenloy et al. 2004). As previously described (section 1.10), cyclosporin A (CsA) 
inhibits mPTP opening via binding to cyclophilin-D, which therefore elicits CsA 
mediated cardioprotection (Xie and Yu 2007). This has been widely documented and 
observed, as significant decreases in infarct size as well as modulation of critical 
mediators of I/R injury, following CsA administration. In the context of the aged 
myocardium, CsA is incapable of reducing infarct size. In conjunction with this, NAD+ 
loss following mPTP opening was not different in the aged hearts following I/R with or 
without CsA administration (Liu et al. 2011b). Given that the cardioprotective effects of 
CsA can be inhibited by elevations of Ca2+, it is possible that the inability for CsA to 
protect in the aged myocardium involves a similar mechanism as Ca2+ levels are 
significantly higher following I/R in aged hearts in comparison with young hearts. Also, 
it is possible that the observed defects within the mitochondria and increases in 
oxidative damage due to aging are sufficient that the mitochondria are less resilient to 
oxidative stress, such that CsA is unable to protect (Liu et al. 2011b). 
Taken in combination, there is sufficient evidence that myocardial damage following 
I/R in the aged heart is more severe. From a clinical perspective, this implies that 
ischaemic damage in elderly patients, following myocardial infarction, may be 
exacerbated as a consequence of myocardial senescence. However, despite this, there 
is a significant lack of literature concentrating on the elucidation of the mechanisms 
involved in I/R in the aged heart, even though the elderly are the population most at 
risk for ischaemic heart disease and myocardial infarction (Valente et al. 2010). 
Aging is associated with a reduction in function and expression of many hormone and 
neurotransmitter receptors (Brodde et al. 1998). In the context of myocardial 
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muscarinic acetylcholine receptors (mAChRs), there is accumulating evidence that M2 
mAChRs (the primary subtype within the myocardium) decrease in number and 
function following aging. The consequence of this is that endogenous acetylcholine is 
incapable of eliciting the negative inotropic and chronotropic effects observed in 
younger individuals (Brodde et al. 1998). Following I/R, this could contribute to the 
increases in arrhythmias which have been observed in senescent hearts. It has not 
been ascertained whether the cardioprotective properties of acetylcholine are 
abolished in the aged myocardium. Also, despite controversial evidence that elderly 
COPD patients require different treatments, clinical trials have not associated age 
dependent changes in the efficacy of anti-cholinergic compounds, such as ipratropium 
(Valente et al. 2010). 
 
1.12 Experimental models for the study of myocardial 
ischaemia/reperfusion injury 
 
In cardiovascular research, one major hurdle in advancing the understanding of the 
mechanisms and related pathophysiological manifestations of I/R injury is the 
availability of appropriate experimental models. Ideally, in vivo models which are 
clinically accurate to disease states observed in human patients would be used, 
however, practical and ethical difficulties prevent this in animal models. The most 
relevant models we have available are from human tissue, however, the availability of 
tissue is limited and both difficult and costly to obtain. In view of this, the majority of 
cardiovascular models are taken from healthy animals (both in vivo and in vitro) and 
specific protocols to mimic disease states are implemented. In this study, two main in 
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vitro experimental models, using rat heart, were used; these were the isolated 
perfused Langendorff heart and also a model of isolated primary ventricular rat 
myocytes. 
 
1.13  Aims and objectives 
 
The primary aim for this work is to determine whether ipratropium bromide is capable 
of eliciting myocardial injury, in the setting of normoxia as well as under conditions of 
ischaemia/reperfusion, in order to ascertain whether there is a real risk for COPD 
patients, with underlying IHD, receiving anti-cholinergic compounds.  
Objectives: 
1. To determine whether ipratropium bromide when administered under normoxic or 
simulated I/R conditions is capable of exacerbating myocardial damage and to identify 
whether the observed injury is due to necrosis or apoptosis. Further to this, to identify 
whether the observed injury, due to ipratropium administration, is via a direct action 
on cardiac muscarinic receptors. 
2. To elucidate the involvement of the components of the RISK pathway, Akt and 
Erk1/2 in myocardial tissue following ipratropium treatment ± acetylcholine. The same 
experimental groups will be used to identify involvement of the stress induced kinases 
SAPK/JNK and the pro-apoptotic BCl-2 protein BAD, which should therefore assist in 




3. To identify the involvement of the mitochondria and mPTP in ipratropium induced 
injury using a model of oxidative stress. Further to this to assess whether the 
cardioprotective agent CsA is capable of attenuating the myocardial damage due to 
ipratropium administration. 
4. To investigate whether ipratropium induced myocardial injury is further exacerbated 





Chapter 2  Materials and Methods 
 
2.1   Materials 
 
All drugs used (ipratropium bromide (ipratropium, Ip), atropine, cyclosporin A (CsA), Z-
DEVD-FMK (DEVD) and wortmannin) were purchased from Tocris Cookson (Bristol, 
UK), with the exception of acetylcholine chloride (acetylcholine, ACh), which was 
purchased from Sigma Aldrich (Poole, UK). All drugs were dissolved, aliquotted into 1.5 
ml centrifuge tubes and stored at -20oC prior to experimental use. Ipratropium, 
atropine and acetylcholine were dissolved in ddH2O. DEVD and Wortmannin were 
dissolved in dimethyl sulphoxide (DMSO), purchased from Fisher Scientific 
(Loughborough, UK). The final concentrations of DMSO, once diluted in the buffers, did 
not exceed 0.02%. This is a concentration which has previously been shown to have no 
effect on myocardial heamodynamic function or infarct development (Mocanu, Baxter 
and Yellon 2000). CsA was dissolved in ethanol, such that the final concentration of 
ethanol did not exceed 0.01% when used experimentally as this concentration of 
ethanol has also shown no adverse effects on myocardial function or infarct 
development (Shanmuganathan et al. 2005). 
All chemicals used to prepare Krebs-Heinsleit buffer (for Langendorff studies) as well as 
10% formalin were purchased from Fisher Scientific (Loughborough, UK). Both Evans 
blue and 2,3,5-triphenyl tetrazolium chloride (TTC), required for staining of the hearts, 
were purchased from Sigma-Aldrich (Poole, UK).  
All salts for the preparation of modified Krebs-Ringer’s buffer (required for cardiac 
myocyte isolation), restoration buffer and Esumi ischaemic buffer (required for cardiac 
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myocyte hypoxia/re-oxygenation protocol) were acquired from Fisher Scientific 
(Loughborough, UK), with the exception of taurine, sodium pyruvate, bovine serum 
albumin (BSA), HEPES, lactate, deoxyglucose and penicillin/streptomycin (all required 
for myocyte studies) which were purchased from Sigma Aldrich (Poole, UK). 
Worthington’s Type II collagenase was bought from Lorne Laboratories (Berkshire, UK). 
For the flow cytometry experiments, all antibodies (cleaved caspase-3, phospho-Akt 
and Phospho-BAD) were acquired from New England Biolabs (Ipswich, MA, USA), as 
were the reagents required for the Vybrant® apoptosis assay kit. For the purposes of 
the acetylcholine assay, a choline/acetylcholine assay kit was purchased from AbCam 
(Cambridge, UK). For the cardiac myocyte model of oxidative stress; HEPES, 
tetramethylthodamine methyl ester (TMRM) and carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) were purchased from Sigma Aldrich (Poole, 
UK). All other reagents were purchased as before. All samples were analysed using a 
FACS Calibur™ flow cytometer from BD systems (St. Edmunds, Suffolk, UK). 
Mini-PROTEAN® TGX™ Precast Gels (4 - 20%) and a Mini PROTEAN® II system were 
used for electrophoretic protein separation and purchased from Bio-Rad (Hemel 
Hempstead, Hertfordshire, UK). For transfer of proteins onto PVDF membranes, Trans-
Blot® Turbo™ transfer packs were used in conjunction with a Trans-Blot® Turbo™  
transfer system (both Bio-Rad (Hemel Hempstead, Hertfordshire, UK)). Reagents 
required for the preparation of solutions used for Western blotting were purchased 
from Fisher Scientific (Loughborough, UK) and Sigma Aldrich (Poole, UK). For the 
Western blotting studies, all antibodies used (phospho-Akt (Ser473), phospho-Erk1/2 
(Thr202/Thr204), phospho-SAPK/JNK (Thr183/Tyr185), Akt, Erk1/2, SAPK/JNK and GAPDH) 
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were purchased from New England Biolabs (Ipswich, MA, USA). For detection of 
proteins on the PVDF membranes, SuperSignal® West Femto Chemiluminescent 
Substrate™ (Thermo Scientific, purchased from Fisher Scientific (Loughborough, UK)) 
was used in order to detect target proteins in ranges as small as femtograms, to ensure 
maximum visualisation of proteins. 
 
2.2  Animals 
 
In all experiments, male Sprague-Dawley rats were used. Adult male Sprague-Dawley 
rats (300 g ± 50 g body weight) were either purchased from Charles River (Margate, 
Kent, UK) or bred in-house (Coventry University, Coventry, UK). For the aged studies, 
rats were purchased as adults and allowed to mature to 12, 18 or 24 months in-house 
(Coventry University, Coventry, UK). All animals resided under the same conditions, 
received humane care, a standard diet and free access to water. Procedures were 
carried out in accordance with the Guidance on the Operation with Animals (Scientific 
Procedures) Act 1986 (The Stationary Office, London, UK). 
 
2.3  Isolated perfused rat heart (Langendorff) model 
 
2.3.1   Principle of the technique 
 
The mechanism of the Langendorff perfused heart model was initially proposed by 
Oskar Langendorff in 1897 (Skrzypiec-Spring et al. 2007) where, primarily, Langendorff 
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used feline hearts to deliver blood to the myocardial tissue via aortic cannulisation. It 
has since been used more extensively than any other isolated organ experimental 
model (Skrzypiec-Spring et al. 2007)and, in particular, has been vital in cardiovascular 
research leading to a myriad of instrumental outputs within the field (Zimmer 1998).  
The Langendorff isolated perfused mammalian heart model was initially based on the 
isolated perfused amphibian (frog) heart, which, at the time, towards the end of the 
19th century, was widely used in the field of cardiovascular physiology. The principle 
behind the model is that the pressure of retrograde perfusion through the aorta 
causes the aortic valves to close, thereby providing the heart with blood (or, 
experimentally, physiological buffers, such as Krebs Heinsleit buffer) via the coronary 
arteries. Despite perfusion essentially being in reverse in comparison with a 
physiological setting, pressure builds up in the ventricles and therefore mimics in vivo 
diastolic conditions (Skrzypiec-Spring et al. 2007). Adequate measurements of 
coronary flow may be taken directly as the volume of perfusate leaving the right 
atrium, is indicative of the rate of perfusate passing through the heart. Under correctly 
controlled conditions, the Langendorff perfusion system enables cardiac function to be 
maintained for several hours, during which time studies to identify the effects of gene 
alteration, novel therapies and, in the context of this investigation, myocardial injury 
due to ischaemia/reperfusion were able to be conducted (Bell, Mocanu and Yellon 
2011, Skrzypiec-Spring et al. 2007). 
The apparatus used consisted of reservoirs of physiological buffers which perfused the 
heart at a constant rate and pressure, flowing through heated coils, to ensure the 
perfusate was at 37 oC when it reached the heart. In order to ensure adequate oxygen 
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consumption of the cardiac tissue could occur, all buffers were saturated with oxygen 
(Figure 2.1).  
 
Figure 2.1: Schematic diagram of Langendorff apparatus used for isolated perfused rat heart 
experiments. Oxygenated, physiological buffer passes from the reservoir through a glass 
heated coil (at 37 oC) for retrograde perfusion of the cannulated heart, via the aorta. The heart 
is further maintained at 37 oC with use of a heated organ chamber. Insertion of a latex, fluid 
filled balloon, connected to a pressure transducer and computer allows for regular 
measurement of haemodynamic parameters. Coronary flow recordings may be taken directly 
from the measurement of the volume of coronary effluent.  
 
2.3.2   Basic protocol 
 
Rats were sacrificed by cervical dislocation prior to excision of the heart. The heart was 
immediately placed in ice cold Krebs-Heinsleit buffer (1.18 x 10-1 M NaCl, 2.5 x 10-2 M 
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NaHCO3, 4.8 x 10
-3 M KCl, 1.2 x 10-3 M MgSO4, 1.2 x 10
-3 M KH2PO4, 1.2 x 10
-2 M 
glucose, 1.7 x 10-3 M CaCl22H2O, KHB). The aortic arch was removed to allow 
cannulation onto Langendorff apparatus (Figure 2.2) and retrograde perfusion with 
KHB (maintained at 37 oC, pH 7.4 and saturated with 95% O2 5% CO2). Cannulated 
hearts were also maintained at 37 oC with use of a heated, water-jacketed organ 
chamber.  
 
Figure 2.2: Representative image showing an adult Sprague-Dawley rat heart mounted onto 
the Langendorff set-up, prior to left atriotomy. The heart was cannulated by the aorta for 
retrograde perfusion with Krebs Heinsleit Buffer, saturated with 95% O2 and 5% CO2. 
 
2.3.3  Determination of haemodynamic function 
 
Following mounting on the Langendorff apparatus, the left atrium was removed, 
allowing insertion of a fluid-filled latex balloon, inflated to constant diastolic pressure 
of 5 - 10 mmHg, into the left ventricle. A calibrated, physiological pressure transducer 
connected to a PowerLab® (AD Instruments Ltd. Chalgrove, UK) via a bridge amp, 
connected to a computer, facilitated the regular measurement of haemodynamic 
function. Left ventricular developed pressure (LVDP, mmHg) and heart rate (HR, bpm) 
were extrapolated from a computerised trace with use of LabChart® (version 6) 
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software developed by AD Instruments Ltd. (Chalgrove, UK) (Figure 2.3). Coronary flow 
(CF, ml.min-1) was measured by collecting the perfusate at regular time intervals. 
Measurements of all three hemodynamic parameters were taken every 5 minutes 
during stabilisation and ischaemia and every 15 minutes throughout reperfusion. 
 
Figure 2.3: Representative trace from LabChart® 6 showing Langendorff perfused rat heart 
haemodynamic function. As indicated, left ventricular developed pressure (LVDP) was 
represented as the peak-to-peak amplitude of the trace and the length of time for one heart 
beat as the wavelength, from which heart rate (bpm) was calculated. Data acquisition was 
every 5 minutes for the first 55 minutes and every 15 minutes for the last 120 minutes of the 
protocol. 
 
2.3.4   Ischaemia/reperfusion protocol 
 
Following 20 minutes stabilisation, ischaemia was induced via insertion of a hooked 6-
0 silk surgical suture under the left descending coronary arteries. The ends of the 
thread were passed through a plastic tube to form a snare (Figure 2.4). The snare was 
tightened to induce regional ischaemia in the left ventricle, for 35 minutes. Loosening 
of the tubes, thereby releasing the threads, initiated reperfusion as this permitted the 
restoration of the flow of KHB to the left ventricle. In studies subjected to the 


















Figure 2.4: Representative image showing a surgical suture inserted around the left 
descending coronary arteries. The thread was passed through two plastic tubes in order to 
form a snare. This was subsequently tightened in order to ligate the coronary arteries, thereby 
initiating regional ischaemia in the left ventricle. 
 
2.3.5   Reperfusion studies 
 
At the onset of reperfusion, Krebs Heinsleit buffer was exchanged for Krebs Heinsleit 
buffer containing appropriate drug concentrations (described in respective 
experimental chapters). The hearts were subsequently perfused with KHB + drug(s) 
throughout reperfusion until Evans blue and TTC staining took place. I/R control hearts 
were perfused with KHB throughout the entire experimental protocol. Figure 2.5 
schematically represents the three major isolated perfused rat heart (Langendorff) 




Figure 2.5: Isolated perfused rat heart protocol to show where ischaemia, reperfusion and 
drug administration occurred. A. Normoxic (Norm) control, hearts perfused for 175 minutes 
with KHB. B. Ischaemia/Reperfusion control, following 20 minutes stabilisation, regional 
ischaemia induced for 35 minutes followed by 120 minutes reperfusion – perfused with KHB 
for all 175 minutes. C. Treatment groups, hearts perfused with KHB for 20 minutes reperfusion 
and 35 minutes regional ischaemia and then with KHB containing the appropriate drug 
concentrations for 120 minutes reperfusion. 
 
2.3.6   Evans blue and 2,3,5-triphenyltetrazolium chloride analysis 
 
To delineate the ischaemic from the non-ischaemic area, at the end of reperfusion the 
coronary arteries were re-ligated and the heart perfused with a 0.25% Evans blue 
saline solution. This enabled visual differentiation between the non-ischaemic area 
(which stained dark blue) and the ischaemic area, which did not stain (Figure 2.6).  
stabilisation ischaemia reperfusion 
0 20 55 175 Time (min) 
B. I/R Control 
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Figure 2.6: Representative image to show Evans blue staining following re-ligation of the 
coronary arteries at the end of reperfusion. Evans blue stains the non-ischaemic region of the 
myocardium in order to differentiate between the viable (non-ischaemic, which stains blue) 
and risk (area of the heart subjected to ischaemia/reperfusion protocol, which does not stain 
with Evans blue) zone. 
 
The hearts were immediately placed at -20 oC until frozen and then transversely sliced 
into 2 mm thick sections and incubated at 37 oC in a phosphate buffer solution 
containing 1% 2,3,5-triphenyltetrazolium chloride, for preservation and development 
of the staining, hearts were placed in a 10% formalin solution for 4 hours before 
analysis. After staining, the viable tissue in the ischaemic area appeared red 
(tetrazolium positive) distinguishing it from the infarct tissue which was pale and white 
(tetrazolium negative). The heart slices were compressed between two Perspex sheets. 
The viable, risk (tissue subjected to ischaemia but viable at the end of the experiment) 
and infarct (tissue subjected to ischaemia which was dead at the end of the 
experiment) tissue were traced onto acetate film (Figure 2.7). The process was blinded, 
to avoid bias, and respective hearts were traced onto acetate by a colleague who had 
no knowledge of the experimental groups. Computerised planimetry (using Image Tool 
as developed by the University of Texas Health Science Centre at San Antonio, 
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UTHSCSA) allowed the percentage of infarct tissue within the ischaemic area to be 
calculated (I/R%).  
 
Figure 2.7: Representative heart slices following Evans blue and TTC staining. A. Shows heart 
slices compressed between two Perspex sheets (blue tissue = viable, red = risk and pale/white 
tissue = infarct). B. Shows slices traced onto acetate film, prior to computerised planimetry 
(blue = viable, red = risk and green = infarct).  
 
2.3.7  Area at risk analysis 
 
In order to determine adequate ischaemia/reperfusion protocol had been followed, 
the area at risk (AAR%) percentage of all hearts subjected to the Langendorff I/R 
protocol was calculated (data not included in this thesis). Hearts where the AAR% 












2.4   Adult rat cardiac myocyte isolation 
 
Adult rat myocytes were isolated by enzymatic digestion of the extracellular matrix. 
Following sacrifice by cervical dislocation, rat hearts were quickly excised and mounted 
on a modified Langendorff apparatus for retrograde perfusion, at 7 ml.min-1, with a 
modified Krebs-Ringer’s buffer (KRB) (2 x 10-2 M NaHCO3, 1.16 x 10
-1 NaCl, 1.2 x 10-3 M 
KH2PO4, 5.4 x 10
-3 M KCl, 4 x 10-4 M MgSO4.7H2O, 1.2 x 10
-3 M glucose, 2 x 10-2 M 
taurine, 5 x 10-3 M sodium pyruvate, oxygenated with 95% O2, 5% CO2, pH 7.4 and 
maintained at 37 oC). After 2 minutes perfusion or until the heart ceased contracting 
and all blood had been washed out, the buffer was switched to KRB supplemented 
with 0.075% Worthingtons type II collagenase and 4.4 x 10-6 M CaCl2, which formed 
the digestion buffer. Hearts were perfused with the digestion buffer for 7 minutes 
prior to removal from the apparatus and separation of the ventricles from the atria 
and vascular tissue. The ventricular tissue was then minced and further incubated in 
the digestion buffer until enzymatic dissociation was complete. Myocytes were filtered 
through a nylon mesh, washed with 15 ml restoration buffer (1.16 x 10-1 M NaCl, 2.5 x 
10-2 M NaHCO3, 5.4 x 10
-3 M KCl, 4 x 10-4 M MgSO4.7.H2O, 1 x 10
-2 M glucose, 2 x 10-2 M 
taurine, 5 x 10-3 M pyruvate, 9 x 10-4 M Na2HPO4.12H2O, 1% BSA and 1% Pen-Strep, at 
37 oC and pH7.4, RB) and maintained, in RB at 37 oC whilst the Ca2+ concentration was 
gradually increased to 1.13 x 10-3 M to avoid calcium overload. This was via 
administration of 5, 34 µl, doses of 1 x 10-1 M CaCl2. Myocytes were subsequently 





Figure 2.8: Image taken from the confocal microscope showing adult rat ventricular 
myocytes following isolation via collagenase digestion, A and B delineate viable, 
striated, cardiac myocytes, whereas C shows a myocyte following hypercontracture 
and subsequent necrotic death (magnification x40).  
 
2.4.1  Hypoxia and re-oxygenation protocol 
 
Cardiac myocytes were incubated, in the same media, at 37 oC for 5 hours. Myocytes 
were retrieved from the incubator and both yields amalgamated into one 50 ml 
centrifuge tube. The cells were centrifuged at 500 rpm for 2 minutes after which the 
supernatant was removed and disposed of using a sterile pastette. The cells were re-
suspended in 10 ml RB (at 37 oC) and diluted to an adequate volume to allow for 1 ml 
per experimental group. 1 ml aliquot was removed and placed in a well on a 24 well 
plate for the normoxic control. This was placed in the incubator at 37 oC for the 
duration of hypoxia and re-oxygenation. The remaining myocytes were centrifuged, 
supernatant carefully decanted and re-suspended in 15 ml Esumi Ischaemic buffer (1.2 
x 10-2 M KCL, 4.9 x 10-4 M MgCl2, 9 x 10
-4 M CaCl2, 4 x 10
-3 M HEPES, 1 x 10-3 M 





a Petri dish and placed in a hypoxic chamber, pre-heated to 37 oC. The atmospheric air 
in the chamber was then removed by use of a suction pump and replaced with argon 
containing 5% CO2. The myocytes remained under hypoxic conditions for 2 hours, after 
which re-oxygenation was initiated by removal of the myocytes from the hypoxic 
chamber and transferring myocytes to a 50 ml centrifuge tube and spun at 500 rpm for 
2 minutes. The supernatant was removed, discarded and cells re-suspended in RB, to 
provide 1 ml per experimental group, giving the same concentration of cells in each 
well as the normoxic control. Cells were stored at 37 oC throughout re-oxygenation and 
re-oxygenation lasted for 4 hours before experimental use of myocytes. 
 
2.4.2  Incubation with drugs at the onset of re-oxygenation 
 
During centrifugation, concentrations of ipratropium, atropine, ACh and CsA were 
prepared in restoration buffer. A single 10 µl aliquot of each concentration was placed 
into its own well in a 24 well plate containing the normoxic control. The hypoxic 
myocytes were plated out at 1 ml per well in the 24 well plate. All drugs were evenly 
distributed throughout the cell suspension by gentle agitation using a pipette. 
Myocytes were then subjected to re-oxygenation for 4 hours before undergoing 
Fluorescence Activated Cell Sorting Analysis (FACS), using a FACS Calibur™ flow 
cytometer, to ascertain the proportions of live, apoptotic and necrotic cells as well as 





2.5  Acetylcholine assay 
 
Choline/acetylcholine assay kit (Abcam, UK, catalogue no. ab65345) was used to 
determine cell lysate acetylcholine levels in myocytes under normoxic conditions and 
those subjected to the H/R protocol. The kit consisted of choline assay buffer, a choline 
probe, choline enzyme mix, acetylcholinesterase and a 5 µmol choline standard. The 
assay was carried out in accordance with the manufacturer’s instruction (Abcam, UK). 
Briefly, working stock solutions were prepared whereby acetylcholinesterase and 
choline enzyme mix were separately dissolved in 220 µl choline assay buffer and the 
choline standard was dissolved in 100 µl choline standard buffer. Following cardiac 
myocyte isolation and hypoxia/re-oxygenation protocol (where necessary), cells were 
centrifuged briefly, counted via haemocytometer, and re-suspended in choline assay 
buffer to give 1 x 106 cells per well when plated in a 96 well mircoplate. The choline 









Volume in well 
End [Choline] in 
well 
0 150 50 µl 0 nmol/well 
6 144 50 µl 1 nmol/well 
12 138 50 µl 2 nmol/well 
18 132 50 µl 3 nmol/well 
24 126 50 µl 4 nmol/well 
30 120 50 µl 5 nmol/well 
 
Table 2.1: Volumes of provided reagents used to prepare the calibration curve required for 
extrapolation of acetylcholine concentrations in cardiac myocyte lysates in normoxic 
conditions and following hypoxia/re-oxygenation protocol. 
 
Standards were plated out in duplicate in the 96 well plate. The reaction mix was 




Reaction mix  
(for total choline) 
Reaction mix  
(for free choline) 
Choline assay buffer 44 µl 46 µl 
Choline probe 2 µl 2 µl 
Acetylcholinesterase 2 µl 0 µl 
Choline enzyme mix 2 µl 2 µl 
 
Table 2.2: Volumes of provided reagents used in order to prepare reaction mixes to ascertain 
levels of total and free choline in the standards (used to produce the calibration curve) and in 





50 µl of reaction mix was added to all wells (choline standards, acetylcholine control 
and myocytes), mixed and incubated in the dark for 30 minutes at room temperature 
(Figure 2.9, A). Colorimetric detection occurred via measurement on a microplate 
reader at OD 570 nm. Standard curves were plotted (Figure 2.9, B), which enabled 
















Figure 2.9: A. Representative 96-well plate showing the acetylcholine assay. Wells 1, 2, 3, 8, 9 
and 10 show choline standards (0, 1, 2, 3, 4 and 5 x 10-9 M, respectively), used to create the 
standard curve. Wells 4, 5 and 6 show adult ventricular cardiac myocytes (1 x 10-6 cells.ml-1). 
Well 7 shows acetylcholine, positive control (1 x10 -6 M of acetylcholine). B. Representative 
standard curve extrapolated from the OD at 570 nm of the choline standards, expressed as a 
mean of triplicates (n = 4).  
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2.6  MTT assay 
 
2.6.1   Principle of the technique 
 
3-(4,5-dimethylthizol-2-yl)-2,5-diphenyl tetrazolium bromide (thiazolyl blue 
tetrazolium bromide, MTT) is a yellow solid which, when reduced by NAD(P)H-
dependent oxidoreducatse enzymes, in particular mitochondrial succinate 
dehydrogenase, forms a purple formazan product. Eukaryotic cell membranes are 
permeable to MTT, which then localises in the mitochondria and is therefore exposed 
to mitochondrial succinate dehydrogenase. Following lysis of cells, the formazan 
becomes evenly distributed throughout the media and, thus, can be measured 
colorimetrically via spectrophotometry or microplate reader at OD 450 nm 
(Weyermann, Lochmann and Zimmer 2005). It is generally accepted that the depth of 
colour due to MTT reduction is directly proportional to the number of cells undergoing 
oxidative phosphorylation, and is therefore frequently used to ascertain cellular 
viability. Previous work has shown the MTT assay as a suitable means of determining 
cellular toxicity following exposure to various compounds and, in particular, has been 
used to assess cardiac myocyte viability (Arstall et al. 1999, Fu et al. 2007). 
 
2.6.2  MTT assay protocol 
 
Ventricular myocytes were counted via Nucleo-counter (Chemometec, Sartorius, 
Surrey, UK). This was confirmed by haemocytometer prior to re-suspension in Esumi 
ischaemic buffer (Esumi et al. 1991), and exposure to 2 hours hypoxia. To initiate re-
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oxygenation, myocytes were randomly assigned to drug treatment groups and re-
suspended at 1 x 106 cells.ml-1 in drug treated restoration buffer (ipratropium, CsA, ACh 
and ipratropium ± CsA or ACh). 1 x 10-5 myocytes (100 µl of myocyte suspension) were 
aliquotted per well in a 96 well microplate. Control wells were also set up whereby 
replicates of 100 µl of restoration buffer (with or without drugs) were produced and 
aliquotted into the 96 well plates (representative plate shown in Figure 2.10). Re-
oxygenation lasted 2 hours before all wells were treated with 20 µl MTT (5 mg.ml-1, in 
PBS) and incubated, in the dark, for a further 2 hours. 100 µl lysis buffer (20% SDS in 
50% N-N-Dimethylformamide) was administered to all groups and further incubated 
on an orbital shaker, in the dark, overnight, prior to colorimetric analysis at OD 450 nm 
via use of a microplate reader.  
 
 
Figure 2.10: Representative 96-well plate showing MTT assay showing adult rat ventricular 
myocytes following H2O2 treatment. Wells 1-5 and 7-10 show myocytes treated with increasing 
concentrations of H2O2 from 0 – 4 x 10
-4 M, from left to right. The depth of purple product 
decreases with decreased call viability, indicative of less mitochondrial dehydrogenase activity. 
Lane 6 shows the background control which contains all reagents, but no myocytes.  
 
Myocytes + H2O2 
[H2O2] 0 - 4 x10
-4 M 
Negative control 
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Myocytes + H2O2 
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In order to analyse the data, the mean absorbance of the negative control was 
subtracted from the mean absorbance of the respective treatment group and 
represented as the percentage change of MTT reductase activity, normalised to the 
untreated positive control. To confirm the method, increasing concentrations of 
hydrogen peroxide (H2O2) (from 0 – 4 x 10
-4 M) were used to create a curve indicative 
of cellular cytotoxicity (Figure 2.11).  
 
 
Figure 2.11: Representative scatter graph showing adult rat ventricular myocytes following 
H2O2 treatment, used to verify the protocol. Increases in H2O2 concentration lead to a dose 
responsive decrease in myocyte viability, as indicated by a decrease in the normalised MTT 
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2.7  Flow cytometric studies 
 
2.7.1   Principle of the method 
 
The underpinning principles of flow cytometry were first employed in a laboratory in 
1953 by Wallace H. Coulter. Flow cytometry is now a frequently utilised technique 
where protein expression and characteristics of cells can be ascertained by passing cell 
suspension through electronic detection apparatus. In particular, the equipment, 
known as a flow cytometer, is equipped with a laser, which illuminates particles or 
fluorochromes coupled to cells via specific antibodies. Cells can be labelled with highly 
specific antibodies which are either coupled, or secondarily stained, to fluorochromes. 
The levels of light are detected by the flow cytometer and converted to an electronic 
signal which passes to a computer system to allow quantitative analysis with use of 
computer software. The relative fluorescence values obtained corresponds to the 
levels of the labelled proteins. In this work, flow cytometry was implemented to assess 
proteins specific to viable, necrotic and apoptotic cells, as well as caspase-3, Akt and 
BAD. 
 
2.7.2 Preparation for fluorescence activated cell sorting (FACS) analysis: 
cell death assay 
 
The following protocol was used in order to discriminate the live, apoptotic and 
necrotic myocytes within a population. The exact percentages of each were then 
quantified by flow cytometric analysis using a FACS Calibur™ flow cytometer. 
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This was achieved using Vybrant® apoptosis assay kit with Allophycocyanine Annexin 
V, C-12 Resazurin and SYTOX® Green Stain. The apoptotic myocytes were identified via 
Allophycocyanine Annexin V which binds with high affinity to phosphatidylserine (PS), 
a protein expressed on the outer leaflet of the plasma membrane of apoptotic cells. C-
12 Resazurin is reduced by viable cells, therefore measurement of this protein allows 
for live cells to be identified. Finally, the population of necrotic cells present are 
identifiable as SYTOX® green stain binds specifically to cellular nucleic acids present in 
necrotic cells. 
A 1 x Annexin V buffer was prepared by diluting 4 ml 5 x Annexin binding buffer (5 x 10-
2 M) HEPES, 7 x 10-1 M NaCl, 1.25 x 10-2 M CaCl2, pH 7.4) in 16 ml ddH2O. The three 
fluorochromes were prepared as stated in the protocol. A 5 x 10-5 M working stock of 
C-12 resazurin (Component B) was achieved by making a 5% solution of 1 x 10
-3 M C-12 
Resazurin stock dissolved in Dimethylsulfoxide (DMSO). A 1 x 10-6 M SYTOX Green 
working stock (Component C) was prepared by producing a 10% solution of 1 x 10 -5 M 
SYTOX Green stock in 1 x Annexin V buffer, and then stored at -20 oC. Allophycocyanine 
Annexin V (2.5 x 10-2 M HEPES, 1.4 x 10-1 M NaCl, 1 x 10-3 M EDTA, pH 7.4, plus 0.1% 
bovine serum albumin (Component A)) did not require dilution before use. 
1.5 ml Eppendorf centrifuge tubes were labelled for all concentrations of ipratropium 
bromide used and normoxic and H/R controls. Myocytes were taken from the 
incubator and removed from the 24 well plate into their respective 1.5 ml centrifuge 
tube. Cells were centrifuged at 500 rpm for 2 minutes before washing with 300 µl 1 x 
Annexin V buffer and spinning again at 500 rpm for 2 minutes. The supernatant was 
aspirated and discarded. 1 µl of, both components, B and C, 1.5 µl of component A and 
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100 µl of 1 x Annexin V buffer was added to each tube and lightly agitated to re-
suspend the cells and distribute the dyes. After this, all tubes containing cells were 
wrapped in foil, to avoid loss of fluorescence, and incubated at 37 oC for 15 minutes. 
When the incubation period had elapsed, 400 µl of 1 x Annexin V buffer was added to 
each tube and the cells re-suspended, finalising the preparation for FACS analysis. 
The fluorochromes used in this kit were deemed to be appropriate as the excitability 
and emission wavelengths differ on all three fluorochromes and their emission peaks 
do not overlap. Therefore, when analysed on the FL-2 and FL-4 wavelengths, three 
distinct populations, representing live, necrotic and apoptotic cells which are easily 
distinguishable from one another can be seen. Thereby giving results which clearly 
showed how many cells in the population were live, necrotic or apoptotic. The 
software (Cell Quest®) enabled this as quadrants were plotted into which the different 
populations fell, as illustrated below (Figure 2.12). The software was setup to count 
the first 10,000 events, therefore counting cells in preparation for FACS analysis was 
not necessary. The protocol used was according to the manufacturer’s instructions 
(Invitrogen, Paisley, UK). 
 
Figure 2.12: Representative flow scattergrams showing the different quadrants for viable, 
apoptotic and necrotic myocytes following FACS analysis with the Vybrant® Apoptosis Assay 
Kit. Panel A. represents normoxic myocytes and B. Myocytes subjected to the 
hypoxia/reoxygenation protocol.  






In order to ascertain that the H/R protocol had been successful, significant differences 
between the levels of viable, apoptotic and necrotic myocytes were required in 
comparison with normoxic myocytes which were not subjected to the H/R protocol (as 
depicted in Figure 2.13). 
 
Figure 2.13: The effect of H/R protocol on levels of viable, apoptotic and necrotic cardiac 
myocytes as determined by the Vybrant® Apoptosis Assay Kit. For all studies conducted using 
this method, normoxic myocytes were analysed to ensure that the H/R protocol had been 









2.4.6 Preparation for fluorescence activated cell sorting (FACS) 
analysis: caspase-3, Akt and BAD assays 
 
The protocol for the intracellular staining of cleaved caspase-3 and phospho-Akt were 
identical, with the exception of the antibody used. In both cases, the antibody was 
conjugated to a fluorochrome, which was Alexa Fluor® 488 and Alexa Fluor® 647 
fluorescent dyes for cleaved caspase-3 and phospho-Akt (Ser473) protocols 
respectively. As phospho-BAD (Ser112) primary antibody was not conjugated to a 
fluorochrome, the protocol was modified to allow for incubation with a secondary, 
fluorescent antibody prior to flow cytometric analysis. All antibodies were specific 
solely for the activated form of the proteins, being the cleaved caspase-3 protein and 
phosphorylated Akt (Ser473) and BAD (Ser112) proteins. The proteins were of particular 
interest as cleaved caspase-3 and BAD are commonly involved in the activation of 
apoptotic pathways and Akt is commonly activated by phosphorylation to inhibit 
apoptotic processes, and is a component of the reperfusion injury salvage kinase (RISK) 
pathway. All three proteins have been previously shown to play an instrumental role in 
the regulation of myocardial I/R injury. 
After the 4 hour re-oxygenation period, the myocytes were transferred from the 24 
well plate to labelled 1.5 ml Eppendorf® centrifuge tubes, as in the cell death assay 
protocol. The cells were centrifuged at 1200 rpm for 2 minutes before the supernatant 
was aspirated and discarded. The cells were re-suspended in 250 µl phosphate 
buffered saline (PBS) before 250 µl 6% formaldehyde solution was added (to give final 
concentration of 3% formaldehyde). The cells were fixed by incubating for 10 minutes 
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at 37 oC, followed by 1 minute incubation on ice. The myocytes were then centrifuged 
at 1200 rpm for 2 minutes, after which the supernatant was removed.  
The cell membranes were then permeabilised by re-suspending in ice-cold 90% 
methanol solution and incubating on ice for 30 minutes. Following permeabilisation, all 
samples were washed twice with 0.5% BSA diluted in PBS (incubation buffer) at 4 oC. 
This involved centrifugation at 1200 rpm for 2 minutes, removal of the supernatant 
and subsequent re-suspension in incubation buffer all of which were repeated for the 
second wash. Myocytes were spun at 1200 rpm for 2 minutes and, following aspiration 
of the supernatant, re-suspended in 100 µl incubation buffer before 10 minutes 
incubation at room temperature. During this incubation period, the antibody dilutions 
were prepared to give a final volume of 100 µl per tube with 1:100 dilution of 
antibody.  
Once the incubation period had elapsed, the myocytes were centrifuged at 1200 rpm 
for 2 minutes. The supernatant was removed and cells re-suspended in 100 µl of the 
prepared antibody dilution. All tubes containing cells were covered in foil, to eliminate 
any loss of fluorescence, and incubated for 1 hour at room temperature. At the end of 
this time the cells were centrifuged at 1200 rpm for 2 minutes and washed once in 
incubation buffer as previously described.  
The cells were re-suspended in 500 µl PBS thereby allowing for immediate FACS 
analysis using the FL-1 channel as both Alexa Fluor® 488 and Alexa Fluor® 647 are 
excited and emit on this channel by red light. Cell Quest® software was used to plot 
histograms for each group (all concentrations of ipratropium, normoxic control and 
H/R control) showing the mean fluorescence of 10,000 cell counts.  
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For the studies where levels of phospho-BAD were measured, the primary antibody 
was not conjugated to a fluorochrome. Therefore, following the final wash in 
incubation buffer, myocytes were re-suspended in 200 µl of incubation buffer per tube 
with 1:1000 dilution of secondary Alexa Fluor® 488 antibody for 30 minutes at room 
temperature in the dark. Cells were centrifuged for 2 minutes at 1200 rpm and washed 
twice with 200 µl incubation buffer, as before, prior to re-suspension in 500 µl PBS and 
analysis on the flow cytometer. These protocols allowed quantification of the levels of 
cleaved caspase-3, phosphorylated-Akt and phosphorylated-BAD, depending on the 
assay. These protocols were carried out according to the manufacturer’s instructions 
(New England Biolabs, Hitchin, UK).  
Figures 2.14, 2.15 and 2.16 show representative scatter plots from the flow cytometer 
indicating the levels of caspase-3, Akt (Ser473) and BAD (Ser112), respectively, in 
myocytes under normoxic conditions (panel A for all Figures) and following H/R 
protocol (panel B) and following H/R and ipratropium administration at the onset of 
re-oxygenation (panel C).  
 
Figure 2.14: Representative flow cytometric scatter plots to show levels of activated cleaved 
caspase-3 in normoxic cardiac myocytes (A), following hypoxia/re-oxygenation protocol (B) 
and with ipratropium administration at the onset of re-oxygenation (C). Arrows indicate the 
peaks which represent cleaved caspase-3 levels. 





Figure 2.15: Representative flow cytometric scatter plots to show levels of phosphorylated Akt 
(Ser473) in normoxic cardiac myocytes (A), following hypoxia/re-oxygenation protocol (B) and 
with ipratropium administration at the onset of re-oxygenation (C). Arrows indicate the peaks 




Figure 2.16: Representative flow cytometric scatter plots to show levels of phosphorylated 
BAD (Ser112) in normoxic cardiac myocytes (A), following hypoxia/re-oxygenation protocol (B) 
and with ipratropium administration at the onset of re-oxygenation (C). Arrows indicate the 
peaks which represent phosphorylated BAD levels. 
 
  
A. Normoxia B. H/R C. Ip (1 x 10-7 M) 
A. Normoxia B. H/R C. Ip (1 x 10-7 M) 
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2.5  Myocyte model of oxidative stress 
 
2.5.1  Experimental protocol 
 
Ventricular myocytes were plated onto laminin coated Petri dishes (35 mm diameter) 
and incubated for ≥2 hours to allow adhesion of the cells. The supernatant, including 
affluent cells was aspirated and discarded. The adhered myocytes were incubated in 
microscopy buffer (modified Krebs-Ringer’s buffer with 1 x 10-2 M HEPES and 1.2 x 10-6 
M CaCl2) containing 3 x 10
-6 M, tetramethylrhodamine methyl ester (TMRM) for 15 
minutes. Cells were washed with microscopy buffer and then incubated for a further 
10 minutes as detailed below. Plates of cells were randomly assigned to one of the 
drug treatment groups and incubated for a further 15 minutes with 1 x 10-9 M – 1 x 10-
7 M ipratropium, 2 x 10-6 M FCCP, 2 x 10-7 M CsA, 1 x 10-7 M ACh or 1 x 10 -7 M 
ipratropium ± CsA or ACh (concentrations as before). To view and analyse myocytes, 
dishes were placed on the stage of a Zeiss 510 CLSM confocal microscope equipped 
with 20x objective lens (NA 1.3) and a heated chamber. A 585-nm long pass filter 
allowed detection of TMRM when viewing the cells. Recording and analysis was 
facilitated by use of the Zeiss software package, LSM® (version 2.8). Laser stimulation 
via 543-nm emission line of HeNe laser was used to induce oxidative stress. Prior to 
laser stimulation, the cationic TMRM selectively localises in the negatively charged 
inner-membrane of the mitochondrion in a potential-dependent manner. Laser 
stimulation initiates photodecomposition of TMRM thus generating mitochondrial 
reactive oxygen species, leading to disruption of the mitochondrial membrane. 
Depolarisation (Dep) (Figures 2.17 and 2.18) was measured as the time at which the 
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TMRM started to become evenly distributed throughout the cell and is indicative of 
loss of mitochondrial membrane potential. Subsequent hypercontracture (Hyp) of 
myocytes occurs shortly afterwards due to ATP depletion. The time to both Dep and 
Hyp were recorded. 
 
Figure 2.17: A, B and C show TMRM loaded adult rat ventricular myocytes as viewed at x40 
magnification under a confocal microscope. A .shows a myocyte prior to depolarisation where 
TMRM can been seen as isolated, yellow areas within the myocyte, indicative of TMRM 
localised in the mitochondria.  B. shows a myocyte following depolarisation where TMRM 
passes into the cytosol, as shown by movement of fluorescence across the myocyte. C. Shows 
a myocyte following hypercontracture due to ATP depletion. Panel D is a representative trace 
from LSM® (version 2.8), where the intensity of fluorescence was measured following laser 
stimulation. The increase in intensity, as shown, is indicative of the initiation of depolarisation. 
 
 
Figure 2.18: Representative TMRM loaded adult rat ventricular myocyte as exposed to 
oxidative stress following laser stimulation. Panel 1 shows the myocyte prior to depolarisation, 
2 and 3 show the onset of and late depolarisation. Panel 4 shows hypercontraction of the 
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2.6  Western Blotting 
 
2.6.1  Background to the method 
 
Despite some controversy as to who initially developed the technique, Western 
blotting is generally attributed to Harry Towbin’s laboratory in 1979 (Towbin 2009). 
The principle builds on that of Southern blotting except instead of separation and 
identification of DNA, proteins are electrophoretically separated on the basis of their 
molecular weight. Following electrophoresis, proteins are transferred onto a 
membrane (generally PVDF) and then the proteins of interest can be identified via 
specific antibody binding. The levels of specific proteins can then be visualised and 
identified via computerised densitometry. 
 
2.6.2  Tissue preparation 
 
In order to collect tissue for Western blots, a modified perfused rat heart protocol was 
used. Briefly, hearts were mounted and perfused with KHB, as before, for a period of 
20 mins stabilisation, 35 mins ischaemia and 5, 15 or 120 mins reperfusion (protocol 
represented in Figure 2.19). As hemodynamic function was not ascertained, atriotomy 
did not occur. Ischaemia and drug administration were conducted as previously 
described, and the following experimental groups were used: normoxic, I/R control, 1 
x10-9 M – 1 x 10-7 M ipratropium, 2 x 10-7 M CsA, 1 x 10-7 M ACh or 1 x 10 -7 M 
ipratropium ± CsA or ACh (concentrations as before). Following reperfusion, hearts 
were dissected to remove the risk area of the left ventricle. The tissue was then 
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immediately wrapped in foil and placed in liquid nitrogen until frozen. All tissue for 
Western blotting analysis was then stored at -80 oC before preparation for 
experimental use.  
 
Figure 2.19: Experimental protocol to detail time points at which tissue was collected for 
Western blot analysis. For all groups subjected to drug administration, all drugs were 
administered at the onset of reperfusion and hearts were perfused with KHB containing the 
drugs for the entire reperfusion period. 
 
2.6.2 Tissue homogenisation, protein concentration estimation and 
storage 
 
Tissue was homogenised with use of an IKA Labortechnik T25 homogeniser in 400 µl 
lysis buffer (1 x 10-1 M NaCl, 1 x 10-2 M Tris Base (pH 7.6), 1 x 10-3 M EDTA (pH 8.0), 2 x 
10-3 M Sodium pyrophosphate, 2 x10-3 M NaF, 2 x 10-3 M β-glycerophosphate, 0.1 
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labelled 1.5 ml centrifuge tubes and centrifuged at 11,000 rpm for 10 minutes (at 4 oC). 
The supernatant, containing protein, was collected and transferred into clean 1.5 ml 
centrifuge tubes. The pelleted homogenate was discarded. 
Protein concentration was ascertained via NanoDrop spectrophotometric analysis at 
280 nm with use of a NanoDrop 1000 Spectrophotometer (NanoDrop Technology, 
Delaware, USA). 100 µl of each sample was then diluted in 100 µl of sample buffer (2.5 
x 10-1 M Tris-HCl (pH 6.8), 10% Glycerol, 0.006% Bromophenol blue, 4% SDS, β-
mercaptoethanol (pH 6.8)) and subsequently incubated at 95 oC for 10 minutes. All 
samples were stored at -20 oC before defrosting for experimental use. 
 
2.6.3  Electrophoresis and blotting protocol 
 
Dilution in sample buffer (2.5 x 10-1 M Tris-HCl (pH 6.8), 10% Glycerol, 0.006% 
Bromophenol blue, 4% SDS, β-mercaptoethanol (pH 6.8)) occurred to provide 60 µg 
protein for each sample to be separated via electrophoresis using precast gels and 
Mini PROTEAN II system (both Bio-Rad, Hemel Hempstead, UK). Gels were placed in 
the electrode assembly unit and the inner chamber was filled with approximately 125 
ml running buffer (14.42 g.l-1 glycine, 1.0 g.l-1 SDS, 3.0 g.l-1 Tris Base). The plastic combs 
were removed from the gels and wells were loaded with 15 µl of sample buffer and 
protein sample, which contained 60 µg protein. Molecular weight markers were used 
in at least one well per gel (New England Biolabs, Ipswich, MA, USA or Bio-Rad, Hemel 
Hempstead, UK). Electrophoresis took place for 90 minutes at 130 V, with use of a 
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Power-Pac 3000 (Bio-Rad, Hemel Hempstead, UK) (representative image showing 
electrophoresis in Figure 2.20).  
 
 
Figure 2.20: Photograph to show gel electrophoretic separation of homogenised adult rat 
ventricular tissue in sample buffer. As denoted by the pre-cast gels, wells were labelled 1-12 
and the movement of the sample can be seen as the blue dye (sample buffer, containing 
protein) moving from the bottom of the wells. 
 
Transfer to the membrane occurred via use of BioRad TransBlot Turbo system prior to 
blocking (TBST + 5% milk) and incubation with primary antibody, phospho-Akt (Ser473), 
phospho-Erk1/2 (Thr202/Thr204), phospho-SAPK/JNK (Thr183/Tyr185), overnight, at 4 
oC. 
Following 3 x 5 minute washes with TBST, all membranes were incubated with anti-
rabbit IgG, HRP-linked antibody on an orbital shaker for 2 hours, at room temperature. 
After 3 x 5 minute washes with TBST, membranes were subsequently probed and 
analysed using SuperSignal West Femto® (Thermo) and Quantity One® (Bio-Rad) 
software for densitometric analysis. Membranes were stripped in boiling water for five 
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minutes, prior to incubation overnight, with primary Akt, Erk1/2 or JNK in order to 
ascertain levels of total protein in the samples (analysed as above). Following 
densitometric analysis for total protein, all membranes were stripped and probed for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), (visualised and analysed as 
before) in order to assess equal loading. For all three proteins assessed and at all time 
points studied, it was necessary to identify significant differences between normoxic 
and I/R treatment groups to show that the experimental protocol had been successful 
(representative plots are shown in Figure 2.21). 
 
Figure 2.21: Representative Western blots to show the differences between basal (normoxic, 
norm) levels of (A) phospho-Akt, (B) phospho Erk1/2 and (C) phospho-JNK, and following 20 
minutes stabilisation, 35 minutes regional ischaemia and 5, 15 and 120 minutes reperfusion. 
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2.7  Statistical Analysis 
 
For all data, results were presented as group means + standard error of the mean 
(SEM) and statistical significance was ascertained using SPSS statistical software (IBM® 
SPSS® Statistics, version 20).  
For all data, SPSS was employed to analyse data via use of a one-way ANOVA (analysis 
of variance) and Fisher’s LSD (least significant difference) post hoc test. A p value of 
≤0.05 was considered as being statistically significant.  
The only exception to this was that for all haemodynamic parameters (LVDP, HR and 
CF) were expressed as a percentage of the mean value for stabilisation (first 20 
minutes). Data were analysed using a two way ANOVA, also with Fisher’s LSD post hoc. 
A p value of ≤0.05 was considered as being statistically significant. 
2.8  Exclusion Criteria 
 
For the Langendorff studies, after the initial 20 minutes stabilisation period, hearts 
were excluded from further experimental protocol if they exhibited one of more of the 
following: Average LVDP of less than 100 mmHg, average heart rate of less than 250 
bpm, average coronary flow of >20 ml.min-1 or obvious, persistent arrhythmias (as 
determined via visual inspection of the heart and LabChart trace). 
Successful ischaemia was established by significant decrease (minimum 30%) in the 
LVDP and coronary flow as well as myocardial blanching at the site of the snare. 
Following analysis of haemodynamic function, hearts which did not comply with these 
were excluded from the study. 
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Following the myocyte isolation protocol, myocyte isolations producing less than 65% 
viability were disregarded. In addition, myocyte isolations not exhibiting clear 
striations were also excluded from the study. Any myocytes from isolations where 
myocyte plasma membrane blebbing was apparent were considered as apoptotic, and 
therefore non-viable, and also excluded. Following H/R, a 40% drop in cell viability was 




Chapter 3  Ipratropium exacerbates myocardial injury 
following simulated ischaemia/reperfusion in 
vitro 
 
3.1  Chapter introduction and purpose 
 
Within the past decade, there has been much controversy as to whether anti-
cholinergic drugs are associated with increased risk of adverse cardiovascular 
outcomes in COPD patients, especially those with underlying IHD (Anthonisen et al. 
2002, Guite, Dundas and Burney 1999, Lee et al. 2008, Macie et al. 2008, Ringbaek and 
Viskum 2003, Singh, Loke and Furberg 2008, Wedzicha et al. 2008). In particular, a 
meta-analysis conducted by Singh et al.,in 2008, indicated a 52% increase in risk of 
mortality due to greater severity and occurrence of cardiovascular events, including 
MI, due to long-term bronchodilator use, in particular anti-cholinergics (Singh, Loke 
and Furberg 2008). In addition to this, the majority of COPD patients die from 
cardiovascular disease with a purported 22% due to complications following an 
ischaemic event (Lofdahl et al. 2007). COPD is emerging as a disease with multiple 
causes and co-morbidities, the most common of which is underlying IHD, attributed to 
underlying, systemic inflammation (Macnee, Maclay and McAllister 2008). However, 
despite this, to our knowledge, there have been no non-clinical studies to assess the 
effects of anti-cholinergic compounds, such as ipratropium, in the setting of IHD or MI. 
Ipratropium is a non-selective muscarinic antagonist which has been prescribed for the 
treatment of COPD and, more recently, as an adjunct therapy for asthma for over 30 
years (Bathoorn et al. 2008). Within the pulmonary system, the antagonist action of 
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ipratropium (primarily at the M3 muscarinic receptor subtype) elicits bronchodilation 
via inhibition of acetylcholine induced smooth muscle contraction (Bathoorn et al. 
2008), as described in detail in Chapter 1, Section 1.9.6. This is therapeutically 
beneficial as it results in facilitated airflow, thereby ameliorating symptoms of COPD 
exacerbations (Restrepo 2007).  
Clinically, ipratropium is administered by inhalation either through nebulisation or 
inhaler. Although an extremely effective drug delivery mechanism, inhalers are one of 
the most frequently abused pharmacological interventions as patients frequently 
administer doses which are higher than prescribed, and also, it is postulated that up to 
90% of the drug may be swallowed rather than inhaled. The bioavailability of 
ipratropium is considered to be approximately 6.9% (Montuschi et al. 2013). In 
combination, these factors therefore give rise to the potential of ipratropium to 
antagonise muscarinic receptors outside the respiratory system and, of particular focus 
in this study, in the cardiovascular system. 
Within the cardiovascular system, endogenous ACh agonise mAChRs (specifically M1, 
M2 and M3 subtypes), and has been shown to couple to cytoprotective downstream 
signalling (Borroto-Escuela et al. 2010, Li et al. 2011, Wang et al. 2012).  
It is postulated that ipratropium is able to displace ACh at cardiac mAChRs, therefore 
inhibiting protective downstream pathways. Endogenous muscarinic activation by ACh 
has also revealed cytoprotective properties against various cellular insults, including 
conditions of myocardial I/R injury (Budd et al. 2003, Buys et al. 2003, Critz, Cohen and 
Downey 2005, De Sarno et al. 2003, Krieg et al. 2002, Li et al. 2011, Resende and 
Adhikari 2009). This includes mechanisms which protect against hypoxia induced 
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apoptosis (Kim et al. 2008a, Liu et al. 2011a) by regulation of Bcl-2 family proteins and 
caspase-3, a pivotal caspase in the machinery leading to apoptotic death. In addition to 
this, activation of the pro-survival kinases Akt and Erk1/2, following ACh induced 
muscarinic activation, have been shown as cardioprotective via mechanisms which 
limit apoptosis and inhibit mPTP opening during reperfusion (Sun et al. 2010a, Zang, 
Sun and Yu 2007).  
Further to this, Shaik et al have demonstrated that ipratropium is capable of eliciting 
suicidal erythrocyte death (eryptosis) via a mechanism due to stimulation of increased 
cytosolic Ca2+ activity (Shaik et al. 2012). Despite differences between eryptosis and 
apoptosis, as apoptosis only occurs in nucleated cells, both of these processes can be 
initiated by increases in Ca2+ concentration, indicating that ipratropium may have the 
ability to also trigger apoptosis.  
Tiotropium bromide (tiotropium, a specific M3 antagonist also used for the treatment 
of COPD) has revealed effects which limit acetylcholine mediated fibroblast 
proliferation (Pieper et al., 2007). This has been further characterised as involving 
MAPK pathways (particularly Erk1/2 and JNK) (Asano et al. 2010). Although this is 
clinically beneficial in the context of COPD patients as it limits pulmonary fibrosis and 
scarring (Pera et al. 2011), it also indicates that anti-cholinergics are capable of eliciting 
anti-proliferative properties by the blockade of normal mAChR signalling.  
It has also been suggested that peripheral blood T-lymphocyte (in particular CD8+) 
directed apoptosis is increased due to administration of tiotropium bromide and 
Hemicholinium-3 (a compound which limits the re-uptake of choline, thus limiting 
acetylcholine synthesis) (Profita et al. 2011). As aforementioned, this is a clinically 
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beneficial trait, and provides potentially putative pharmacological targets for emerging 
COPD treatments to limit inflammation. However, taken in combination, in the context 
of I/R, it could be possible that the limitation of cellular proliferation via anti-
cholinergic administration may abrogate the endogenous protective mechanisms of 
acetylcholine, thereby promoting a shift from muscarinic-driven cytoprotective 
mechanisms towards pathways which may promote myocyte death. Previous work has 
also shown that antagonists of the M3 muscarinic subtypes are pro-apoptotic as well 
as, in the context of cancer, ACh secreting tumours have been shown to stimulate 
tumour growth, which is limited by the addition of a muscarinic antagonist (Rosso, 
2014).  
In this study, it was proposed that the antagonist action of ipratropium may prevent 
the protective mechanism of acetylcholine and induce myocardial injury. 
The purpose of this study was to determine whether ipratropium was capable of 
eliciting a toxic effect under normoxic conditions and, also, the effect of ipratropium 
bromide administration in the context of simulated I/R in isolated perfused rat heart (1 
x 10-9 M – 1 x 10-6 M) and primary rat ventricular myocyte models (1 x 1 0-11 M – 1 x 10-
4 M). Acetylcholine (1 x 10-7 M) was also administered concomitantly with ipratropium 
to ascertain whether the observed effects of ipratropium were due to a specific action 
on the muscarinic receptors. The involvement of apoptosis, necrosis and cleaved 
caspase-3 were evaluated by flow cytometry. Additional experiments were undertaken 
via the use of Z-DEVD-FMK (DEVD, 7 x 10-8 M), a potent caspase-3 inhibitor, to confirm 
whether the observed effects of ipratropium were dependent on caspase-3 activation. 
Further to this, Atropine (1 x 10-7 M), another non-selective muscarinic antagonist was 
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used to support the hypothesis that it was the action of ipratropium at the muscarinic 





3.2  Methods 
  
 
Adult, male, Sprague-Dawley rats (300 g ± 50 g body weight) were used throughout the 
experiments detailed in this chapter. All experiments were subject to the exclusion 
criteria detailed in Chapter 2, Section 2.8. For all data, results were presented a group 
means + standard error of the mean (SEM). For the flow cytometry data, values were 
normalised to the respective untreated control, which was represented as 100%. 
Statistical differences were ascertained with the use of one-way ANOVA, with the 
exception of haemodynamics which where a two-way ANOVA was employed, and 
Fisher’s LSD post-hoc test. 
 
3.2.1  Isolated perfused rat heart model  
 
Following sacrifice by cervical dislocation and excision, rat hearts were mounted on 
Langendorff perfusion apparatus. For the normoxic studies, hearts were subjected to 
retrograde perfusion for a total of 175 minutes, ipratropium (1 x 10-8 M – 1 x 10-6 M) 
was administered following 55 minutes stabilisation, for the remaining 120 minutes of 
the experiment. This protocol was used in order to time-match Langendorff 
experiments where the I/R protocol was used. For the experiments using the 
Langendorff model of I/R (further detail in Section2.3.4), ipratropium (1 x 10-7 M) was 
added at different time points (0 mins, 20 mins, 40 mins and 55 mins) following the 
start of the experiment. In subsequent experiments, ipratropium (1 x 10-9 M – 1 x 10-6 
M), acetylcholine (1 x 10-7 M), atropine (1 x 10-7 M) and DEVD (7 x 10-8 M)  as well as 
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ipratropium (1 x 10-7 M) + acetylcholine (1 x 10-7 M), atropine (1 x 10-7 M) + 
acetylcholine (1 x 10-7 M) and  ipratropium (1 x 10-7 M) + DEVD (7 x 10-8 M) were 
administered after 55 mins, the onset of reperfusion. At the end of the experimental 
protocol, infarct size to risk ratio (I/R %) was determined via Evans blue and TTC 
staining. Throughout all experiments, left ventricular developed pressure (LVDP, 
mmHg), heart rate (HR, beats.min-1) and coronary flow (CF, ml.min-1) were measured 
to assess the stability of the hearts. 
 
3.2.2  Analysis of adult rat ventricular myocytes via flow cytometry 
 
Throughout these studies, simulated I/R was achieved in isolated ventricular rat 
myocytes using a hypoxia/re-oxygenation protocol (as described in further detail in 
Section 2.4.1). For the normoxic study, isolated cardiac myocytes were incubated with 
ipratropium (1 x 10-11 M – 1 x 10-6 M) for four hours prior to flow cytometric analysis 
for apoptosis, necrosis and viable myocytes. For the hypoxia/re-oxygenation (H/R) 
studies, ipratropium (1 x 10-9 M – 1 x 10-6 M), acetylcholine (1 x 10-7 M) and atropine (1 
x 10-7 M) )  as well as ipratropium (1 x 10-7 M) + acetylcholine (1 x 10-7 M), atropine (1 x 
10-7 M) + acetylcholine (1 x 10-7 M),  were administered for four hours, following two 
hours hypoxia. At the end of the experimental protocol, caspase-3, apoptosis, necrosis 





3.2.3  Analysis of adult rat ventricular myocytes via MTT assay 
 
Isolated adult rat ventricular myocytes underwent two hours hypoxia after which, at 
the onset of re-oxygenation, ipratropium (1 x 10-9 M – 1 x 10-6 M), acetylcholine (1 x 
10-7 M) and atropine (1 x 10-7 M) )  as well as ipratropium (1 x 10-7 M) + acetylcholine (1 
x 10-7 M), atropine (1 x 10-7 M) + acetylcholine (1 x 10-7 M) were administered for four 
hours, in the precence of MTT. Myocytes were subsequently lysed and analysed for 
MTT reductase activity. 
 
3.2.4  Acetylcholine assay 
 
Choline/Acetylcholine Assay Kit (Abcam, UK) was used to determine cell lysate 
acetylcholine levels in myocytes under normoxic conditions and those subjected to the 




3.3  Results 
 
3.3.1  Isolated perfused rat heart pilot experiments 
 
The initial study was designed in order to establish whether ipratropium was capable 
of eliciting myocardial injury under normoxic conditions, in both perfused Langendorff 
hearts and isolated adult rat ventricular myocytes. 
 
3.3.1.1  The effect of ipratropium on infarct development (I/R %) when 
administered under normoxic conditions 
 
Isolated perfused rat hearts were subjected to 55 minutes perfusion with Krebs 
Heinsleit Buffer (KHB) prior to administration of ipratropium (1 x 10-8 M – 1 x 10-6 M) 
for 120 minutes. Infarct development was ascertained as a percentage of tetrazolium 
negative tissue compared with tetrazolium positive tissue (Infarct/Risk (%), I/R%). 
These data demonstrated that in comparison with the untreated normoxic control (5.8 
± 1.7%) there was no statistical increase in I/R% with any of the concentrations of 
ipratropium tested (8.7 ± 3.5% (1 x 10-8 M), 9.6 ± 2.2% (1 x 10-7 M), 7.2 ± 2.5% (1 x 10-6 





Figure 3.1: Infarct development in normoxic perfused isolated rat hearts. Following 55 minutes 
perfusion, ipratropium (1 x 10-8 M – 1 x 10-6 M) was administered for 120 minutes. Results are 
presented as Infarct size to risk ratio (%). Results expressed as arithmetic mean + SEM, n=5 for 
all groups, p>0.05. 
 
3.3.1.2  Haemodynamic parameters 
 
Throughout all Langendorff preparation experiments, left ventricular developed 
pressure (LVDP), heart rate (HR) and coronary flow (CF) were recorded every five 
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3.3.1.3  Left ventricular developed pressure (LVDP) 
 
Left ventricular developed pressure (LVDP) was ascertained via use of a water filled 
latex balloon, coupled to a pressure transducer, which was inserted into the left 
ventricle. Results are expressed as a percentage of the mean LVDP during the 
stabilisation period (first 20 minutes). There was no significant difference in LVDP in 
comparison with the normoxic control with the hearts treated with ipratropium (1 x 
10-8 M) at any time point. However, at the 75, 90, 105 and 120 minutes time points, 
both 1 x 10-7 M and 1 x 10-6 M ipratropium showed a significant increase in LVDP in 













Figure 3.2: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 55 minutes perfusion with KHB (20 minutes stabilisation) followed by 120 
minutes perfusion with KHB ± ipratropium (1 x 10-8 M – 1 x 10-6 M). *p<0.05, Ip (1 x 10-7 M and 
1 x 10-6 M) vs. untreated control. Values expressed as mean percentage of the stabilisation 
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3.3.1.4  Heart rate (HR) 
 
Heart rate (HR) was also measured via use of a water filled latex balloon, coupled to a 
pressure transducer, which was inserted into the left ventricle. Results are expressed 
as a percentage of the mean HR during the stabilisation period (first 20 minutes). 
There was no significant difference in HR in comparison with the normoxic control with 
the hearts treated with ipratropium (1 x 10-8 M – 1 x 10-6 M) at any time point (Figure 
3.3).  
 
Figure 3.3: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 55 minutes 
perfusion with KLB (20 minutes stabilisation) followed by 120 minutes perfusion with KHB ± 
ipratropium (1 x 10-8 M – 1 x 10-6 M). Values expressed as mean percentage of the stabilisation 
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3.3.1.5 Coronary flow (CF) 
 
Coronary flow (CF) measurements were taken by collecting and recording the volume 
of coronary effluent from perfused hearts for one minute. Results are expressed as a 
percentage of the mean CF during the stabilisation period (first 20 minutes). There was 
no significant difference in CF in comparison with the normoxic control with the hearts 
treated with ipratropium (1 x 10-8 M – 1 x 10-6 M) at any time point (Figure 3.4).  
 
Figure 3.4: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 55 
minutes perfusion with KLB (20 minutes stabilisation) followed by 120 minutes perfusion with 
KHB ± ipratropium (1 x 10-8 M – 1 x 10-6 M). Values expressed as mean percentage of the 
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3.3.2 Assessment of viable, apoptotic and necrotic primary cardiac 
myocytes under normoxic conditions exposed to ipratropium 
treatment 
 
This study was carried out to ascertain whether ipratropium (1 x 10-11 M – 1 x 10-6 M) 
had an effect on cellular viability, apoptosis or necrosis in isolated adult rat ventricular 
myocytes. Following isolation, normoxic myocytes were exposed to ipratropium 
treatment for 6 hours and relative cell populations were determined via use of flow 
cytometry using Vybrant® Apoptosis Assay Kit #10 (Figure 3.5). There was no statistical 
change in myocyte viability, apoptosis or necrosis in the ipratropium treated groups in 


























Figure 3.5: Representative flow cytometric scatter graphs (A) showing viable, apoptotic and 
necrotic cell populations in both untreated and following ipratropium (1 x 10-7 M) 
administration. Assessment of adult rat ventricular myocyte viability (C), apoptosis (D) and 
necrosis (E) following ipratropium (1 x 10-11 M – 1 x 10-6 M) treatment under normoxic 
conditions. Results are represented as mean % change in comparison with the untreated 
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3.3.3  Ipratropium administration throughout ischaemia in the 
absence of reperfusion 
 
Following the elucidation that ipratropium did not significantly increase myocardial 
injury in isolated perfused rat heart or adult ventricular cardiac myocytes under 
normoxic conditions, it was determined that ipratropium would be administered 
during ischaemic conditions in the Langendorff model. 
 
3.3.3.1 The effect of ipratropium on infarct development (I/R %) when 
administered under ischaemic conditions 
 
Throughout these experiments, both normoxic and ischaemic controls were used. The 
normoxic control was subjected to 55 minutes perfusion with KHB, whereas the 
ischaemic control was perfused with KHB for the 20 minutes stabilisation period and 
35 minutes regional ischaemia. In the groups treated with ipratropium, ipratropium 
was added following 20 minutes stabilisation, and throughout 35 minutes ischaemia, 
after which hearts were removed from the apparatus for Evans blue and TTC staining, 
prior to analysis (results presented in Figure 3.6). In comparison with the untreated 
normoxic control (white bar), the untreated ischaemic control (grey bar) showed a 
statistically significant increase in I/R% (5.8 ± 1.7%, normoxic, vs. 17.1 ± 4.2%, 
ischaemia, p<0.01). In addition to this, at all concentrations of ipratropium tested (1 x 
10-7 M and 1 x 10-6 M), there was a statistical increase in I/R% compared with the 
normoxic control (5.8 ± 1.7%, normoxic, vs. 18.0 ± 4.5%, Ip, 1 x 10-7 M and 17.3 ± 5.0%, 
Ip, 1 x 10-6 M, p<0.01). However, in comparison with the untreated ischaemic control 
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Figure 3.6: Infarct development in the risk zone after administration of ipratropium (1 x 10-7 M 
and 1 x 10-6 M) at the onset of, and throughout, ischaemia. Results are presented as 
infarct/risk ratio (Infarct/Risk %). Expressed as arithmetic mean + SEM. **p<0.01 vs. normoxic 
control (white bar), n=5. 
 
3.3.3.2 Haemodynamic parameters 
 

























3.3.3.3 Left ventricular developed pressure (LVDP) 
 
There was no significant difference in LVDP in comparison with the control group 
compared with hearts treated with ipratropium (1 x 10-7 M or 1 x 10-6 M) at any time 
point (p>0.05) (Figure 3.7). 
 
Figure 3.7: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation and 35 minutes ischaemia. Ipratropium (1 x 10-7 M 
and 1 x 10-6 M) was administered at the onset of, and throughout, ischaemia. Values expressed 
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3.3.3.4 Heart rate (HR) 
 
There was no significant difference in HR in comparison with the control group with 




Figure 3.8: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 minutes 
stabilisation and 35 minutes ischaemia. Ipratropium (1 x 10-7 M and 1 x 10-6 M) was 
administered at the onset of, and throughout, ischaemia. Values expressed as mean 
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3.3.3.5 Coronary flow (CF) 
 
There was no significant difference in CF in comparison with the control group with 




Figure 3.9: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation and 35 minutes ischaemia. Ipratropium (1 x 10-7 M and 1 x 10-6 M) was 
administered at the onset of, and throughout, ischaemia. Values expressed as mean 
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3.3.4  Ipratropium administration at different time points during 
ischaemia/reperfusion protocol 
 
In order to elucidate whether ipratropium administration had an effect on the 
myocardium following ischaemia and reperfusion (I/R), further isolated perfused 
Langendorff heart studies were conducted whereby hearts were subjected to 20 
minutes stabilisation, 35 minutes regional ischaemia (via ligation of the left descending 
coronary arteries) and 120 minutes reperfusion (as previously described).  
 
3.3.4.1  The effect of ipratropium on infarct development (I/R %) when 
administered at different time points throughout the 
ischaemia/reperfusion protocol 
 
As presented in Figure 3.10, ipratropium (1 x 10-7 M) was administered at the onset of 
stabilisation and throughout the full experimental protocol (0 mins), at the onset of 
ischaemia (20 mins), 15 minutes before the onset of reperfusion (40 mins) and at the 
onset of reperfusion (55 mins). In all experimental groups, there was a statistical 
increase in I/R% in comparison with the untreated control, which was subjected to the 
same protocol, but perfused with KHB only. Results presented in Table 3.1, p<0.01 for 




Figure 3.10: Infarct development in the risk zone after administration of ipratropium (1 x 10-7 
M) at different time points, throughout stabilisation, ischaemia and reperfusion (0 mins), 
throughout ischaemia and reperfusion (20 mins), administered 15 minutes prior to the end of 
ischaemia and throughout reperfusion (40 mins) and throughout reperfusion only (55 mins). 
Results are presented as infarct/risk ratio (Infarct/Risk %). Expressed as arithmetic mean + 
SEM. **p<0.01 vs. untreated control, n=6. 
 
  Time at which ipratropium (1 x 10-7 M) administered 
Group Control 0 mins 20 mins 40 mins 55 mins 
I/R (%) 51.8  
± 3.0 % 
72.6  
± 3.4 % ** 
73.8  
± 4.7 % ** 
71.0  
± 3.2 % ** 
74.3  
± 4.5 % ** 
 
Table 3.1: Values for infarct development in the risk zone following ipratropium (1 x 10-7 M) 
administration at different time points stabilisation, ischaemia and reperfusion (0 mins), 
throughout ischaemia and reperfusion (20 mins), administered 15 minutes prior to the end of 
ischaemia and throughout reperfusion (40 mins) and throughout reperfusion only (55 mins). 
Results are presented as infarct/risk ratio (Infarct/Risk %). Expressed as arithmetic mean ± 
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3.3.4.2 Haemodynamic parameters 
 
All haemodynamic parameters were measured and expressed as previously described.  
 
3.3.4.3 Left ventricular developed pressure (LVDP) 
 
There was no significant difference in LVDP in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 












Figure 3.11: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Administration of ipratropium (1 x 10-7 M) occurred at different time points, 
throughout stabilisation, ischaemia and reperfusion (0 mins), throughout ischaemia and 
reperfusion (20 mins), administered 15 minutes prior to the end of ischaemia and throughout 
reperfusion (40 mins) and throughout reperfusion only (55 mins).Values expressed as mean 








































































3.3.4.4 Heart rate (HR) 
 
There was no significant difference in HR in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 
experimental groups (p>0.05) (Figure 3.12). 
 
Figure 3.12: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Administration of 
ipratropium (1 x 10-7 M) occurred at different time points, throughout stabilisation, ischaemia 
and reperfusion (0 mins), throughout ischaemia and reperfusion (20 mins), administered 15 
minutes prior to the end of ischaemia and throughout reperfusion (40 mins) and throughout 
reperfusion only (55 mins).Values expressed as mean percentage of the stabilisation period ± 


























































3.3.4.5 Coronary flow (CF) 
 
There was no significant difference in CF in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 
experimental groups (p>0.05) (Figure 3.13). 
 
 
Figure 3.13: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Administration of 
ipratropium (1 x 10-7 M) occurred at different time points, throughout stabilisation, ischaemia 
and reperfusion (0 mins), throughout ischaemia and reperfusion (20 mins), administered 15 
minutes prior to the end of ischaemia and throughout reperfusion (40 mins) and throughout 
reperfusion only (55 mins).Values expressed as mean percentage of the stabilisation period + 































































3.3.5  Ipratropium administration at the onset of reperfusion 
 
Having ascertained that ipratropium administration under conditions of ischaemia and 
reperfusion significantly increased myocardial injury, in subsequent experiments, it 
was decided that ipratropium would be administered at the onset of, and throughout, 
reperfusion. This was in order to identify the signalling mechanisms within reperfusion 
which were affected by ipratropium administration. 
 
3.3.5.1 Infarct size to risk ratio (%) analysis 
 
Figure 3.14 shows the observations from isolated perfused heart experiments where 
ipratropium (1 x 10-9 – 1 x 10-6 M) was administered at reperfusion following 35 
minutes regional ischaemia. This data showed that ipratropium increases the 
development of infarct in a dose responsive manner. Infarct/Risk (%) (I/R (%)) was 
statistically different from control hearts (51.8 ± 3.0 %) at concentrations of 1 x 10-8 M 
and above (Table 3.2). A sub-maximal concentration of ipratropium (1 x 10-7 M) was 






Figure 3.14: Infarct development in the risk zone after administration of different 
concentrations of Ipratropium (1 x 10-9 M – 1 x 10-6 M) when administered at the onset of, and 
throughout, reperfusion. Results are presented as infarct/risk ratio (Infarct/Risk %). Expressed 
as arithmetic mean + SEM. *p<0.05 and **p<0.01 vs. control, n=6. 
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Table 3.2: Values for infarct development in the risk zone after administration of different 
concentrations of Ipratropium (1 x 10-9 M – 1 x 10-6 M) when administered at the onset of, and 
throughout, reperfusion. Results are presented as infarct/risk ratio (Infarct/Risk %). Expressed 
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3.3.5.2 Haemodynamic data analysis 
 
All haemodynamic parameters were measured and expressed as previously described.  
 
3.3.5.3 Left ventricular developed pressure (LVDP) 
 
There was no significant difference in LVDP in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 
experimental groups (p>0.05) (Figure 3.15). 
 
Figure 3.15: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium bromide (1 x 10-9 M – 1 x 10-6 M) was administered at the onset of, 
and throughout, reperfusion. Values expressed as mean percentage of the stabilisation period 
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3.3.5.4 Heart rate (HR) 
 
There was no significant difference in HR in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 
experimental groups (p>0.05) (Figure 3.16). 
 
 
Figure 3.16: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium 
bromide (1 x 10-9 M – 1 x 10-6 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 6 for 
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3.3.5.5 Coronary flow (CF) 
 
There was no significant difference in LVDP in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M) administration at any time point, for any of the 
experimental groups (p>0.05) (Figure 3.17). 
 
 
Figure 3.17: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium 
bromide (1 x 10-9 M – 1 x 10-6 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 6 for 










5 10 15 20 5 10 15 20 25 30 35 15 30 45 60 75 90 105 120








5 10 15 20 5 10 15 20 25 30 35 15 30 45 60 75 90 105 120


































3.3.6 Effect of ipratropium administration on cardiac myocyte 
viability with use of the MTT assay following 
hypoxia/reoxygenation 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) is reduced to 
purple formazan by mitochondrial dehydrogenase, and therefore provides a 
colorimetric assay for cellular viability. During these experiments, all groups were 
subjected to the H/R protocol (outlined in Section 2.4.1), with ipratropium or atropine 
administered at the onset of reoxygenation. Figure 3.18 shows percentage change in 
MTT reductase activity, indicative of myocyte viability, of the control in comparison 
with myocytes administered ipratropium or atropine (1 x 10-11 M – 1 x 10-6 M). 
Administration of ipratropium or atropine at the onset of re-oxygenation produced a 
significant reduction in cell viability in a concentration responsive manner, values 


















Figure 3.18: Assessment of myocyte viability via changes in MTT reductase activity in isolated 
rat ventricular myocytes following hypoxia/re-oxygenation. Administration of ipratropium or 
atropine (1 x 10-11 M – 1 x 10-4 M) occurred at the onset of, and throughout, re-oxygenation. All 
groups were subjected to hypoxia/re-oxygenation protocol. Values are mean + SEM, n=6. 


































































































































Group MTT Reductase activity c/w Control (%) (Mean ± SEM) 
  
Control 100 ± 0.0 
  
 Ipratropium bromide: Atropine: 
1 x 10-11 M 95.1 ± 2.9 * 98.3 ± 8.6 
3 x 10-11 M 96.2 ± 12.0 97.3 ± 7.8 
1 x 10-10 M 91.6 ± 14.4 96.6 ± 11.6 
3 x 10-10 M 91.3 ± 10.7 92.3 ± 6.5 * 
1 x 10-9 M 79.9 ± 3.0 * 90.2 ± 4.6 * 
3 x 10-9 M 80.1 ± 7.3 * 93.2 ± 9.1 
1 x 10-8 M 76.7 ± 3.8 * 88.7 ± 6.9 * 
3 x 10-8 M 77.0 ± 4.4 * 82.5 ± 6.9 * 
1 x 10-7 M 69.0 ± 6.2 ** 78.0 ± 8.5 * 
3 x 10-7 M 72.5 ± 5.1 * 74.4 ± 5.5 * 
1 x 10-6 M 67.6 ± 5.0 ** 71.1 ± 9.7 * 
3 x 10-6 M 65.6 ± 9.8 * 76.0 ± 13.5 * 
1 x 10-5 M 56.6 ± 4.4 ** 73.4 ± 10.2 * 
3 x 10-5 M 48.7 ± 5.4 ** 69.0 ± 11.2 * 
1 x 10-4 M 52.7 ± 7.3 ** 68.5 ± 8.0 ** 
 
Table 3.3: Values for myocyte viability via changes in MTT reductase activity in isolated rat 
ventricular myocytes following hypoxia/re-oxygenation. Administration of ipratropium or 
atropine (1 x 10-11 M – 1 x 10-4 M) occurred at the onset of, and throughout, re-oxygenation. All 
groups were subjected to hypoxia/re-oxygenation protocol. Values are mean ± SEM, n=6. 





3.3.7  Acetylcholine assay 
 
In order to elucidate that the observed ipratropium induced injury involved disruption 
of muscarinic receptor signalling, it was necessary to ascertain whether levels of 
endogenous acetylcholine were present in the experimental model being utilised. With 
use of the Choline/Acetylcholine Assay kit, cell lysate acetylcholine levels in myocytes 
under normoxic conditions and those subjected to the H/R protocol were determined. 
The assay was conducted in the absence and presence of acetylcholinesterase in order 
to identify values of total and free choline to establish the concentration of 
acetylcholine in myocyte lysates (Figure 3.19). Choline standards were prepared to 
produce standard curves (A).  Following colorimetric analysis at 450 nm, these allowed 
quantification of acetylcholine levels. Under normoxic conditions (B & C), levels of 
acetylcholine were found to be 1.7 x 10-9 M. In cell lysates from myocytes subjected to 
the H/R protocol (D & E), the concentration of acetylcholine was 1.3 x 10-9 M. 







Figure 3.19: Endogenous levels of acetylcholine as determined by choline/acetylcholine assay, 
myocytes plated out at 1 x 106 cells.ml-1. A, representative 96 well plate in which the 
acetylcholine assay has been carried out. Panels B and C: Levels of total choline (B, 4.92 x 10-9 
M ± 0.04) and free choline (C, 3.41 x 10-9 M ± 0.03) in normoxic, untreated adult rat ventricular 
myocytes. Panels D and E: Levels of total choline (D, 4.49 x 10-9 M ± 0.03) and free choline (E, 
3.16 x 10-9 M ± 0.02) in untreated adult rat ventricular myocytes subjected to hypoxia/re-
oxygenation protocol. Expressed as arithmetic mean ± SEM, n=5.   
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3.3.8 Effect of acetylcholine ± ipratropium treatment on isolated 
perfused rat hearts 
 
Having identified endogenous levels of acetylcholine, it was postulated that 
administration of exogenous acetylcholine may have an effect on ipratropium induced 
myocardial injury. Further isolated perfused rat heart experiments were conducted 
with the use of ipratropium ± acetylcholine (both 1 x 10-7 M) and atropine ± 
acetylcholine (both 1 x 10-7 M) to further identify the involvement of muscarinic 
signalling. 
 
Figure 3.20: The effect of 1 x 10-7 M acetylcholine (ACh) administration at reperfusion on 
ipratropium (1 x 10-7 M) and atropine (1 x 10-7 M) induced myocardial injury in the isolated 
perfused rat heart. Results are presented as infarct/risk ratio (I/R%). Mean + SEM, n=6, 












                                     
  
   
   
  
   
  
  

















3.3.8.1 Ipratropium induced exacerbation of myocardial I/R injury is 
significantly abrogated by acetylcholine in the isolated perfused 
rat heart 
 
The results presented in Figure 3.20 show the effect of acetylcholine (1 x 10-7 M) 
administration at reperfusion. Acetylcholine significantly reduced infarct size in 
comparison with the control (42.7 ± 2.9 % (ACh, 1 x 10-7 M) vs. 51.8 ± 3.0 % (control), 
p<0.05). The observed increase in infarct size due to ipratropium treatment was 
significantly attenuated when administered in conjunction with acetylcholine. Atropine 
(1 x 10-7 M) administration at reperfusion was also shown to significantly increase 
infarct development in comparison with the control (58.64 ± 1.7 % (Atr, 1 x 10-7 M) vs. 
51.8 ± 3.0 % (control), p<0.05), which was also significantly attenuated upon 
acetylcholine administration. 
 
3.3.8.2 Haemodynamic parameters 
 





3.3.8.3 Left ventricular developed pressure (LVDP) 
 
There was no significant difference in LVDP in comparison with the control with hearts 
treated with ipratropium (1 x 10-7 M), atropine (1 x 10-7 M) or the groups where 
ipratropium and atropine were co-administered with acetylcholine (1 x 10-7 M) for any 
of the experimental groups in comparison with the untreated control. However, at 60, 
75, 90, 105 and 120 mins time points, acetylcholine significantly increased LVDP in 
comparison with the control (*p<0.05, **p<0.01, data presented in table 3.4) (Figure 
3.21). 
 
Figure 3.21: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium (1 x 10-7 M), atropine (1 x 10-7 M) and acetylcholine (1 x 10-7 M) ± 
ipratropium or atropine (both 1 x 10-7 M) were administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 6 for 
all groups.*p<0.05 and ** p<0.01 vs. Control. 




3.3.8.4 Heart Rate (HR) 
 
There was no significant difference in HR in comparison with the control with hearts treated 
with ipratropium (1 x 10-7 M), atropine (1 x 10-7 M), acetylcholine (1 x 10-7 M) or the groups 
where ipratropium and atropine were co-administered with acetylcholine (all drugs 1 x 10-7 M) 




Figure 3.22: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium (1 x 10-7 
M), atropine (1 x 10-7 M) and acetylcholine (1 x 10-7 M) ± ipratropium or atropine (both 1 x 10-7 
M) were administered at the onset of, and throughout, reperfusion. Values expressed as mean 





























































3.3.8.5 Coronary flow (CF) 
 
There was no significant difference in CF in comparison with the control with hearts treated 
with ipratropium (1 x 10-7 M), atropine (1 x 10-7 M), acetylcholine (1 x 10-7 M) or the groups 
where ipratropium and atropine were co-administered with acetylcholine (all drugs 1 x 10-7 M) 




Figure 3.23: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium (1 x 10-7 
M), atropine (1 x 10-7 M) and acetylcholine (1 x 10-7 M) ± ipratropium or atropine (both 1 x 10-7 
M) were administered at the onset of, and throughout, reperfusion. Values expressed as mean 


































































3.3.9  Assessment of MTT reductase activity following acetylcholine ± 
ipratropium treatment 
 
The cell viability assay was conducted in the presence and absence of acetylcholine (1 
x 10-7 M) ± ipratropium (1 x 10-7 M) or atropine (1 x 10-7 M) (Figure 3.24). Treatment 
with acetylcholine significantly increased cell viability (108.0 ± 4.6 %, (ACh, 1 x 10-7 M) 
vs. 100 ± 0.0 % (control), p<0.05) in comparison with the control. Concomitant 
treatment with ipratropium and acetylcholine significantly increased viability in 
comparison with myocytes treated with ipratropium alone (88.7 ± 4.5 % (Ip + Ach) vs. 
73.0 ± 2.1 % (Ip, 1 x 10-7 M), p<0.05). A significant decrease in myocyte viability was 
observed in the group treated with atropine (81.3 ± 8.3 % (Atr, 1 x 10-7 M) vs. 100 ± 0.0 
% (control), p<0.05). In comparison with the group treated with both atropine and 
acetylcholine, there was a small increase in viability in comparison with the atropine 





















Figure 3.24: Effect of ipratropium (1 x 10-7 M), atropine (1 x 10-7 M) and acetylcholine (1 x 10-7 
M) ± ipratropium or atropine on MTT reductase activity in isolated rat ventricular myocytes 
following hypoxia/re-oxygenation, normalised as a percentage of the untreated control. 
Administration of ipratropium (Ip 1 x 10-7 M), atropine (Atr, 1 x 10-7 M) and acetylcholine (ACh, 
1 x 10-7 M) occurred at the onset of, and throughout, re-oxygenation. Values are mean + SEM, 
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3.3.10 Assessment of apoptosis and necrosis in primary cardiac 
myocytes following hypoxia/re-oxygenation and ipratropium 
treatment 
 
Additional experiments were conducted to identify whether the observed ipratropium 
induced increase in I/R (%) and reduction in cell viability was due to apoptosis or 
necrosis. For all experiments, normoxic controls were carried out in order to verify the 
H/R protocol (as described in section 2.4.1). A 40% decrease in viable myocytes 
following H/R in comparison with the normoxic control was required to ascertain that 
the H/R protocol had been successful.  
Viable, necrotic and apoptotic myocytye populations were recorded via flow cytometry 
from cardiac myocytes exposed to ipratropium treatment (1 x 10-9 M – 1 x 10-6 M) 
throughout re-oxygenation (Figures 3.25 and 3.26). Viable cells were calculated by the 
percentage of cells able to metabolise C-12 resazurin and, within metabolically active, 
viable cells, resazurin is reduced to C-12-resorufin which is fluorescent on the red 
spectrum, thereby enabling identification on the flow cytometer. At all concentrations 
of ipratropium tested (1 x 10-9 – 1 x 10-6 M), there was a significant decrease in 
myocyte viability in comparison with the untreated, H/R control (Figure 3.25, values in 








Figure 3.25: Assessment of viable adult rat ventricular myocytes following H/R protocol and 




Group Control Ipratropium bromide (M) 
  1 x 10-9 1 x 10-8 1 x 10-7 1 x 10-6 
Viable 
myocytes (%) 
100 ± 0.0 44.5±10.2** 56.1±15.9** 64.4±13.2** 54.0±9.3** 
 
Table 3.4: Values for flow cytometric assessment of viable adult rat ventricular myocytes 
following H/R protocol and ipratropium administration. **p<0.01 in comparison with 
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Apoptosis and necrosis were estimated by Annexin V and SYTOX® Green positive 
myocytes, respectively. All concentrations of ipratropium tested, caused a significant 
increase in apoptosis (Annexin V positive) in comparison with the untreated control 
(100 ± 0.0 %, control vs. 169.8 ± 19.7 % (1 x 10-9 M), 160.9 ± 23.3 % (1 x 10-8 M), 139.9 ± 
18.1 % (1 x 10-7 M) and 153.1 ± 17.9 % (1 x 10-6 M), all p<0.05. In addition ipratropium 
administration caused a significant increase in necrosis (SYTOX® Green positive) above 
the control group at 1 x 10-8 M, 1 x 10-7 M and 1 x 10-6 M ipratropium (100 ± 0.0 %, 
control vs. 142.6 ± 15.5 % (1 x 10-8 M), 141.6 ± 23.9 % (1 x 10-7 M) and 140.9 ± 17.7 % 
















Figure 3.26: Assessment of apoptosis and necrosis in adult rat ventricular cardiac myocytes 
following H/R protocol and ipratropium treatment. A and B, original representative flow 
cytometric scatter graphs presenting myocytes subjected to hypoxia and re-oxygenation in the 
absence (A) and presence (B) of ipratropium to indicate the differentiation between necrotic, 
apoptotic and viable myocytes. C. Depicts normalised data for apoptotic and necrotic myocyte 
populations expressed as percentage of untreated control. *p<0.05 in comparison with 
respective untreated control, values are mean + SEM (n=10). 
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3.3.11  Assessment of cleaved caspase-3 levels following hypoxia/ 
  re-oxygenation in primary cardiac myocytes 
 
Having established an increase in apoptotic death, following ipratropium 
administration at the onset of re-oxygenation, the involvement of caspase-3, a pivitol 
caspase in the apoptotic machinery was investigated. In order to ascertain that the H/R 
protocol had been successful, a significant increase in caspase-3 in the H/R control 
group in comparison with the normoxic group was required (as shown in Figure 3.27). 
In order to display the data as a single channel histogram, the FL1-H channel was used. 
The FL1-H flow channel was used as it was appropriate for the AlexaFluor488® 
conguated antibody for cleaved caspase-3 (with excitation laser lines of 488 nm) and 
this channel allowed for maximum excitation of 495 nm and maximum emission of 519 
nm.  
 
Figure 3.27: Representative flow cytometric scatter plots to show levels of activated cleaved 
caspase-3 in normoxic cardiac myocytes (A), following hypoxia/re-oxygenation protocol (B) 
and with ipratropium administration at the onset of re-oxygenation (C). Arrows indicate the 
peaks which represent cleaved caspase-3 levels. 
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3.3.11.1 Assessment of caspase-3 levels in primary cardiac myocytes 
following hypoxia/re-oxygenation and acetylcholine ± 
ipratropium treatment 
 
Levels of cleaved caspase-3 were evaluated by flow cytometry. The data are presented 
in Figure 3.28. Panel A shows a representative histogram from the flow cytometer. B 
shows that exposure of ventricular cardiac myocytes to ipratropium throughout re-
oxygenation is associated with an increase in levels of cleaved caspase-3 (Asp 175), an 
effect which was significant when ipratropium was administered at 1 x 10-7 M and 1 x 
10-6 M (100 ± 0.0%, control vs. 128.7 ± 5.82% (1 x 10-7 M), p<0.05, 147.5 ± 12.8% (1 x 
10-6 M), p<0.01. Addition of acetylcholine (1 x 10-7 M) (C) significantly decreased the 
level of cleaved caspase-3 compared with the control (70.2 ± 10.5% vs. 100 ± 0.0% 
(control), p<0.05). Administration of atropine also produced a significant increase in 
caspase-3 levels in comparison with the control (119.8 ± 6.73% vs. 100 ± 0.0% 
(control), p<0.05). However, the co-administration of ipratropium or atropine with 
acetylcholine produced effects which, although showed a decrease in cleaved caspase-
3, were statistically insignificant in comparison with the respective groups treated with 























Figure 3.28: Effect of ipratropium (Ip), atropine (Atr) and acetylcholine (Ach) on cleaved 
caspase-3 levels in ventricular myocytes, following hypoxia and re-oxygenation. Ipratropium, 
atropine and acetylcholine administered throughout re-oxygenation. A. Original histogram 
depicting cleaved caspase-3 fluorescence (Alexa Fluor 488® conjugate) in myocytes following 2 
hours hypoxia and exposure to re-oxygenation without (-) and with (+) 1 x 10-7 M ipratropium. 
B. Effect of ipratropium (1 x 10-9 M – 1 x 10-6 M) on caspase-3 levels of normalised histogram 
data expressed as percentage of untreated control (white bar). C. Effect of acetylcholine (ACh, 
1 x 10-7 M) ± ipratropium (Ip, 1 x 10-7 M) and atropine (Atr, 1 x 10-7 M) on levels of cleaved 
caspase-3 in isolated rat ventricular myocytes following hypoxia/re-oxygenation, as 
determined by flow cytometric analysis. Expressed as arithmetic means, normalised to 
untreated control, + SEM, (n=6), *p<0.05 and **p<0.01 vs. respective control. For C, #p<0.05 
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3.3.12 Isolated perfused rat heart experiments with DEVD ± 
ipratropium treatment 
 
The identification of increases in both apoptosis and caspase-3, as established via flow 
cytometry, led to the conclusion that caspase-dependent apoptotic death was involved 
in ipratropium induced myocardial injury following simulated I/R.  In order to more 
fully elucidate the involvement of caspases, a potent caspase-3 inhibitor (Z-DEVD-
FMK), known to significantly attenuate injury following I/R (AL-Rajaibi et al. 2008), was 
co-administered with ipratropium. 
 
3.3.12.1 DEVD significantly attenuates ipratropium induced myocardial 
injury following I/R in the perfused rat heart 
 
The involvement of caspase-3 in myocardial cell death following ipratropium 
treatment was assessed in perfused hearts via the administration of Z-DEVD-FMK 
(DEVD, 7 x 10-9 M) in conjunction with ipratropium (1 x 10-7 M) at the onset of 
reperfusion. These data are presented in Figure 3.29. Administration of DEVD 
produced a significant reduction in I/R (%) in comparison with the untreated control 
(51.8 ± 3.0%, control vs. 29.7 ± 4.7%, DEVD, p<0.01). As previously demonstrated, the 
group treated with 1 x 10-7 M ipratropium induced a significant increase in infarct/risk 
(%) of 75.1 ± 4.3%. In the group treated with both DEVD and Ipratropium, infarct 
development was significantly inhibited in comparison with both the untreated control 
and ipratropium (1 x 10-7 M) treatment group (36.7 ± 3.7% (DEVD + Ip), vs. 51.8 ± 3.0% 





Figure 3.29: Infarct development in the risk zone following Z-DEVD-FMK (7 x 10-9 M) treatment 
± ipratropium (1 x 10-7 M) in isolated perfused rat heart. DEVD and ipratropium both 
administered at the onset of reperfusion. Results are presented as infarct/risk (%).* p<0.05 
(36.7 ± 3.7% (DEVD + ipratropium) and ** p<0.01 (29.7 ± 4.7% (DEVD) and 75.1 ± 4.3% 
(ipratropium) vs. control (51.8 ± 3.0%). $$p<0.01 (36.7 ± 3.7% (DEVD + ipratropium) vs. 75.1 ± 
4.3% (ipratropium)). Mean + SEM, n=6. 
 
3.3.12.2 Haemodynamic parameters 
 
All haemodynamic parameters were measured and expressed as previously described 
































3.3.12.3 Left ventricular developed pressure (LVDP) 
 
There was no significant difference in LVDP in comparison with the control with hearts 
subjected to ipratropium (1 x 10-7 M) or DEVD (7 x 10-8 M) ± ipratropium (1 x 10-7 M) 
administration at any time point, for any of the experimental groups (Figure 3.30). 
 
 
Figure 3.30: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium bromide (1 x 10-7 M) ± DEVD (7 x 10-8 M) was administered at the 
onset of, and throughout, reperfusion. Values expressed as mean percentage of the 




















































































3.3.12.4 Heart rate (HR) 
 
There was no significant difference in HR in comparison with the control with hearts 
subjected to ipratropium (1 x 10-7 M) or DEVD (7 x 10-8 M) ± ipratropium (1 x 10-7 M) 




Figure 3.31: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium 
bromide (1 x 10-7 M) ± DEVD (7 x 10-8 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 6 for 




































































3.3.12.5 Coronary flow (CF) 
 
There was no significant difference in CF in comparison with the control with hearts 
subjected to ipratropium (1 x 10-7 M) or DEVD (7 x 10-8 M) ± ipratropium (1 x 10-7 M) 




Figure 3.32: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium 
bromide (1 x 10-7 M) ± DEVD (7 x 10-8 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 6 for 









































































3.4  Chapter Discussion 
 
The identification that ipratropium induced injury did not occur under normoxic 
conditions is of particular importance as it indicates that the action of ipratropium on 
specific signalling pathways activated during ischaemia, reperfusion, or both is 
responsible for the increase in myocardial injury. In particular, it appears that the 
observed ipratropium induced effect is due to ipratropium induced alteration of 
reperfusion signalling, as when ipratropium was administered at different time points 
throughout the Langendorff protocol, the observed increase in infarction was 
statistically insignificant across the different time points. 
The major finding of this work is that ipratropium significantly exacerbates myocardial 
injury under in vitro conditions of simulated myocardial I/R and oxidative stress. This 
was observed as an increase in infarct size (I/R%) in the isolated perfused rat heart and 
as a decrease in myocyte viability in primary rat ventricular myocytes, established via a 
decrease in MTT reductase activity. The present study also demonstrates the ability of 
acetylcholine to abrogate the exacerbation of I/R injury in these two models. This 
accords with previous studies that have shown muscarinic activation is cytoprotective 
following an ischaemic insult (Davidson et al. 2006, Qin, Downey and Cohen 2003, 
Zhao et al. 2010). Interestingly, in the current study, acetylcholine was capable of 
attenuating some of the observed ipratropium induced injury when ipratropium and 
acetylcholine were co-administered. This indicates that the inhibitory action of 
ipratropium, as a competitive antagonist, at the cardiac mAChRs is responsible for 
eliciting the observed injury.  
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In the current study, the presence of acetylcholine in in vitro tissue was confirmed. It 
has been approximately three decades since the interest in synthesis of ACh in non-
neuronal cells became a particular focus for research (Grando et al. 2007). It has since 
been shown that ACh is actually synthesised, in vivo, by the majority of non-neuronal 
cells and plays integral roles in various non-neuronal capacities (Wessler and 
Kirkpatrick 2008).  
It was initially shown by Dolezal and Tucek that ACh synthesis occurs ex vivo in the 
diaphragm of the rat (Tucek 1982). It has since been demonstrated that ChAT mRNA, 
as well as ChAT protein, are active in isolated human epithelial and lymphocytes 
(Grando et al. 1993, Kawashima and Fujii 2004) as well as ChAT activity and ACh 
synthesis in the airway epithelium and placenta (Grando et al. 1993, Reinheimer et al. 
1996, Wessler et al. 2001). 
For the purposes of the work in the current study, it was necessary to identify 
endogenous ACh levels within the in vitro models utilised, given that it was postulated 
that it was a specific action on the mAChRs by ipratropium, which was eliciting the 
cardio-toxic effects. Concentrations of 1.3 – 1.7 x 10-9 M were identified in the myocyte 
lysates. This is in-line with previous work which indicates endogenous, non-neuronal, 
ACh levels range from 9 x 10-12 M and 6 x 10-8 M (Wessler and Kirpatrick, 2008). 
Further to this, ipratropium administration was sufficient to significantly increase 
myocardial injury in the absence of exogenous acetylcholine (1 × 10−7 M). Previous 
work has shown that acetylcholine protects the myocardium following I/R (Li et al. 
2011) by permitting activation of reperfusion injury salvage kinase (RISK) signalling 
cascades (Hausenloy, Tsang and Yellon 2005, Shanmuganathan et al. 2005), 
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maintenance of gap junctional integrity (Yue et al. 2006, Zhao et al. 2010), and 
prevention of apoptosis (Kim et al. 2008a, Liu et al. 2011a). This study supports the 
protective properties of acetylcholine and postulates that the administration of 
ipratropium is sufficient to compete with endogenous acetylcholine, which accounts 
for the observed inhibition of acetylcholine induced myocardial protection following 
I/R. 
The parallel studies using atropine have generated supporting evidence for muscarinic 
involvement as, through this work, increases in infarct development and cleaved 
capase-3 levels as well as decreased myocyte viability were observed with atropine 
administration. It was also demonstrated that acetylcholine was capable of 
compensating for some of the observed atropine induced injury when administered in 
conjunction with atropine. Ipratropium is a synthetic atropine derivative (Wood et al. 
1995), and both drugs are non-selective muscarinic antagonists. The ability for both 
atropine and ipratropium to exacerbate myocardial injury in the experimental models 
presented here implies a common mechanism of action of the two drugs which 
reinforces the theory that muscarinic signalling may be involved in ipratropium-
induced exacerbation of myocardial injury. During reperfusion, myocyte loss can occur 
through both apoptosis and necrosis (Kung, Konstantinidis and Kitsis 2011). 
Administration of ipratropium was associated with an increase in both necrotic and 
apoptotic myocyte death in comparison with the untreated group, as well as an overall 
decrease in viable myocytes. 
Furthermore, it was demonstrated that ipratropium administration, at the onset of re-
oxygenation in isolated rat cardiac myocytes, was associated with an increase in levels 
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of cleaved caspase-3. Caspase-3 is an essential effector caspase in the caspase-
dependent apoptotic signalling cascade. Caspases exist as zymogens but are only 
cleaved to form active enzymes following the onset of apoptosis. Significant increases 
in cleaved caspase-3 levels were observed following ipratropium administration, 
thereby indicating that ipratropium exacerbation of myocardial injury involves a 
caspase-dependent apoptotic component. This was further supported by the isolated 
perfused heart studies using ipratropium and Z-DEVD-FMK (DEVD), an irreversible 
inhibitor of caspase-3 activation. These data identified that the observed ipratropium-
induced increase in I/R (%) was abrogated when administered in conjunction with 
DEVD. The levels of caspase-3 in the acetylcholine treatment group were significantly 
lower than in the control group, indicating that acetylcholine myocardial protection is, 
in part, due to a reduction in apoptosis. This is also supported by other studies where 
acetylcholine-induced cardioprotection has been shown to protect via regulation of 
apoptosis (Kim et al. 2008a, Liu et al. 2011a) and promotes the hypothesis that caspase 
activation is necessary in order for ipratropium to exacerbate myocardial injury 
following I/R. However, from other results in this study, it is implied that there is also a 
necrotic component to the observed ipratropium induced myocyte loss in an in vitro 





Chapter 4 Elucidation of the cellular signalling pathways 
which lead to ipratropium induced myocardial 
injury 
 
4.1  Chapter introduction and purpose 
 
In the previous chapter (Chapter 3), it was demonstrated that ipratropium is capable of 
exacerbating myocardial injury following simulated ischaemia/reperfusion (I/R) in the 
isolated Langendorff perfused rat heart model as well as primary rat ventricular 
myocytes. This was identified as a significant increase in both apoptosis and necrosis 
following ipratropium administration, coupled with an overall decrease in viability of 
cardiac myocytes. The presence of endogenous acetylcholine (ACh) was ascertained, 
however the administration of exogenous acetylcholine was capable of partially 
reversing the ipratropium induced injury, implying that it is the specific antagonist 
action of ipratropium at cardiac muscarinic receptors that is responsible for the 
observed increase in injury. The cytoprotective properties of muscarinic activation, by 
ACh, have been well documented. In the context of I/R, ACh has been shown as cardio-
protective (Kim et al. 2008a, Li et al. 2011, Yang et al. 2005) as well as effective in both 
pre-conditioning (Critz, Cohen and Downey 2005, Krieg et al. 2004, Yang et al. 2005) 
and post-conditioning (Xiong et al. 2010, Zang, Sun and Yu 2007).  
Mechanistically, ACh mediated cardio-protection has also been shown to inhibit 
hypoxia-induced apoptosis through regulation of MAPKs, Akt and PI3K (Kim et al. 
2008a, Krieg et al. 2002, Li et al. 2011), as well as Bcl-2 family proteins and caspase-3 
(Kim et al. 2008a, Yao et al. 1999). The work presented in the previous chapter 
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supports this as administration of acetylcholine induced a reduction in apoptosis which 
was accompanied by decreases in caspase-3 levels. However, this effect was 
ameliorated following co-administration of ACh and ipratropium. It has previously 
been demonstrated that synthesis of ACh, in the myocardium, is increased following 
conditions of I/R in feline (Kawada et al. 2007) and rabbit models (Kawada et al. 2009). 
In particular, ACh levels rapidly increase during ischaemia, and remain elevated 
throughout reperfusion (Kumagae and Matsui 1991). This provides an innate 
protection to myocytes following an ischaemic event (Kawada et al. 2009). It is 
therefore postulated that ipratropium is capable of blocking endogenous ACh at the 
cardiac muscarinic receptors, therefore blocking cardio-protective cholinergic 
mechanisms.  
The reperfusion injury salvage kinase (RISK) pathway comprises of PI3K-Akt and, the 
mitogen-activated protein kinases (MAPKs), p42/p44, extracellular signal-regulated 
kinases (Erk1/2) pathways (Davidson et al. 2006). Its activation at the onset of 
reperfusion is capable of decreasing the severity of reperfusion injury (Hausenloy, 
Tsang and Yellon 2005). Previous work has shown that ACh is capable of protecting the 
myocardium following I/R by permitting activation of pivotal kinases in the RISK 
pathway (Li et al. 2011).  More specifically, ACh has been shown as protective against 
I/R when used in both pre- and post-conditioning due to its ability to activate the RISK 
pathway (Li et al. 2011, Mioni et al. 2005, Yang et al. 2005, Zhao et al. 2010). 
MAPKs are serine and threonine kinases which are also instrumental in regulating a 
myriad of cellular processes including cellular survival and apoptosis (Chen et al. 2001). 
The MAPK JNK is stress activated and known to play an integral role in the initiation of 
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apoptosis in various disease states, including I/R, following its phosphorylation and 
subsequent activation (Zhao and Herdegen 2009). The activation of JNK includes both 
intrinsic and extrinsic apoptotic pathways, whereas inhibition of JNK permits the 
attenuation of apoptosis in several cell types and under various cellular contexts (Son, 
Rhee and Pyo 2006, Venugopal et al. 2007). The activation of muscarinic receptors, in 
particular the M3 subtype, following innervation by endogenous ACh, has also been 
shown to inhibit JNK activation (Kim et al. 2008a, Wang et al. 2003). Thereby providing 
evidence for another potential mechanism by which ACh employs cardio-protective 
signalling pathways. 
During I/R, increases of intracellular Ca2+ and oxidative stress lead to rapid ATP 
depletion, causing rupture of the outer mitochondrial membrane and, thus, MOMP. 
This facilitates the influx of toxic mitochondrial proteins into the cytosol, consequently 
initiating apoptosis (Halestrap and Pasdois 2009, Hausenloy et al. 2002) as well as 
myocyte death by necrosis (Yellon and Hausenloy 2007b) which occurs via the 
resultant collapse of mitochondrial function after disruption of mitochondrial 
membrane potential (Crompton 1999) due to opening of the mPTP (Yellon and 
Hausenloy 2007b). In contrast to MOMP, mPTP opening is primarily responsible for 
myocyte loss through necrosis, rather than apoptosis, as attributed to the former. The 
two were previously considered as distinct components responsible for separate cell 
death mechanisms (Siu et al. 2008), however, it has recently emerged that Bax/Bak 
channels may be integral for mPTP functioning (Whelan et al. 2012).  
Irrespective of the mechanisms involved, ACh has shown roles in protecting the 
myocardium from I/R injury via regulation of the MOMP, through modulation of Bak 
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and Bax (Liu et al. 2011a) as well as prevention of mPTP opening whereby ACh induced 
cardioprotection has been shown to be abolished by atractyloside, a known opener of 
the mPTP (Sun et al. 2010a). This indicates an integral role for both the MOMP and 
mPTP in acetylcholine mediated cardio-protection.  
Due to the convergence of muscarinic and RISK signalling, as well as the association 
with the mPTP, it is therefore possible that the antagonist action of ipratropium on 
mAChRs in the heart, and the observed exacerbation of myocardial injury, may involve 
PI3K-Akt and Erk1/2 signalling. The aim of the following work was to attempt to 
elucidate whether the pro-apoptotic Bcl-2 family member BAD (to further define the 
involvement of apoptosis), Akt and Erk1/2 (components of both the RISK and 
muscarinic signalling cascades), JNK (an integral component in the apoptotic 
machinery following cellular stresses) and mitochondrial membrane potential and rigor 
contracture of cardiac myocytes (following oxidative stress, which indicate 
involvement of the mPTP) are involved in the cellular mechanisms which lead to 





4.2  Methods 
 
70 adult, male, Sprague-Dawley rats (300 g ± 50 g body weight) were used throughout 
the experiments detailed in this chapter. All experiments were subject to the exclusion 
criteria detailed in Chapter 2, section 2.8. For all data, results are presented a group 
means + standard error of the mean (SEM). For the Western blotting data, values have 
been normalised to the respective untreated control, which is represented as 100%. 
Statistical differences were ascertained with the use of one-way ANOVA, with the 
exception of haemodynamics which where a two-way ANOVA was employed, and 
Fisher’s LSD post-hoc test. 
 
4.2.1  mPTP model of oxidative stress 
 
Cardiac myocytes were isolated according to the protocol in Chapter 2, section 2.4. 
Following adhesion to laminin coated cover slips, adhered myocytes were incubated in 
microscopy buffer containing 3 x 10-6 M, tetramethylrhodamine methyl ester (TMRM) 
for 15 minutes. Cells were washed and randomly assigned to one of the following 
groups: untreated control, Ip (1 x 10-8 M - (1 x 10-6 M),), ACh (1 x 10-7 M), or Ip + ACh 
(both 1 x 10-7 M). Myocytes were viewed and analysed via confocal microscopy. 
Depolarisation (Dep) was measured as the time at which the TMRM started to become 
evenly distributed throughout the cell and is indicative of the initiation of the mPTP 
opening. Subsequent hypercontracture (Hyp) of myocytes occurs shortly afterwards 




4.2.2   Western blotting 
 
Tissue was harvested from Langendorff perfused rat hearts following 20 minutes 
stabilisation, 35 minutes regional ischaemia and then 5, 15 or 120 minutes reperfusion, 
as described in Chapter 2, section 2.6. All drugs were administered at the onset of, and 
throughout, reperfusion, for this study, these were ipratropium (1 x 10-9 M – 1 x 10-7 
M), ACh (1 x 10-7 M) and wortmannin (1 x 10-8 M), as well as ipratropium (1 x 10-7 M) 
administered concomitantly with either ACh or wortmannin (concentrations as 
before). For groups where drugs were co-administered, 1 x 10-7 M of ipratropium was 
used. Following homogenisation and storage in suspension buffer, 60 µg of protein 
from each sample was diluted with sample buffer and loaded into precast gels. After 
separation by electrophoresis, proteins were transferred onto PVDF membranes and 
probed for the phosphorylated forms of Akt (Ser473, 60 KDa), Erk 1/2 (Erk) 
(Thr202/Thr204, 44/42 KDa) and SAPK/JNK (JNK) (Thr183/Tyr185, 54/46 KDa). To assess 
relative changes in protein levels, membranes were subsequently probed for the total, 
unphosphorylated forms of Akt, Erk and JNK and relative changes in phosphorylated 
protein were calculated as a percentage of these. To ensure protein loading was equal, 




4.2.3  Analysis of adult rat ventricular myocytes via flow cytometry 
 
Isolated cardiac myocytes were subjected to the H/R protocol, as detailed in Chapter 2, 
section 2.4.1. Ipratropium (1 x 10-9 M – 1 x 10-6 M), atropine (1 x 10-7 M) and ACh (1 x 
10-7 M), as well as ipratropium (1 x 10-7 M) in conjunction with either atropine or ACh 
(concentrations as before) were administered for four hours, following two hours 
hypoxia. At the end of the experimental protocol, levels of phospho-Akt (Ser473) and 
phospho-BAD (Ser112) were assessed by flow cytometry (protocol outlined in Chapter 
2, section 2.4.6). 
 
4.2.4  Isolated perfused rat heart model of ischaemia/reperfusion 
 
Following sacrifice by cervical dislocation and excision, rat hearts were mounted on 
Langendorff perfusion apparatus. For all experiments, the Langendorff model of I/R 
was used. Ipratropium (1 x 10-7 M) ± Wortmannin (1 x 10-8 M) and Wortmannin alone 
(1 x 10-8 M) were administered after 55 mins, the onset of reperfusion. At the end of 
the experimental protocol, infarct size to risk ratio (I/R(%)) was determined via Evans 
blue and TTC staining. Throughout all experiments, left ventricular developed pressure 
(LVDP, mmHg), heart rate (HR, beats.min-1) and coronary flow (CF, ml.min-1) were 




4.3  Results 
 
4.3.1 Involvement of mitochondria following ipratropium and 
acetylcholine administration in a mPTP model of oxidative 
stress 
 
Having identified involvement of both apoptotic and necrotic myocyte death following 
ipratropium administration in Chapter 3, a myocyte model of oxidative stress was 
employed to determine the action of ipratropium on mitochondria. Figure 4.1 (A) 
portrays the time points which were visualised and measured (depolarisation and 
hypercontracture) via confocal microscopy. The administration of ipratropium (1 x 10-8 
M and 1 x 10-7 M) significantly decreased the time taken for depolarisation to occur in 
comparison with the control group (201.2 ± 9.9 s, control vs. 173.8 ± 14.6 s (1 x 10-8 M) 
and 147.5 ± 17.5 s (1 x 10-7 M), p<0.05, Figure 4.1 (B)). The subsequent time to 
hypercontracture was also recorded, as presented in Figure 4.1 (C). As with 
depolarisation, there was a significant decrease in hypercontracture following 
ipratropium (1 x 10-8 M and 1 x 10-7 M) administration (585.3 ± 33.9 s, control vs. 460.5 
± 19.0 s (1 x 10-8 M) and 455.2 ± 15.3 s (1 x 10-7 M), p<0.05). In order to determine 
whether ACh elicited protection via a mechanism involving mitochondria, the same 
protocol in the presence of ACh ± ipratropium was conducted. ACh administration, 
alone (277.2 ± 26.1 s, p<0.01), and in conjunction with ipratropium (237.0 ± 9.4 s, 
p<0.05), was capable of significantly delaying time to depolarisation in comparison 
with the control (Figure 4.1 (D)). The subsequent time to hypercontracture was also 
recorded (Figure 4.1 (E)). These results mirrored those from depolarisation (455.1 ± 
15.2 s, Ip, p<0.01, 572.9 ± 23.4 s, ACh, p<0.05 and 547.7 ± 12.1 s, Ip + ACh vs. 550.2 ± 
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1.7 s in control), with the exception that statistically there was no difference between 




Figure 4.1 Determination of myocyte depolarisation and hypercontracture as established using 
TMRM loaded cells subjected to laser stimulated oxidative stress generation. Time points 
measured are schematically represented (A) the time to depolarisation, 2nd panel, (201.2 ± 9.9 
secs) and hypercontracture, 4th panel (585.3 ± 33.9 secs), as visualised by confocal microscopy. 
Effect of ipratropium (1 x 10-9 M – 1 x 10-7 M) on time to depolarisation (B) and 
hypercontracture (C). Effect of acetylcholine (ACh, 1 x 10-7 M) ± ipratropium (Ip, 1 x 10-7 M) on 
time to depolarisation and hypercontracture (D and E, respectively), values are mean + SEM, 
n=6 animals, with between 10 and 15 myocytes measured, per animal, for each group. 

























Control 1 nM 10 nM 100 nM


























































1x10-9 x10-8 1x10-7 1x10-9 x10-8 1x10-7 
201 
 
4.3.2 Effect of ipratropium treatment on the levels of Akt 
phosphorylation following ischaemia/reperfusion 
 
As Akt is an integral protein in the RISK signalling machinery and also involved in 
muscarinic signalling, the levels of phospho- and total-Akt following 35 minutes 
ischaemia and 5, 15 and 120 minutes of reperfusion were quantified via Western blot 
analysis. Administration of all drugs (ipratropium (1 x 10-9 M – 1 x 10-7 M), ACh (1 x 10-7 
M), wortmannin (1 x 10-8 M) and ipratropium (1x10-7 M) administered in conjunction 
with either ACh or wortmannin (concentrations as before) occurred at the onset of, 
and throughout, reperfusion.  
 
4.3.2.1 Ipratropium induced myocardial injury is associated with an 
up-regulation of phospho-Akt 
 
Figure 4.2 presents the data from Western blot analysis where isolated perfused 
hearts were exposed to ipratropium (1 x 10-9 – 1 x 10-7 M) throughout reperfusion 
(which lasted for 5 (A), 15 (B) and 120 (C) minutes. A significant increase in levels of 
phospho-Akt was observed following administration of ipratropium (all 
concentrations) at all time points, as described in Fig. 4.2 (D) (p<0.01 vs. respective 








Figure 4.2: The effects of ipratropium (1 x 10-9 M – 1 x 10-7 M) treatment on the levels of 
phosphorylated Akt following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 (C) 
minutes reperfusion. Corresponding representative blots of GAPDH, p-Akt and total Akt for 
each time point shown above figures with treatment groups in the following order for all blots: 
Control, Ip (1 x 10-9 M), Ip (1 x 10-8 M),  and Ip (1 x 10-7 M),. All values expressed as mean + SEM 
of p-Akt/Akt as a percentage of the control (D). * p<0.05 and ** p<0.01 vs. respective control, 
n=3 for all groups.  
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4.3.2.2 Acetylcholine mediated protection against ipratropium induced 
myocardial injury is associated with downregulation of 
phospho-Akt 
 
Figure 4.3 presents the results from the Western blot experiments designed to 
ascertain levels of Akt following ipratropium ± ACh. Administration of ACh (1 x 10-7 M) 
produced an effect which was statistically indifferent from the respective control 
groups at all time points measured. However, at all time points there was a significant 
decrease in Akt phosphorylation in the groups treated with ACh in comparison with 
the respective ipratropium treated group (Figure 4.3 (D), p<0.05 for all groups). The co-
administration of ipratropium and ACh, following 5 minutes reperfusion, significantly 
reduced Akt phosphorylation in comparison with the group treated with ipratropium 
alone (260.2 ± 36.1%, Ip, vs. 178.7 ± 23.2%, Ip + ACh, p<0.05). The relative change in 
Akt phosphorylation following 15 minutes reperfusion was also statistically different 
between the ipratropium and Ip + ACh treatment groups (258.3 ± 64.6%, Ip, vs. 127.6 ± 
28.7%, Ip + ACh, p<0.05), however, the difference between the same two respective 
groups (Ip compared with Ip + ACh) following 120 minutes reperfusion was 














Figure 4.3: The effects of ipratropium (1 x 10-7 M) ± acetylcholine (1 x 10-7 M) treatment on the 
levels of phosphorylated Akt following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 
(C) minutes reperfusion. Corresponding representative blots of GAPDH, p-Akt and total Akt for 
each time point shown above figures with treatment groups in the following order for all blots: 
Control, Ip, ACh and Ip + ACh. All values expressed as mean + SEM of p-Akt/Akt as a percentage 
of the control (D). * p<0.05 and ** p<0.01 vs. respective control, # p<0.05 vs. respective Ip 
treated group, n=3 for all groups. 
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4.3.2.3 Western blotting – AKT ipratropium ± wortmannin study 
 
In order to ascertain whether the observed increases in Akt phosphorylation following 
ipratropium administration involved the PI3K, wortmannin, a selective PI3K inhibitor, 
was administered at reperfusion in the presence and absence of ipratropium (Figure 
4.4). Administration of wortmannin (1 x 10-8 M) blocked Akt phosphorylation when 
administered alone and in conjunction with ipratropium (1 x 10-7 M) (Figure 4.4 (B). 
 
Figure 4.4 (A) The effects of ipratropium (1 x 10-7 M) ± wortmannin (1 x 10-8 M) treatment on 
the levels of phosphorylated Akt following 35 minutes regional ischaemia 15 minutes 
reperfusion. Corresponding representative blots of GAPDH, p-Akt and total Akt shown above 
figures with treatment groups in the following order for all blots: Control, Ip, Wort and Ip + 
Wort. All values expressed as mean + SEM of p-Akt/Akt as a percentage of the control (B). ** 
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4.3.2.4 Isolated Perfused Rat Heart Experiments with ipratropium ± 
wortmannin Treatment 
 
Following the identification that wortmannin was capable of limiting ipratropium 
induced Akt phosphorylation, perfused Langendorff rat heart experiments were 
carried out using ipratropium ± wortmannin. Interestingly, as presented in Figure 4.5, 
co-administration of ipratropium and wortmannin was incapable of limiting the 
observed increase in infarct development due to ipratropium administration.   
Figure 4.5: Infarct development in the risk zone following wortmannin (Wort, 1 x 10-8 M) 
treatment ± ipratropium (Ip, 1 x 10-7 M) in isolated perfused rat heart. Wortmannin and 
ipratropium both administered at the onset of reperfusion. Results are presented as 
infarct/risk (%). **p<0.01 vs. Control, ^^p<0.01 vs. wortmannin (Wort, 1 x 10-8 M). Data 



























4.3.2.5 Haemodynamic data analysis 
 
The haemodynamic parameters of left ventricular developed pressure, heart rate and 
coronary flow were measured at regular intervals throughout perfusion on the 
Langendorff apparatus. All haemodynamic parameters were measured and expressed 
as previously described (Chapter 2, section 2.3.3) and are presented in Figures 4.6 
(LVDP), 4.7 (HR) and 4.8 (CF). There were no significant differences in LVDP, HR or CF 











Figure 4.6: Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium bromide (1 x 10-7 M) ± wortmannin (1 x 10-8 M) was administered at 
the onset of, and throughout, reperfusion. Values expressed as mean percentage of the 


























































































Figure 4.7: Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium bromide (1 x 10-
7 M) ± wortmannin (1 x 10-8 M) was administered at the onset of, and throughout, reperfusion. 












































































Figure 4.8: Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. Ipratropium 
bromide (1 x 10-7 M) ± wortmannin (1 x 10-8 M) was administered at the onset of, and 
throughout, reperfusion. Values expressed as mean percentage of the stabilisation period + 









































































4.3.3 Effect of ipratrpoium treatment on the levels of Erk1/2 
phosphorylation following ischaemia/reperfusion  
 
In order to ascertain whether Erk1/2 expression is involved in ipratropium induced 
myocardial injury, hearts were harvested for Western blot analysis as previously 
described, following 5, 15 and 120 minutes reperfusion where ipratropium ± ACh were 
administered at the onset of and throughout reperfusion.  
 
4.3.3.1  Ipratropium induced myocardial injury is associated with an 
up-regulation of Erk1/2 phosphorylation 
 
Figure 4.9 presents the data from this study. An increase in levels of phospho-Erk1/2 
was observed at all time points following ipratropium (1 x 10-9 M – 1 x 10-7 M) 
administration in comparison with the respective untreated control groups. These 
observed increases were significant in comparison with the control groups (p<0.05 or 
p<0.01, values in Figure 4.9 (D)) with the exception of the 1 x 10-9 M treatment group 







Figure 4.9 The effects of ipratropium (1 x 10-9 M – 1 x 10-7 M) treatment on the levels of 
phosphorylated Erk1/2 following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 (C) 
minutes reperfusion. Corresponding representative blots of GAPDH, p-Erk1/2 and total Erk1/2 
for each time point shown in the above figures. Treatment groups are presented in the 
following order for all blots: Control, Ip (1 x 10-9 M), Ip (1 x 10-8 M), and Ip (1 x 10-7 M),. All 
values expressed as mean + SEM of p-Erk1/2/Erk1/2 as a percentage of the control (D). * 
p<0.05 and ** p<0.01 vs. respective control, n=3 for all groups. 
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4.3.3.2 Acetylcholine mediated protection against ipratropium induced 
myocardial injury is associated with attenuation of Erk1/2 
phosphorylation  
 
To determine whether ACh protects against ipratropium induced myocardial injury via 
a mechanism which involves phosphorylation of Erk1/2, western blot analysis was used 
to determine the expression levels in homogenised heart tissue samples, collected as 
previously described, in the presence of ipratropium (1 x 10-7 M) ± ACh (1 x 10-7 M). 
Figure 4.10 shows the results from this study. 
A significant increase in levels of Erk1/2 phosphorylation was observed at all time 
points following ipratropium (1 x 10-7 M), ACh (1 x 10-7 M) and concomitant 
administration of ipratropium and ACh (concentrations as before) (p<0.05 or 0.01, 
values and statistical significance depicted in Figure 4.10 (D). 
There was no significant change in Erk1/2 phosphorylation in comparison with the 
respective ipratropium (1 x 10-7 M) group following 15 or 120 minutes reperfusion. 
However, following 5 minutes reperfusion, both the ACh and ipratropium + ACh 
treatment groups showed a significant decrease in Erk1/2 (phosphorylation in 
comparison with the ipratropium alone group). However, despite reiterating, neither 










Figure 4.10 The effects of ipratropium (1 x 10-7 M) ± acetylcholine (1 x 10-7 M) treatment on 
the levels of phosphorylated Erk1/2 following 35 minutes regional ischaemia and 5 (A), 15 (B) 
and 120 (C) minutes reperfusion. Corresponding representative blots of GAPDH, p-Erk1/2 and 
total Erk1/2 for each time point shown above figures with treatment groups in the following 
order for all blots: Control, Ip, ACh and Ip + ACh. All values expressed as mean + SEM of p-
Erk1/2/Erk1/2 as a percentage of the control (D). *p<0.05 and **p<0.01 vs. respective control, 
#p<0.05 and vs. respective Ip treated group, n=3 for all groups.  
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4.3.4 Effect of ipratropium treatment on the levels of JNK 
phosphorylation following ischaemia/reperfusion 
 
JNK is a stress activated kinase with a well defined role in I/R injury. Following 
phosphorylation, JNK permits myocyte loss through activation of apoptosis and 
autophagy. JNK is also a downstream effector of muscarinic receptor signalling (Fujino 
et al. 2000, Hornigold et al. 2003) Of particular interest in the context of the 
myocardium, is the observation for potential cross-talk between the signalling 
pathways of the M2 and M3 subtypes via a mechanism which involves JNK (Hornigold 
et al. 2003). 
 
4.3.4.1  Ipratropium induced myocardial injury is associated with a 
down-regulation of JNK phosphorylation 
 
Tissue was harvested, as previously described, following 5, 15 and 120 minutes 
reperfusion. Figure 4.11 presents data from Western blot analysis where ipratropium 
(1x10-9 M - 1x10-7 M) was administered throughout reperfusion. At all time points, 
there was a decrease in JNK phosphorylation following ipratropium administration (all 
concentrations). However, this was only significant following 15 minutes reperfusion in 
comparison with the respective untreated control (Figure 4.11 (B), values in 4.11 (D), 
p<0.05) and also for the group treated with 1 x 10-8 M ipratropium following 120 








Figure 4.11 The effects of ipratropium (1 x 10-9 M – 1 x 10-7 M) treatment on the levels of 
phosphorylated JNK following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 (C) 
minutes reperfusion. Corresponding representative blots of GAPDH, p-JNK and total JNK for 
each time point shown above figures with treatment groups in the following order for all blots: 
Control, Ip (1x10-9 M), Ip (1 x 10-8 M), and Ip (1 x 10-7 M). All values expressed as mean + SEM 
of p-JNK/JNK as a percentage of the control (D). * p<0.05 vs. respective control, n=3 for all 
groups. 
  
54 KDa  
46 KDa  
















Control 1x10-9 1x10-8 1x10-7 















































Ipratropium bromide (M) 





75.4 ±  
20.8 
99.3 ±  
19.1 





65.7 ±  
13.4 * 
69.8 ±  
17.3 * 





84.7 ±  
21.1 
78.3 ±  
10.6 * 
86.4 ±  
23.4 
















































Ipratropium bromide (M) 
Control 1x10-9 1x10-8 1x10-7 
Ipratropium bromide (M) 
* 
* * 
37 KDa  
54 KDa  
46 KDa  
54 KDa  
46 KDa  
37 KDa  
54 KDa  
46 KDa  
54 KDa  
46 KDa  
54 KDa  
46 KDa  
217 
 
4.3.4.2 Acetylcholine mediated protection against ipratropium induced 
myocardial injury is associated with increased phosphorylation 
of JNK 
 
Following administration of ipratropium ± ACh throughout 5 minutes of reperfusion, 
there was no significant difference in JNK phosphorylation between any of the 
treatment groups and the respective control (Figure 4.12 (A)).  
At the 15 minute time point, there was a significant decrease in JNK phosphorylation in 
the group treated with ipratropium (66.7 ± 20.2%, ip, vs. 100.0 ± 0.0%, control, 
p<0.05). In contrast to this, there was a significant increase in JNK phosphorylation in 
the group treated with acetylcholine alone, in comparison with the untreated control 
(181.7 ± 19.4, ACh vs. 100.0 ± 0.0%, control, p<0.05). As well as this, in comparison 
with the group treated with ipratropium alone, there were statistical increases in JNK 
phosphorylation in the groups treated with ACh, both alone and in conjunction with 
ipratropium (Figure 4.12 (B), values in (D)). However, the group treated with 
ipratropium and ACh was statistically indistinct in comparison with the untreated 
control. 
For the studies which looked at the effect of ipratropium and ACh following 120 
minutes reperfusion, there was no significance between the control group and the 
groups treated with either ipratropium alone, or the group where ipratropium and ACh 
were co-administered. However, there was a statistical increase in JNK 
phosphorylation in the group treated with ACh alone in comparison with both the 
untreated control and the group treated with ipratropium alone (159.2 ± 17.5%, ACh, 






Figure 4.12: The effects of ipratropium (1 x 10-7 M) ± acetylcholine (1 x 10-7 M) treatment on 
the levels of phosphorylated JNK following 35 minutes regional ischaemia and 5 (A), 15 (B) and 
120 (C) minutes reperfusion. Corresponding representative blots of GAPDH, p-JNK and total 
JNK for each time point shown above figures. Treatment groups in the following order for all 
blots: Control, Ip, ACh and Ip + ACh. All values expressed as mean + SEM of p-JNK/JNK as a 
percentage of the control (D). * p<0.05 vs. respective control, ## p<0.01 vs. respective Ip 
treated group, n=3 for all groups. 
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4.3.5  BAD 
 
BAD, a BH-3 only domain member of the Bcl-2 family, is a potent mediator of 
apoptosis. Phosphorylation of BAD confers anti-apoptotic actions whereas, upon 
desphosphorylation, BAD is permitted to heterodimerise with Bcl-2 and Bcl-xL and 
initiate intrinsic apoptosis via Bax/Bak channel formation on the outer mitochondrial 
membrane fully described in section 1.4.2).  
 
4.3.5.1 Ipratropium induced myocardial injury is associated with 
decreased phosphorylation of BAD 
 
Flow cytometry was employed using isolated primary ventricular myocytes which had 
been exposed to the hypoxia/re-oxygenation protocol with administration of all drugs 
(ipratropium (1 x 10-9 M – 1 x 10-6 M), ACh (1 x 10-7 M), atropine (1 x 10-7 M) and 
ipratropium (1 x 10-7 M) administered concomitantly with either ACh or atropine 
(concentrations as before)) occurring throughout re-oxygenation. 
The results from these flow cytometry studies are presented in Figure 4.13. Following 
ipratropium (1 x 10-9 M – 1 x 10-6 M) administration, there was a decrease in levels of 
BAD phosphorylation, which was significant in comparison with the control group, 
following 1 x 10-6 M and 1 x 10-7 M ipratropium (71.4 ± 9.5%, 1 x 10-6 M and 72.6 ± 
11.7, 1 x 10-7 M, vs. 100.0 ± 0.0%, control, p<0.05, Figure 4.13 (A)). The decrease in 
BAD phosphorylation was also observed following 1 x 10-7 M atropine administration 




4.3.5.2  Acetylcholine mediated protection against ipratropium induced 
myocardial injury is associated with increased phosphorylation 
of BAD 
 
The administration of ACh significantly increased the levels of BAD phosphorylation in 
comparison with the control group (132.9 ± 10.6% vs. 100.0 ± 0.0%, control, p<0.05). 
Interestingly, co-administration of ACh with either ipratropium or atropine was 
capable of increasing the levels of phosphorylated BAD to levels which were 
statistically insignificant from the untreated control group (104.1 ± 9.8% (Ip + ACh) and 
103.0 ± 12.5% (Atr + ACh). However, in both of these treatment groups, the change in 
level of BAD phosphorylation was also statistically indifferent from the groups treated 




Figure 4.13: (A) Representative flow cytometric histograms to show the difference in BAD 
phosphorylation following ipratropium administration in comparison with the untreated 
control.  (B) Effect of ipratropium (Ip, 1 x 10-9 M – 1 x 10-6 M) on levels of BAD phosphorylation 
in isolated rat ventricular myocytes following hypoxia/re-oxygenation, as determined by flow 
cytometric analysis. (C) Effect of ipratropium (Ip, 1 x 10-7 M) or atropine (Atr, 1 x 10-7 M) ± 
acetylcholine (ACh, 1 x 10-7 M) on levels of phosphorylated BAD. All drugs administered at the 
onset of, and throughout, re-oxygenation. Values are expressed as mean + SEM. * p<0.05 vs. 
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4.4  Chapter Discussion 
 
The primary findings of this chapter are that ipratropium induced myocardial injury via 
a mechanism which involves up-regulation of the pro-survival kinases Akt and Erk1/2 
as well as a decrease in phosphorylated JNK and BAD. This was also associated with a 
decreased time for depolarisation and hypercontracture, indicative of mPTP opening 
and myocyte death due to lack of ATP, respectively. In all models, the addition of ACh 
was shown to have, overall, opposing effects to ipratropium which was accompanied 
by a reduction in myocardial injury in comparison with control groups. Also, ACh was 
capable of eliciting protection against ipratropium injury when ipratropium and ACh 
were co-administered. 
The opening of the mPTP during reperfusion has been shown to promote both necrotic 
and apoptotic cell death (Crompton, 1999). The conditions of oxidative stress, as 
associated with I/R, lead to mPTP opening (Halestrap, 2009, Halestrap and Pasdois, 
2009, Hausenloy et al., 2002). The oxidative stress model used in this work measured 
depolarisation, indicative of mPTP opening and also subsequent hypercontracture, 
rigor of cardiac myocytes due to ATP depletion. The results from the oxidative stress 
myocyte model showed that administration of ipratropium rendered myocytes less 
resilient to injury following TMRM free radical generation. This was quantified by a 
reduction in time to both depolarisation and hypercontracture following ipratropium 
treatment. In contrast, acetylcholine exerts a protective effect via inhibition of the 
mPTP (Okorie et al. 2011, Sun et al. 2010). This has been attributed to a mechanism 
which links RISK signalling (including activation of Akt and Erk1/2) (Krieg at al. 2003). It 
has also been shown that acetylcholine elicits a cardioprotective response in I/R via a 
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mitochondrial ATP-sensitive potassium channel leading to blocking of mPTP opening 
(Sun et al. 2010). These previous experimental observations support the findings 
reported in this study. 
In addition, the ability for acetylcholine to attenuate the ipratropium induced 
reduction in time to depolarisation and hypercontracture indicates involvement of the 
mPTP in ipratropium induced myocardial injury following oxidative stress. Despite all 
treatment groups (Ip, ACh and Ip + ACh) showing significance in comparison with the 
untreated control group at depolarisation, the differences between treatment groups 
and control were not as marked when hypercontracture was measured. 
Hypercontracture is rigour contracture of cardiac myocytes due to ATP depletion, 
however, depolarisation is indicative of loss of mitochondrial membrane integrity due 
to opening of the mPTP and subsequent outer membrane rupture (Halestrap 2010).  
The opening of the mPTP has been described as a “point of no return” such that, once 
this event has occurred, cells are committed to death, either by necrosis or apoptosis 
(Baines 2009). Therefore although it is interesting that the times to hypercontracture 
vary less among groups, it is the time to depolarisation which has determined the fate 
of the myocyte and ostensibly this is more important as, following depolarisation the 
mitochondrion will no longer be capable of producing its own ATP, and also quickly 
deplete ATP levels from surrounding, still functioning mitochondria, initiating the first, 
irreversible steps towards a cellular death pathway. The phenomenon of mitochondrial 
depolarisation occurs as a consequence of mPTP opening. Within the context of a 
healthy mitochondrion, H+ is produced following electron transport through the redox 
complexes. These protons are transported across the inner mitochondrial membrane 
224 
 
(IMM) and, thus, H+ accumulates within the intermembrane space, thereby causing a 
membrane potential across the IMM. During regular oxidative phosphorylation, the 
protons flow back into the matrix and are used by ATPase in ATP synthesis. However, 
under the pathological conditions of ischaemia, deregulation of Ca2+ and the 
associated lack of oxygen causes disruption to the electron transport chain which 
subsequently results in mPTP opening at the onset of reperfusion (Andrews, Royse and 
Royse 2012). This leads to rapid depolarisation of the IMM, due to H+ flow into the 
matrix independent of ATP production, which is accompanied by uncoupling of 
oxidative phosphorylation and, therefore rapid ATP depletion. Following mPTP 
opening, solute and water influx into the mitochondrial matrix leads to rapid swelling 
and eventual rupture of the outer mitochondrial membrane. In combination, these 
constitute irreversible mitochondrial damage which determines the fate of the 
myocyte to death by either necrosis or apoptosis (Halestrap 2009).  
In a sense, the time to hypercontracture is irrelevant as myocyte death following 
depolarisation is inevitable. Hypercontracture occurs as a result of excessive 
contractile activation following the onset of reperfusion due to the sudden restoration 
of oxidative phosphorylation and ATP production. However, intracellular Ca2+ levels are 
elevated during this time (Padilla et al. 2000). In this work it is postulated that the 
decrease in variation following hypercontracture is attributed to the time for Ca2+ 
levels to reduce after ischaemic injury, or oxidative stress, and this is dependent on the 
restoration of correct sodium-calcium exchanger (NCX) and inositol tri-phosphate 
receptor (IP3R) function. Despite the severity of the ischaemic injury, this time frame 
does not significantly change. In order to further elucidate the involvement of the 
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mPTP in ipratropium induced myocardial injury, the immunosuppressant and mPTP 
blocker, cyclosporin A was also investigated in the context of I/R following ipratropium 
treatment (fully investigated in Chapter 5). 
The data presented here reveal that ipratropium elicits cardiotoxic effects and support 
the previously published ability of acetylcholine to protect against the detrimental 
effects of I/R. In addition to this, the ability for acetylcholine to partially abrogate the 
ipratropium induced injury, at these concentrations, implies a specific role for 
muscarinic signalling in ipratropium induced myocardial injury. In particular, 
acetylcholine has been shown to promote cellular viability, differention and survival 
following a cellular insult, such as I/R through activation of GPCR coupled signalling 
leading to activation of Akt (This includes activation of Akt following muscarinic 
stimulation by ACh). However, although in this study, there was an observed increase 
in Akt phosphorylation following simulated I/R (5, 15 and 120 mins reperfusion) and 
ACh administration, this was not statistically distinct from the respective, untreated 
control groups.  
It is well-documented that Akt activation is cytoprotective following various cellular 
stresses, such as I/R injury (Li et al. 2011, Liu et al. 2011a, Wang et al. 2012), through 
its inclusion in RISK pathway signalling (Cohen et al. 2001, Qin, Downey and Cohen 
2003, Zang, Sun and Yu 2007). However, in this work, despite having observed an 
increase in myocardial injury following I/R,  at all the time points measured (5, 15 and 
120 minutes of reperfusion), there was an increase in Akt phosphorylation following 
ipratropium (1 x 10-9 M – 1 x 10-7 M) administration. This observation corresponds to 
previously published data which associate Akt phosphorylation with a reduction in 
226 
 
myocardial injury following I/R (Miyamoto, Murphy and Brown 2009, Su et al. 2012, 
Zhang et al. 2011).  
However, it has also been ascertained that constitutive over expression of Akt 
mediated cellular signalling is detrimental to cellular survival (Sussman et al. 2010). It is 
therefore postulated here that the mechanism of ipratropium induced myocardial 
injury that has been observed in this work is, in part, attributed to over stimulation of 
Akt signalling (Nagoshi et al. 2005, O'Neill and Abel 2005). However, following 
wortmannin treatment, in conjunction with ipratropium administration, although 
there was a significant decrease in Akt phosphorylation (as determined by Western 
blot anyalysis) this was not accompanied by a decrease in infarct size (as identified 
through Langendorff experiments).  
Erk1/2, as with Akt, is also a downstream kinase of PI3K. In this study, the pattern of 
phosphorylation following I/R and ipratropium ± ACh, mirrored those observed in the 
Western blots which ascertained Akt levels. As with Akt, Erk1/2 has well documented 
cardio-protective properties via its involvement in the RISK pathway (Davidson et al. 
2006, Rabkin and Tsang 2008). The proposed mechanism for action is that Erk1/2 
activation is able to prevent dephosphorylation of BAD and, subsequently, restrict 
caspase activation due to inhibition of MOMP and apoptosome formation (Bullard et 
al. 2005). However, as with Akt, over expression of Erk1/2 has been shown to have 
detrimental effects. Therefore it is proposed here that ipratropium elicits myocardial 
damage following I/R via a mechanism which involved constituitive over-activation of 




With use of wortmannin, a PI3K inhibitor, via Western blot, it was elucidated that 
wortmannin can entirely abrogate the increases in Akt observed following ipratropium 
administration. However, in further Langendorff studies, this was not associated with a 
decrease in infarct size. This indicates that, although a mechanism involving up-
regulation of Akt, and also Erk1/2 phosphorylation occurs following ipratropium 
treatment, this is not a specific determinant for the development of injury due to 
ipratropium and, therefore potentially gives rise to a role for necrosis, rather than 
apoptosis in ipratropium induced myocardial injury. 
The activation of the pro-apoptotic MAPK, JNK, has been shown to elicit myocardial 
injury, through both apoptosis and autophage, following I/R injury (Xu et al. 2014). It 
has also been documented that muscarinic activation has been shown to inhibit JNK, 
therefore affording the activation of cyto-protective mechanisms (Wang et al. 2003). In 
this study, it was hypothesised that ipratropium administration may block this 
protective mechanism and lead to an up-regulation of JNK. However, from the results 
presented in this chapter, (with the exception of the 15 minutes time point) there was 
no significant change in JNK phosphorylation in comparison with the untreated control 
groups. Further to this, ACh administration was shown to constitutively increase levels 
of JNK phosphorylation. As JNK signalling couples to autophagy as well as apoptosis, it 
is possible that the observed increases in JNK following ACh couple to an autophagy 
phenotype, rather than apoptosis, and thereby may act as an endogenous protective 
mechanism. It has previously been demonstrated that, following oxidative stress, 
artificial elevation of JNK can promote autophagy rather than apoptosis in order to 
assist in salvage of functional cells (Wu, Wang and Bohmann 2009).  
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It was also shown that levels of BAD phosphorylation were significantly elevated 
following ACh administration, but significantly reduced following ipratropium, or 
atropine, treatment. Co administration of ACh with either ipratropium or atropine 
ameliorated this effect. The ability for both atropine and ipratropium, in conjunction 
with ACh, to elicit similar effects indicates that it is a specific action on muscarinic 
signalling pathways that is responsible for the observed ipratropium induced 
myocardial injury, as both a non-selective muscarinic antagonists. BAD is an integral 
member of the Bcl-2 family that, following de-phosphorylation, potently couples to an 
apoptotic mechanism. These results support this as, in the groups treated with ACh, an 
increase in BAD phosphorylation was observed which was associated with cardio-
protection. It has also been previously shown that, via a PI3K-dependent mechanism, 
phosphorylation of Akt and BAD are able to promote cellular survival and proliferation 
(Kuwahara et al. 2000). The ability for both ipratropium and atropine to reduce levels 
of phosphorylated BAD indicates that there is a role for apoptosis in anti-muscarinic 
mediated myocardial injury following I/R.  
Despite previous findings in Chapter 3 that, within the in vitro models employed in 
these studies, endogenous levels of acetylcholine were present, from the work in this 
chapter, it is hypothesised that ipratropium is capable of blocking the cytoprotective 
properties of ACh at the cardiac muscarinic receptors, therefore promoting cellular 
mechanisms which lead to cell death. The ability for exogenous ACh to abrogate some 
of this observed injury implies that it is a mechanism which involves disruption of 




Chapter 5  Cyclosporin A protects against ipratropium 
induced myocardial injury following 
ischaemia/reperfusion and oxidative stress 
 
5.1  Chapter introduction and purpose 
 
Although the mechanism by which ischaemia/reperfusion (I/R) injury occurs has not 
been fully elucidated, there is increasing evidence for the involvement of the 
mitochondrial Permeability Transition Pore (mPTP). First reported in 1987 (Crompton, 
Costi and Hayat 1987), the mPTP is a non-specific pore in the mitochondrial membrane 
which opens at the onset of reperfusion. The mPTP is a major determinant in myocyte 
fate following I/R (Shanmuganathan et al. 2005).  
In 1988, it was first discovered that Cyclosporin A (CsA), previously used as an 
immunosuppressive agent, was capable of potently inhibiting the opening of the mPTP 
(Crompton, Ellinger and Costi 1988). It has since been confirmed that CsA binds with 
high affinity to Cyclophilin D, a key component of the mPTP, thus inhibiting binding of 
Cyclophilin D to adenine nucleotide translocase and preventing subsequent opening of 
the mPTP (Basso et al. 2005). The successful delay in mPTP opening exerted by CsA has 
since elicited a multitude of studies to identify its potential use as a cardioprotective 
agent (Cohen, Yang and Downey 2008, Crompton 1999, Halestrap 2009, Halestrap and 
Pasdois 2009, Hausenloy, Boston-Griffiths and Yellon 2011). Alongside prevention of 
mPTP opening, the activation of the reperfusion injury salvage kinase (RISK) pathway is 
also a main target for cardioprotection (Hausenloy and Yellon 2004), The pro-survival 
RISK pathway consists of the kinase signalling cascades, phosphatidylinositol-3-OH 
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kinase (PI(3)K)-Akt and p42/p44 extra-cellular signal-regulated kinases (Erk 1/2) 
(Davidson et al. 2006). It was previously unknown whether prevention of mPTP 
opening and the RISK pathway were connected, however it has been shown that, in 
the context of insulin mediated cardioprotection, RISK pathway activation is necessary 
for protection by delaying opening of the mPTP (Davidson et al. 2006).  
More recently, acetylcholine mediated cardioprotection (in both pre- and post-
conditioning) has been associated with activation of the RISK pathway (Li et al. 2011, 
Zhao et al. 2010). Also, acetylcholine induced cardioprotection has been shown to be 
abolished by atractyloside, a known opener of the mPTP. This indicates an integral role 
of the mPTP in acetylcholine mediated cardioprotection (Sun et al. 2010a). This was 
supported by the results presented in Chapter 4, where acetylcholine was capable of 
delaying the onset of mitochondrial depolarisation and hypercontracture when 
administered alone and significantly abrogating the observed reduction in time to both 
depolarisation and hypercontracture associated with ipratropium administration. In 
addition to this, significant changes in phosphorylated Akt and Erk1/2 in comparison 
with ipratropium administration were observed with acetylcholine treatment (both 
alone and in conjunction with ipratropium). 
This study aimed to identify whether the previously observed exacerbation of 
myocardial injury attributed to ipratropium (1 x 10-7 M) administration was abrogated 
when co-administered with CsA (2 x 10-7 M).  Ipratropium and CsA were administered 
concomitantly using the Langendorff model of I/R and also simulated I/R in primary rat 
cardiac myocyte models to identify myocyte viability (via MTT (3-(4,5-Dimethylthiazol-
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2-yl)-2,5-diphenyltetrazolium bromide) assay) and the involvement of apoptosis, 
necrosis, cleaved caspase-3 and phospho-BAD (evaluated by flow cytometry). 
To further elucidate the involvement of the mPTP we used a cardiac myocyte model of 
oxidative stress (as previously described in Chapter 4) where the effect of CsA, when 
administered with ipratropium, was explored. In Chapter 4, it was established that 
ipratropium induced myocardial injury was associated with significant increases in the 
phosphorylation of the RISK pathway proteins Akt and Erk1/2. Western blot analysis 
was subsequently carried out to identify whether CsA ± ipratropium administration 




5.2  Methods 
 
60 adult, male, Sprague-Dawley rats (300 g ± 50 g body weight) were used throught 
the experiments detailed in this chapter. All experiments were subject to the exclusion 
criteria detailed in Chapter 2, section 2.8. For all data, results are presented as group 
means + standard error of the mean (SEM). For the Western blotting, MTT assay and 
flow cytometry data, values have been normalised to the respective untreated control, 
which is represented as 100%. Statistical differences were ascertained with the use of 
one-way ANOVA, with the exception of haemodynamics where a two-way ANOVA was 
employed, and Fisher’s LSD post-hoc test. 
 
5.2.1  Isolated perfused rat heart model  
 
Following sacrifice by cervical dislocation and excision, rat hearts were mounted on 
Langendorff perfusion apparatus. For all experiments, the Langendorff model of I/R 
was used. Ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) were administered after 55 mins, 
the onset of reperfusion. At the end of the experimental protocol, infarct size to risk 
ratio (I/R %) was determined via Evans blue and TTC staining. Throughout all 
experiments, left ventricular developed pressure (LVDP, mmHg), heart rate (HR, 
beats.min-1) and coronary flow (CF, ml.min-1) were measured to assess the stability of 





5.2.2  Analysis of adult rat ventricular myocytes via MTT assay 
 
Isolated adult rat ventricular myocytes underwent two hours hypoxia after which, at 
the onset of re-oxygenation, ipratropium (1 x 10-7 M), CsA (2 x 10-7 M) and Ip + CSA 
(concentrations as previously stated) were administered for four hours, in the 
precence of MTT. Myocytes were subsequently lysed and analysed for MTT reductase 
activity. 
 
5.2.3  Analysis of adult rat ventricular myocytes via flow cytometry 
 
Isolated cardiac myocytes were subjected to the H/R protocol. Ipratropium (1 x 10-7 M) 
± CsA (2 x 10-7 M) were administered for 18 hours, following four hours hypoxia. At the 
end of the experimental protocol, apoptosis, necrosis and viable myocytes and levels 
of caspase-3 and BAD were assessed by flow cytometry. 
 
5.2.4  mPTP model of oxidative stress 
 
Following adhesion to laminin coated cover slips, adhered myocytes were incubated in 
microscopy buffer containing 3 x 10-6 M, tetramethylrhodamine methyl ester (TMRM) 
for 15 minutes. Cells were washed and randomly assigned to one of the following 
groups: untreated control, FCCP (2 x 10-6 M), Ip (1 x 10-7 M), CsA (2 x 10-7 M), or Ip + 
CsA (concentrations as before). Myocytes were viewed and analysed via confocal 
microscopy. Depolarisation (Dep) was measured as the time at which the TMRM 
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started to become evenly distributed throughout the cell and is indicative of the 
initiation of the mPTP opening. Subsequent hypercontracture (Hyp) of myocytes 
occurs shortly afterwards due to ATP depletion. The time to both Dep and Hyp were 
recorded. 
5.2.5   Western Blotting 
 
Tissue was harvested, following 5, 15 and 120 min reperfusion, as previously 
described. All drugs were administered at the onset of reperfusion. Following 
homogenisation and storage in suspension buffer, 60 µg of protein from was diluted 
with sample buffer and loaded into precast gels from samples of the following groups: 
untreated I/R control, ipratropium (1 x 10-7 M), CsA (2 x 10-7 M) and Ip + CSA 
(concentrations as before). After separation by electrophoresis, proteins were 
transferred onto PVDF membranes and probed for the phosphorylated forms of AKT, 
Erk1/2 and SAPK/JNK. To assess relative changes in protein levels, membranes were 
subsequently probed for the total, unphosphorylated forms of AKT, Erk1/2 and JNK 
and relative changes in phosphorylated protein were calculated as a percentage of 
total protein level. To ensure protein loading was equal, all membranes were also 





5.3  Results 
 
5.3.1 The observed exacerbation of myocardial 
ischaemia/reperfusion injury is abrogated by cyclosporine A in 
the isolated perfused rat heart  
 
To further elucidate the mechanism by which ipratropium exerted its cardiotoxic 
effect, cyclosporin A (CsA), a known inhibitor of the mPTP was used in conjunction with 
ipratropium. The present study was aimed at assessing whether CsA (2 x 10-7 M), a 
known cardioprotective agent, was capable of attenuating the observed ipratropium 
induced myocardial injury. In all experiments, a sub-maximal concentration of 
ipratropium (1 x 10-7 M) was used as has been previously demonstrated to elicit 
myocardial injury following I/R and H/R. 
 
5.3.1.1  Effect of ipratropium ± cyclosporin A treatment on infarct 
development following ischaemia/reperfusion 
 
The results presented in Figure 5.1 show the effect of cyclosporin A (2 x 10-7 M) 
administration at reperfusion. CsA significantly reduced infarct size in comparison with 
the control (22.9 ± 3.9 % (CsA, 2 x 10-7 M) vs. 51.8 ± 3.0 % (control), p,0.05). The 
observed increase in infarct size due to ipratropium treatment was significantly 
attenuated when administered in conjunction with cyclosporin A (75.1 ± 4.3 % (Ip, 1 x 
10-7 M) vs. 62.7 ± 4.8 % (Ip + CsA, 1 x 10-7 M and 2 x 10-7 M, respectively), p<0.05). 





Figure 5.1: Infarct development in the risk zone following CsA (2x10-7 M) treatment ± 
ipratropium (1x10-7 M) in isolated perfused rat heart. CsA and ipratropium both administered 
at the onset of reperfusion. Results are presented as infarct/risk (%). **p<0.01 vs. control, 
$$p<0.01 vs. CsA, #p<0.05 vs. Ip. Results expressed as mean + SEM, n=6. 
 
 Control Ipratropium CsA Ip + CsA 
  1x10-7 M 2x10-7 M 1x10-7 + 2x10-7 
M  
I/R% 51.8 75.1 ** $$ 22.9 ** 62.7 **$$ # 
SEM ± 3.0 ± 4.3 ± 3.9 ± 4.8 
 
Table 5.1: Infarct to risk percentage values in the isolated perfused rat heart following CsA (2 x 
10-7 M) treatment ± ipratropium (1 x 10-7 M). CsA and ipratropium both administered at the 
onset of reperfusion. **p<0.01 vs. control, $$p<0.01 vs. CsA, #p<0.05 vs. Ip. Results expressed 
as mean ± SEM, n=6. 
 
























5.3.1.2  Haemodynamic parameters 
 
All haemodynamic parameters were measured and expressed as previously described, 
and are presented in Figures 5.2 (LVDP), 5.3 (HR) and 5.4 (CF). There were no observed 
differences in LVDP, HR or CF in comparison with hearts in the control group with any 
treatment group (ipratropium (Ip, 1 x 10-7 M), CsA (2 x 10-7 M) or Ip + CsA 
(concentrations as before)) at any time point throughout the experimental procedure. 
5.3.1.3  Left ventricular developed pressure (LVDP) 
 
 
Figure 5.2 Changes in left ventricular developed pressure (mmHg) in isolated perfused rat 
hearts subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. CsA (2x10-7 M) ± ipratropium (1x10-7 M) was administered at the onset of, and 
throughout, reperfusion. Values expressed as mean percentage of the stabilisation period + 































































Figure 5.3 Changes in heart rate (bpm) in isolated perfused rat hearts subjected to 20 minutes 
stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. CsA (2 x 10-7 M) ± 
ipratropium (1 x 10-7 M) was administered at the onset of, and throughout, reperfusion. Values 
















































Figure 5.4 Changes in coronary flow (ml.min-1) in isolated perfused rat hearts subjected to 20 
minutes stabilisation, 35 minutes ischaemia and 120 minutes reperfusion. CsA (2 x 10-7 M) ± 
ipratropium (1 x 10-7 M) was administered at the onset of, and throughout, reperfusion. Values 
















































5.3.2 Assessment of MTT Reductase Activity following cyclosporin A ± 
ipratropium Treatment 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced to 
purple formazan by mitochondrial dehydrogenase, and therefore provides an assay for 
cellular viability. The cell viability assay was conducted in the presence and absence of 
CsA ± ipratropium (2 x 10-7 M and 1 x 10-7 M, respectively), as well as ipratropium 
alone (concentration as before), with all drugs being administered at the onset of re-
oxygenation. Figure 5.5 shows percentage change in MTT reductase activity of the 
control in comparison with myocytes administered ipratropium ± CsA (concentrations 
and experimental groups as before). 
 
Figure 5.5: Assessment of myocyte viability via changes in MTT reductase activity in isolated 
rat ventricular myocytes following hypoxia/re-oxygenation. Administration of ipratropium (Ip, 
1 x 10-7 M) ± CsA (2 x 10-7 M) occurred at the onset of, and throughout, re-oxygenation. All 
groups were subjected to hypoxia/re-oxygenation protocol. Values are mean + SEM, n=6. 















































Administration of ipratropium at the onset of re-oxygenation produced a significant 
reduction in cell viability (73.0 ± 2.1% (Ip, 1 x 10-7 M) vs. 100 ± 0.0%, control, p<0.05). 
Treatment with CsA statistically increased cell viability in comparison with both the 
control and ipratropium treated groups (112.4 ± 7.9 (CsA, 2 x 10-7 M) vs. 100 ± 0.0%, 
control, p<0.05 and vs. 73.0 ± 2.1%, Ip, p<0.01). In the group where ipratropium was 
administered concomitantly with CsA, there was a significant increase in myocyte 
viability in comparison with the group treated with ipratropium alone (89.3 ± 4.9% (Ip 
+ CsA) vs. 73.0 ± 2.1% (Ip), p<0.05). This is indicative that CsA is capable of partially 
compensating for the observed ipratropium induced loss of myocyte viability. 
However, although myocyte viability was significantly increased in the group where 
ipratropium and cyclosporin A were co-administered, the level of myocyte viability was 
still statistically less than in the untreated control group (89.3 ± 4.9% (Ip + CsA) vs. 100 
± 0.0%, control, p<0.05). 
 
5.3.3 Assessment of apoptosis and necrosis in primary cardiac 
myocytes following hypoxia/re-oxygenation and ipratropium ± 
cyclosporin A treatment 
 
In order to elucidate whether the observed protection of CsA against ipratropium 
mediated myocardial injury was via protection against necrosis or apoptosis, additional 
experiments were conducted which recorded, via flow cytometry, viable, apoptotic 
and necrotic myocyte populations, following ipratropium (Ip, 1 x 10-7 M) ± CsA (2 x 10-7 
M) treatment, at the onset of re-oxygenation. Apoptosis and necrosis were estimated 




Figure 5.6: Assessment of apoptosis and necrosis in adult rat ventricular cardiac myocytes 
following H/R protocol and ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) treatment, administered 
at re-oxygenation. A, shows original representative flow cytometric scatter graphs presenting 
myocytes subjected to hypoxia and re-oxygenation in the absence (control) and presence of 
ipratropium (1 x 10-7 M ), CsA (2 x 10-7 M) and ipratropium + CsA (Concentrations as before). B. 
Depicts normalised data for apoptotic and necrotic myocyte populations expressed as a 
percentage of untreated control. *p<0.05 in comparison with respective untreated control, $ 
p<0.05, $$ p<0.01 in comparison with respective ipratropium treated group. Values expressed 
as mean + SEM (n=8). 
 
As shown in Figure 5.6, ipratropium (1 x 10-7 M) was capable of eliciting significant 
increases in both apoptosis (Annexin V positive) and necrosis (SYTOX® Green positive) 
in comparison with the respective untreated control (139.9 ± 18.1 %, Ip, vs. 100 ± 0.0 
%, apoptosis and 141.6 ± 23.9 %, Ip, vs. 100 ± 0.0 %, necrosis, both p<0.05). As 
expected, a decrease in both apoptosis and necrosis was observed in the CsA (2 x 10-7 
M) treated groups. However, only the decrease in necrosis produced a significant 
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Interestingly, when ipratropium and CsA were co-administered, there was a statistical 
decrease in apoptosis in comparison with the group treated with ipratropium alone 
(139.9 ± 18.1 %, Ip, vs. 103.0 ± 10.6 %, Ip + CsA, p<0.05). There was also a significant 
decrease in the levels of necrosis in comparison with the group treated with 
ipratropium alone (141.6 ± 23.9 %, Ip, vs. 73.1 ± 18.5 %, Ip + CsA, p<0.01).  
In groups treated with CsA (with and without ipratropium) the levels of apoptosis were 
not statistically distinct from the levels of apoptosis in the control group (80.8 ± 18.3 % 
(CsA) and 103 ± 10.6 % (Ip + CsA)). However, in contrast to this, in the CsA and Ip + CsA 
groups, a significant decrease in necrosis was observed in comparison with the control 
(78.8 ± 15.4 % (CsA) and 73.1 ± 18.5 % (Ip + CsA) vs. 100 ± 0.0 %, control, p<0.05). This 
is indicative that the action of CsA promotes protection via a mechanism which 
primarily prevents necrosis with only a small contribution to the prevention of 
apoptosis. It is well documented that cyclosporin A is capable of inhibiting mPTP 
opening during reperfusion, thereby promoting myocyte survival (Halestrap 2009). 
Upon mPTP opening, myocyte loss occurs via necrosis and also apoptosis (Yellon and 
Hausenloy 2007). These data suggest that ipratropium induced myocardial injury 
occurs via both necrosis and apoptosis and that cyclosporin A is capable of partially 




5.3.4 Assessment of Caspase-3 levels in Primary Cardiac Myocytes 
following Hypoxia/Re-oxygenation and cyclosporin A ± 
Ipratropium Treatment 
 
To further identify the involvement of apoptosis in CsA mediated protection against 
ipratropium induced injury, levels of cleaved caspase-3 were evaluated via flow 
cytometry, as described previously, in the presence of ipratropium (1 x 10-7 M) ± CsA (2 
x 10-7 M). These data are presented in Figure 5.7. 
 
 
Figure 5.7: Effect of ipratropium (Ip, 1 x 10-7 M) ± CsA (2 x 10-7 M) on cleaved caspase-3 levels 
in ventricular cardiac myocytes following hypoxia and re-oxygenation protocol. Ipratropium 
and CsA administered at the onset of, and throughout, re-oxygenation. *p<0.05 vs. untreated 
control, $p<0.05 vs. CsA (2 x 10-7 M). Results expressed as arithmetic mean, normalised to 





















































Exposure of ventricular myocytes to ipratropium (1 x 10-7 M) throughout re-
oxygenation was associated with a significant increase in levels of caspase-3 in 
comparison with the untreated control (128.7 ± 5.8 % vs. 100 ± 0.0 %, p<0.05), as 
previously shown in chapter 3. Addition of CsA (2 x 10-7 M) did not cause a significant 
difference in levels of caspase-3 in comparison with the control (91.9 ± 12.0 % vs. 100 
± 0.0 % (control)). The co-administration of ipratropium with CsA produced effects 
which were statistically indistinct from the group treated with ipratropium alone 
(128.7 ± 5.8 % (Ip) vs. 124.1 ± 9.4 % (Ip + CsA)) however were significantly higher than 
both the untreated control and group treated with CsA alone (124.1 ± 9.4 % (Ip + CsA) 
vs. 100 ± 0.0 % (control) and vs. 91.9 ± 12.0 % (CsA), both p<0.05). This is indicative 
that CsA does not protect against ipratropium induced myocardial injury via a 
mechanism which is dependent on a caspase-dependent apoptotic cascade. However, 
due to the observed decrease in apoptotic death following CsA administration (Fig. 
5.6) it may be the case that the mode of CsA protection is primarily reliant on the 
mitochondria, or extracellular “death signals” which instigate apoptosis through a 




5.3.5 Assessment of phospho-BAD levels in Primary Cardiac Myocytes 
following Hypoxia/Re-oxygenation and cyclosporin A ± 
Ipratropium Treatment 
 
To further identify the involvement of apoptosis in CsA mediated protection against 
ipratropium induced injury, levels of phospho-BAD were evaluated via flow cytometry, 
as described previously, in the presence of ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M). 
These data are presented in Figure 5.8.  
 
Figure 5.8: Effect of ipratropium (Ip, 1 x 10-7 M) ± CsA (2 x 10-7 M) on levels of phospho-BAD in 
ventricular cardiac myocytes following hypoxia and re-oxygenation protocol. Ipratropium and 
CsA administered at the onset of, and throughout, re-oxygenation, *p<0.05 vs. untreated 













































BAD is a BH-3 only domain member of the Bcl-2 protein family which, in the context of 
a healthy cell, is phosphorylated by Akt. When phosphorylated, BAD dissociates with 
Bcl-2 and Bcl-xL (anti-apoptotic members of the Bcl-2 family) this permits the 
association of Bcl-2 with Bax, thereby inhibiting apoptosis. Dephosphorylation of BAD 
(frequently triggered by increases in Ca2+ and conditions of ischaemia/reperfusion) 
induces caspase-dependent and –independent apoptosis via a mitochondrial 
associated pathway due to heterodimeric formation with Bcl-2 and Bcl-xL.  
When ipratropium was administered at the onset of re-oxygenation, there was a 
significant decrease in levels of phospho-BAD in comparison with the untreated 
control (86.3 ± 6.7 %, Ip (1 x 10-7 M) vs. 100.0 ± 0.0 %, control, p<0.05). CsA (2 x 10-7 M) 
administration (both alone and in conjunction with ipratorpium) produced effects 
which were statistically indistinct from the control groups (106.7 ± 9.5 % (CsA) and 
92.1 ± 8.4 % (CsA + Ip)). This is indicative that ipratropium mediated myocardial injury 
is associated with dephosphorylation of BAD, thereby initiating apoptosis. CsA did not 
exhibit the ability to significantly protect against BAD de-phosphorylation. Also, there 
was no significant increase in phospho-BAD in comparison with the group treated with 





5.3.6 The role of cyclosporin A and mPTP opening following 
ipratropium administration in a model of oxidative stress 
 
As previously shown in Chapter 4, administration of ipratropium (1 x 10-7 M) was 
shown to reduce the time for depolarisation (indicative of mPTP opening) and 
subsequent hypercontracture (myocyte rigor due to ATP depletion), in a dose 
responsive manner, this was partially reversed by the co-administration of 
acetylcholine. To determine whether the mPTP also plays a role in the observed 
protection afforded by CsA, these experiments were repeated using ipratropium (1 x 
10-7 M) in the presence and absence of CsA (2 x 10-7 M), a known inhibitor of the mPTP 
and cardioprotective agent. 
 
 
Figure 5.9: Effect of FCCP (2 x 10-6 M) and ipratropium (Ip, 1 x 10-7 M) ± CsA, (2 x 10-7 M) on 
time to depolarisation (B) and hypercontracture (C) under the conditions of sustained 
oxidative stress. *p<0.05, ** p<0.01, *** p<0.001 vs. respective control (white bars), $p<0.05, 
$$p<0.001 vs. respective Ip treated group. Values expressed as mean + SEM, n=6 animals, with 
















Table 5.2: Time taken, in seconds, for depolarisation and hypercontracture under the 
conditions of sustained oxidative stress following FCCP (2 x 10-6 M) and ipratropium (Ip, 1 x 10-7 
M) ± CsA (2 x 10-7 M) treatment. 
 
The model of mPTP opening was used to determine myocyte depolarisation and 
hypercontracture as established using TMRM loaded cells subjected to laser stimulated 
oxidative stress generation. As shown in Figure 5.9, time points measured are 
schematically represented (A) the time to depolarisation, 2nd panel, and 
hypercontracture, 4th panel, as visualised by confocal microscopy. Time for ventricular 
myocyte depolarisation (B) and subsequent hypercontracture (C) were recorded. FCCP 
(carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone) is known to disrupt oxidative 
phosphorylation and was included in the experiments as a positive control as it has 
previously been shown as a potent uncoupler of mitochondrial membrane potential.  
FCCP caused a significant reduction in time to both depolarisation and 
hypercontracture in comparison with the untreated control (11.3 ± 9.8 s vs. 201.2 ± 9.9 
s and 136.9 ± 17.5 s vs. 585.3 ± 33.9 s, respectively, both p<0.001). As before, 
ipratropium (1 x 10-7 M) also significantly reduced time to both depolarisation and 
hypercontracture in comparison with the respective untreated controls, both p<0.01. 
When administered alone, CsA (2 x 10-7 M) was capable of significantly prolonging time 
to hypercontracture and depolarisation (283.1 ± 24.0 s vs. 201.2 ± 9.9 s and 638.9 ± 
 Control FCCP 
(2 x 10-6 M) 
CsA 
(2 x 10-7 M) 
Ip 
(1 x 10-7 M) 
Ip + CsA 
 Dep Hyp Dep Hyp Dep Hyp Dep Hyp Dep Hyp 
Time (s) 201.2 585.3 11.3 136.9 283.1 638.9 147.5 455.2 217.1 559.0 
SEM 9.9 33.9 9.8 22.9 24.0 41.0 17.5 15.3 16.4 23.8 
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41.1 s vs. 585.3 ± 33.9 s, p<0.01 and p<0.05 respectively). Co-administration of 
ipratropium with CsA was capable of significantly attenuating the observed reduction 
in time to depolarisation (217.1 ± 16.4 s, Ip + CsA, vs. 147.5 ± 17.5 s, Ip, p<0.05) and 
hypercontracture (559.0 ± 23.8 s, Ip + CsA, vs. 455.2 ± 15.3 s, Ip, p<0.05) due to 
ipratropium treatment alone.  
 
5.3.7 Cyclosporin A mediated protection against ipratropium induced 
myocardial injury is associated with downregulation of 
phospho-Akt  
 
Increased levels of phospho-Akt associated with ipratropium induced exacerbation of 
myocardial injury were reported in chapter 4. It was observed that the 
cardioprotective properties of acetylcholine were associated with a decrease in the 
levels of phospho-Akt, following 5, 15 and 120 minutes reperfusion. In this study, 
hearts were harvested 5, 15 and 120 minutes after the onset of reperfusion where 
ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) were administered as reperfusion was 
initiated. Western blot analysis was used to determine the expression levels of 
phospho-Akt as a percentage of total Akt in the homogenised heart samples. 
As shown in Figure 5.10, at all three time points, hearts subjected to 35 minutes 
ischaemia and ipratropium (1 x 10-7 M) administration at the onset of reperfusion 
showed a statistically significant increase in p-Akt in comparison with control I/R hearts 
for the corresponding time point (Values in Figure 5.10 (D), p<0.01 for all groups). In 
contrast to this, at all time points, there was a significant decrease in p-Akt levels 
following cyclosporin A administration in comparison with the respective controls (44.9 
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± 18.6 %, 5 mins, 55.7 ± 26.7 %, 15 mins and 49.8 ± 23.3 % vs. 100.0 ± 0.0 % (respective 
control), p<0.01 for all groups). 
For the groups where CsA (2 x 10-7 M) and ipratropium (1 x 10-7 M) were co-
administered at the onset of reperfusion, at all time points, there was an increase in p-
Akt levels in comparison with both the control and treatment groups where CsA (2 x 
10-7 M)  was administered alone. At all time points, these were significant, as denoted 
in panel D in Figure 5.10. However, it was only at the 5 minute time point that there 
was a significant result in comparison with the ipratropium treatment group (183.4 ± 
16.6 %, Ip + CsA, vs. 260.2 ± 36.1%, Ip, p<0.05). At the other time points, despite not 
being significant in comparison with the group treated with ipratropium alone, there 
was a statistical increase in p-Akt levels in comparison with the groups treated with 





Figure 5.10 The effects of ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) treatment on the levels of 
phosphorylated Akt following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 (C) 
minutes reperfusion. Corresponding representative blots of GAPDH, p-Akt and total Akt for 
each time point shown above figures with treatment groups in the following order for all blots: 
Control, Ip, CsA and Ip + CsA. All values expressed as mean + SEM of p-Akt/Akt as a percentage 
of the control (D). * p<0.05 and ** p<0.01 vs. respective control, $ p<0.05 and $$ p<0.001 vs. 
respective Ip treated group, n=3 for all groups.  
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5.3.8 Effect of cyclosporin A and ipratropium on levels of phospho-
Erk 1/2 following in vitro I/R myocardial injury  
 
In chapter 4, following 5, 15 and 120 minutes reperfusion, ipratropium administration 
was associated with a statistical increase in levels of phospho-Erk1/2. This increase was 
abolished following acetylcholine treatment; thereby associating a reduction in 
phospho-Erk1/2 with the observed protective properties of acetylcholine against 
ipratropium induced myocardial injury. In the present study, hearts were harvested 5, 
15 and 120 minutes after the onset of reperfusion where ipratropium (1 x 10-7 M) ± 
CsA (2 x 10-7 M) were administered as reperfusion was initiated, in order to elucidate 
whether CsA protects against ipratropium induced injury via a mechanism involving 
phospho-Erk1/2. Western blot analysis was used to determine the expression levels of 
phospho-Erk1/2 as a percentage of total Erk1/2 in homogenised heart samples. 
Figure 5.11 presents the data from this study. A significant increase in levels of 
phospho-Erk1/2 was observed at all time points following ipratropium (1 x 10-7 M) 
administration at reperfusion in comparison with the untreated control groups (157.5 
± 24.6 %, 5 mins, 145.5 ± 27.2 %, 15 mins and 172.4 ± 21.3 %, 120 mins vs. 100.0 ± 0.0 
% (respective control), p < 0.01 for all groups). Treatment with CsA alone caused a 
reduction in the levels of Erk1/2 phosphorylation at all time points as compared with 
the respective untreated control (58.8.5 ± 32.1 %, 5 mins, 61.7 ± 24.6 %, 15 mins and 
43.4 ± 15.7 %, 120 mins vs. 100.0 ± 0.0 % (respective control), p < 0.05 for 5 and 15 
mins groups, p<0.01 for 120 mins group). Interestingly, concomitant treatment of 
ipratropium and CsA caused significant increases in Erk1/2 phosphorylation in 
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comparison with the control, however these levels were statistically indifferent from 




Figure 5.11 The effects of ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) treatment on the levels of 
phosphorylated Erk 1/2 following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 (C) 
minutes reperfusion. Corresponding representative blots of GAPDH, p-Erk 1/2 and total Erk 1/2 
for each time point shown above figures with treatment groups in the following order for all 
blots: Control, Ip, CsA and Ip + CsA. All values expressed as mean + SEM of p-Erk 1/2/Erk 1/2 as 
a percentage of the control (D). * p<0.05 and ** p<0.01 vs. respective control $ p<0.05 vs. Ip, 
n=3 for all groups.  
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5.3.9 Cyclosporin A mediated protection against ipratropium induced 
myocardial injury is not associated with phosphorylation of JNK 
 
It was previously shown (in Chapter 4), following 5, 15 and 120 minutes reperfusion, 
ipratropium (1 x 10-7 M) administration was only associated with a statistical difference 
in phospho-JNK in comparison with the untreated control following 15 minutes 
reperfusion (66.7 ± 20.2%, Ip, vs. 100.0 ± 0.0%, control, p<0.05). JNK has been shown 
to initiate apoptosis via phosphorylation of BAD. However, significant decreases in 
phospho-BAD levels were observed, via flow cytometry, following ipratropium (1 x 10-7 
M) administration. As CsA protects via mitochondrial mechanisms which regulate both 
apoptosis and necrosis, this study aimed to identify whether CsA administration had an 
effect on the phosphorylation of BAD and, if this would provide additional information 
as to the mechanism by which CsA abrogates ipratropium induced myocardial injury. 
The results of the Western blots are presented in Figure 5.12. As previously described, 
tissue was harvested following 5, 15 and 120 mins reperfusion where ipratropium (1 x 
10-7 M) ± CsA (2 x 10-7 M) were administered as reperfusion was initiated. Although 
CsA (2 x 10-7 M) showed increases in JNK phosphorylation (when administered alone 
and co-administered with ipratropium) in comparison with the ipratropium treated 
groups, at all time points investigated, these were statistically insignificant in 
comparison with the respective ipratropium (1 x 10-7 M) treated groups. In comparison 
with the respective control groups, none of the groups treated with CsA (either alone 








Figure 5.12 The effects of ipratropium (1 x 10-7 M) ± CsA (2 x 10-7 M) treatment on the levels of 
phosphorylated SAPK/JNK following 35 minutes regional ischaemia and 5 (A), 15 (B) and 120 
(C) minutes reperfusion. Corresponding representative blots of GAPDH, p-SAPK/JNK and total 
SAPK/JNK for each time point shown above figures with treatment groups in the following 
order for all blots: Control, Ip, CsA and Ip + CsA. All values expressed as mean + SEM of p-
JNK/total JNK as a percentage of the control (D). * p<0.05 vs. untreated control (15 mins), n=3 
for all groups.  
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5.4  Chapter Discussion 
 
In this study, it was determined that CsA protects the myocardium following an 
ischaemic insult, when administered at the onset of reperfusion or re-oxygenation in 
the isolated perfused rat heart and primary cardiac myocytes. As CsA is known to be 
cardioprotective via its inhibition of mPTP opening, these results were expected and 
verified the experimental techniques used.  
It was also demonstrated that CsA also protects the myocardium from ipratropium 
induced cardiac injury following ischaemia/reperfusion, when administered at the 
onset of reperfusion. This is shown by a reduction in infarct size and myocyte viability 
in comparison with the groups treated with ipratropium (1 x 10-7 M) alone in the 
Langendorff model and MTT assay. CsA is known to exert its protective effect by 
blocking mPTP opening via interaction with Cyclophilin D, a key component of the 
mPTP (Basso et al. 2005, Schinzel et al. 2005), situated in the inner mitochondrial 
membrane (Hausenloy et al. 2010). The ability for CsA to partially reverse the observed 
ipratropium induced toxicity, in these two models, therefore indicates a role for the 
mitochondria in ipratropium induced myocardial injury. 
Interestingly, as shown by flow cytometry, administration of CsA in conjunction with 
ipratropium was capable of reducing overall myocyte loss, but only significantly 
compensated for loss of myocytes by necrosis rather than caspase mediated apoptosis. 
Further to this, there were no observed changes in levels of the cleaved caspase-3 or 
phospho-BAD in comparison with the untreated controls in the groups treated with 
CsA alone, indicating that intrinsic apoptosis does not play a role in CsA induced 
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cardioprotection. In line with this, CsA, when co-administered with ipratropium, was 
not capable of significantly attenuating the increased levels of cleaved caspase-3 or 
phospho-BAD associated with ipratropium treatment. However, as observed by the 
Langendorff model and MTT assay, CsA is capable of eliciting significant protection 
against ipratropium induced myocardial injury. This indicates that CsA exerts its 
protective effect, primarily, via prevention of necrosis. These data promote the 
hypothesis that ipratropium induced injury has both apoptotic and necrotic 
components, and that the ability for CsA to protect against the necrotic component is 
sufficient to significantly compensate for ipratropium induced injury. 
The mPTP studies support mitochondrial involvement more comprehensively, as in this 
model depolarisation is indicative of mPTP opening and hypercontracutre occurs as 
subsequent cell death from associated ATP depletion. The ability of ipratropium 
treatment to drecease the time for both depolarisation (indicative of the mPTP 
opening) and hypercontracture indicates that ipratropium exerts a toxic effect via 
disruption of the mPTP. This is further supported by the ability of CsA to compensate 
for the ipratropium induced reduction in these times, thereby protecting myocytes 
against ipratropium induced injury following oxidative stress. 
It was previously shown that the administration of ipratropium in non-ischaemic and in 
ischaemic, but with the absence of reperfusion, models (as shown in Chapter 3) has no 
toxic effect in comparison with untreated controls. This indicates that ipratropium 
specifically exacerbates reperfusion injury rather than exerting a generalised toxic 
effect on the heart. It has been documented that the mPTP opens at reperfusion 
(Griffiths and Halestrap 1995), whereas it remains closed during ischaemia. Further to 
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this the mPTP plays a central role in mediating reperfusion induced damage to the 
myocardium (Yellon and Hausenloy 2007b) as opening of the mPTP determines the 
fate of myocytes. The mPTP was previously considered to comprise of ANT (Adenine 
Nucleotide Transferase), VDAC (Voltage Dependent Anion Channel) and Cyclophilin-D, 
with a role for the mitochondrial phosphate carrier. However, recently it has been 
elucidated that ANT and VDAC do not appear to be critically involved in forming the 
channel of the mPTP (Baines 2009) as genetic ablation of both ANT and VDAC do not 
prevent mPTP opening (Miura and Tanno 2011). This gives rise to the hypothesis that 
although Cyclophilin D is involved as a critical regulatory component of the mPTP, it is 
not structurally involved (Baines 2009, Elrod et al. 2010).  
Despite the fact the components of the mPTP remain as a matter of some contention, 
it is known that initiation of reperfusion following a period of ischaemia, causes 
opening of the mPTP. The mPTP mediates the increase in mitochondrial permeability. 
When the non-specific mPTP opens, it permits passage of molecules ≤1.5 KDa (66 
Yellon,Derek M. 2007; 61 Halestrap,A.P. 2009; 367 Pasdois,P. 2011), leading to 
increased osmotic pressure on the mitochondrial membrane causing subsequent 
mitochondrial swelling and outer mitochondrial membrane rupture. This is associated 
with the initiation of cell death, both by apoptosis, via movement of cytochrome c into 
the cytosol, however, necrotic death also occurs via collapse of the mitochondrial 
membrane potential, ultimately leading to ATP depletion (Hausenloy and Yellon 2004) 
accompanied by disruption of ionic and metabolic homeostasis. This study indicates 
that CsA protects primarily by a mechanism which prevents necrosis rather than 
caspase-3 mediated apoptosis. 
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Alongside prevention of mPTP opening, the activation of the reperfusion injury salvage 
kinase (RISK) pathway is also a main target for cardioprotection (Hausenloy and Yellon 
2004), The pro-survival RISK pathway consists of the kinase signalling cascades, 
phosphatidylinositol-3-OH kinase (PI(3)K)-Akt and p42/p44 extra-cellular signal-
regulated kinases (Erk 1/2) (Davidson et al. 2006). RISK pathway activation is necessary 
for protection by delaying opening of the mPTP (Davidson et al. 2006). Multiple, 
although not all, G-protein-coupled-receptor, pro-survival signalling pathways appear 
to target the mPTP (Miura and Tanno 2011). The use of acetylcholine has been shown 
to potently protect against reperfusion injury in both pre- (Critz, Cohen and Downey 
2005, Qin, Downey and Cohen 2003) and post-(Xiong et al. 2009, Zang, Sun and Yu 
2007) conditioning and, there has since been categorical links to the RISK pathway, as 
many of the components involved (including PI3K and Erk1/2) in acetylcholine induced 
protection are necessary players in the RISK pathway (Qin, Downey and Cohen 2003, 
Zang, Sun and Yu 2007). 
It is possible that the antagonist action of ipratropium on muscarinic receptors in the 
heart may cause down regulation of PI3K and Erk1/2 and may, therefore, deregulate 
RISK pathway signalling which may induce pore opening at the mPTP level. In Chapter 
4, it was demonstrated that ipratropium administration actually produced a significant 
increase in levels of phosphorylated Akt and Erk1/2. This supports previous work which 
associates increased Akt phosphorylation with exacerbation of myocardial injury 
following ischaemia/reperfusion due to the formation of reactive oxygen species and 
an increase in oxidative stress (Ushio-Fukai et al. 1999). In this study, it is postulated 
that the observed increases in phospho-Erk1/2 were as a consequence of increased 
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Akt levels. The current study provided evidence that CsA is capable of eliciting 
protection from ipratropium induced myocardial injury, and this is associated with 
relative down-regulation of Akt and Erk1/2 phosphorylation. It is interesting; however, 
that CsA was capable of significantly decreasing phospho-Akt levels when co-
administered with ipratropium (in comparison with the ipratropium group) whereas 
CsA co-administration had no statistical effect on levels of phospho-Erk1/2. Both Akt 
and Erk1/2 serve as upstream regulators of apoptosis, however, Erk1/2 activation is 
involved in caspase-dependent apoptosis whereas Akt phosphorylation plays a larger 
role in caspase-independent apoptosis (Hausenloy 2004). There was no observed 
significant difference in cleaved caspase-3 when ipratropium and CsA were 
administered concurrently in comparison with the group treated with ipratropium 
alone. The Western blot analysis supports these results, as CsA is also incapable of 
eliciting a significant difference in phospho-Erk1/2 in comparison with the group 
treated with ipratropium alone, however statistically attenuated Akt levels. 
Interestingly, it has been previously shown that, in the context of doxorubicin 
myocardial injury, in the context of I/R, that Akt and Erk1/2 levels are significantly 
decreased following CsA administration. In this study, CsA was capable of partially 
abrogating doxyrubicin injury (Gharanei et al. 2013). Despite major differences in the 
clinical application of ipratropium and doxyrubicin, doxyrubicin has been shown to 
elicit anti-muscarinic properties (Sasaki et al. 2010). It is therefore possible that the 
mode of action by which CsA protects against doxyrubicin injury is similar to that by 
which CsA protects against ipratropium induced myocardial injury following I/R. 
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Further to this, following I/R, Erk1/2 and Akt have been shown to induce necrosis 
when over expressed. In particular, this involves the action of p53 in initiating 
mitochondrial permeability transition, therby leading to mPTP opening and necrosis 
(Vaseva et al. 2012). Also, constitutive over expression of Erk1/2 is capable of coupling 
towards cellular death mechanisms (Xie and Yu 2007). 
Given the evidence that CsA co-administration with ipratropium limits myocardial 
injury in comparison with ipratropium administration alone and that BAD is 
phosphorylated by JNK activation (Yu et al 2004), Western blot analysis for JNK was 
also conducted. There were no observed differences in levels of phospho-JNK in 
comparison with the respective ipratropium treated groups or untreated controls with 
groups treated with CsA (either alone or concomitantly with ipratropium). It has 
previously been demonstrated that dephosphorylation of BAD promotes apoptosis as 
it enables formation of Bak/Bax channels, thereby permitting release of pro-apoptotic 
factors such as cytochrome C and APAF-1 into the cytosol (Murriel et al 2004). This 
further supports the accumulating evidence that CsA does not protect against 
ipratropium induced myocardial injury through an apoptotic mechanism.  
Despite much controversy, it was previously assumed that the mPTP and Bax/Bak 
channels may be structurally linked, or, indeed, consist of the same components (Karch 
et al 2013). This assumes that myocyte loss following ischaemia/reperfusion and mPTP 
opening would be attributed to apoptosis. It has, however, recently been elucidated 
that, although Bax and Bak are, in context, responsible for intrinsic apoptosis, loss of 
Bax/Bak limits function of the mPTP. Further to this, Bax has subsequently been shown 
to regulate necrosis via its association (potentially as the outer mitochondrial 
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membrane component of) the mPTP (Whelan et al. 2012). Given the evidence that CsA 
co-administration with ipratropium limits myocardial injury via a mechanism which 
limits necrosis rather than apoptosis, it is postulated that, even though the mPTP may 
consist of regulatory proteins which regulate apoptosis, they may also have a 
secondary role whereby CsA can protect via necrosis.  
In this study, it has been established that CsA protects against ipratropium induced 
myocardial injury following ischaemia reperfusion via a protective mechanism which 





Chapter 6  Ipratropium further exacerbates myocardial 
ischaemia reperfusion in the aged rat 
myocardium 
 
6.1  Chapter introduction and purpose 
 
Individuals who are over 60 years of age are classified as elderly and it is currently 
estimated that within the next decade, over 20% of total global population will classify 
as the “elderly population” (Liu et al. 2002). In addition to this, the average age for a 
chronic obstructive pulmonary disease (COPD) diagnosis is 67 years and over 80% of 
patients with ischaemic heart disease (IHD) are over 65 years of age (Rosamond et al. 
2008). 
Despite the knowledge that myocardial infarction is more common in the elderly 
(Valente et al. 2010) and mounting evidence that myocardial I/R injury is more severe, 
as shown both clinically and experimentally (Lesnefsky et al. 1994, Lesnefsky et al. 
2003, Kajstura et al. 1996, Boengler et al. 2009), the cellular mechanisms responsible 
are yet to be fully elucidated. However, despite this, there is a significant lack of 
literature concentrating on the physiological mechanisms involved in I/R in the aged 
heart. 
From the perspective of anti-cholinergics, there is controversial evidence that elderly 
COPD patients require different pharmacological therapies in comparison with younger 
patients with respiratory diseases (Valente et al. 2010). However, although clinical 
trials have not identified any age-associated loss in the efficacy of anti-cholinergics, 
such as ipratropium (Valente et al. 2010), there are no clinical or pre-clinical studies to 
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address whether ipratropium, or other anti-cholinergic compounds, are associated 
with increased myocardial injury. In particular, due to the frequent concurrence of IHD 
and COPD, and with the knowledge that COPD patients are at a high risk of myocardial 
infarction, there is a distinct lack of research to identify whether anti-cholinergics are 
capable of exacerbating myocardial ischaemia/reperfusion injury in the senescent 
heart. 
Within the respiratory and cardiovascular systems, the primary subtypes of muscarinic 
receptors present are M2 and M3 (Haddad et al. 1999, Wessler and Kirkpatrick 2008). 
The antagonistic action of ipratropium at the M3 receptors in the airways is responsible 
for the alleviation of bronchoconstriction, thereby facilitating airflow and relieving 
COPD exacerbations (Barnes 2004). The agonistic action of acetylcholine within the 
myocardium has been shown as instrumental in limiting infarct size following I/R injury 
via a mechanism which activates the reperfusion injury salvage kinase (RISK) pathway 
and preservation of mitochondrial integrity through prevention of mitochondrial 
transition pore (mPTP) opening (Sun et al. 2010).  
There is accumulating evidence that aging is associated with a reduction in functional 
expression of the M2 (the subtype which accounts for the majority of mAChRs by 
density in the myocardium) (Abrams et al. 2006). The consequence of this is that 
endogenous acetylcholine is incapable of eliciting the negative inotropic and 
chronotropic effects observed in younger individuals (Brodde et al. 1998). However, it 
has not been ascertained whether the cardioprotective properties of acetylcholine are 
abolished in the aged myocardium. Under conditions of I/R, muscarinic pro-survival 
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signalling is instrumental in limiting infarct size, prevention of mPTP opening and 




6.2  Methods 
 
21 adult (3 month), 21 12 month, 21 18 month and 15 24 month male, Sprague-Dawley 
rats were used throught the experiments detailed in this chapter. All experiments were 
subject to the exclusion criteria detailed in Chapter 2, section 2.8. For all data, results 
are presented a group means + standard error of the mean (SEM). For the Western 
blotting data, values have been normalised to the respective untreated control, which 
is represented as 100%. Statistical differences were ascertained with the use of one-
way ANOVA, with the exception of haemodynamics which where a two-way ANOVA 
was employed, and Fisher’s LSD post-hoc test. 
 
6.2.1   Isolated perfused rat heart model 
 
Following sacrifice by cervical dislocation and excision, hearts from 3, 12, 18 and 24 
month old rats were mounted on Langendorff perfusion apparatus. For all 
experiments, the Langendorff model of I/R was used. Ipratropium (1 x 10-7 M) was 
administered after 55 mins, at the onset of reperfusion. At the end of the experimental 
protocol, infarct size to risk ratio (I/R %) was determined via Evans blue and TTC 
staining. Throughout all experiments, left ventricular developed pressure (LVDP, 
mmHg), heart rate (HR, beats.min-1) and coronary flow (CF, ml.min-1) were measured 




6.2.2  mPTP model of oxidative stress 
 
Cardiac myocytes were isolated as described in Chapter 2, section 2.6. Following 
adhesion to laminin coated cover slips, adhered myocytes from 3, 12 and 18 month old 
rats were incubated in microscopy buffer containing 3 x 10-6 M, tetramethylrhodamine 
methyl ester (TMRM) for 15 minutes. Cells were washed and randomly assigned to one 
of the following groups: untreated control, Ip (1 x 10-7 M), ACh (1 x 10-7 M) CsA (2 x 10-7 
M), Ip + ACh or Ip + CsA (concentrations as before). Myocytes were viewed and 
analysed via confocal microscopy. Depolarisation (Dep) was measured as the time at 
which the TMRM started to become evenly distributed throughout the cell and is 
indicative of the initiation of the mPTP opening. Subsequent hypercontracture (Hyp) of 
myocytes occurs shortly afterwards due to ATP depletion. The time to both Dep and 
Hyp were recorded. 
6.2.3   Western blotting 
 
Ventricular tissue was collected via Langendorff perfusion, following the protocol in 
Chapter 2, sections 2.6.1 and 2.6.2. Tissue was harvested following 5, 15 and 120 min 
reperfusion, as previously described, from 3, 12, 18 and 24 month old rats. Ipratropium 
(1 x 10-7 M) was administered at the onset of reperfusion. Following homogenisation 
and storage in suspension buffer, 60 µg of protein from was diluted with sample buffer 
and loaded into precast gels from samples of the following groups: untreated I/R 
control or ipratropium (1 x 10-7 M). After separation by electrophoresis, proteins were 
transferred onto PVDF membranes and probed for the phosphorylated forms of Akt, 
Erk1/2 and JNK. To assess relative changes in protein levels, membranes were 
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subsequently probed for the total, unphosphorylated forms of Akt, Erk1/2 and JNK and 
relative changes in phosphorylated protein were calculated as a percentage of total 






6.3  Results 
 
6.3.1 The observed exacerbation of myocardial 
ischaemia/reperfusion injury following ipratropium 
administration is more severe in the aged myocardium 
 
In order to ascertain whether ipratropium also elicits a cardiotoxic effect following I/R 
in the aged myocardium, isolated Langendorff heart experiments were conducted on 
3, 12, 18 and 24 month old Sprague Dawley rat hearts. In all different age control 
groups, hearts were subjected to the I/R protocol (as previously described, section 
2.3.4), in the ipratropium treatment groups, ipratropium (1 x 10-7 M) was administered 
at the onset of reperfusion. 
 
6.3.1.1  Effect of aging and ipratropium treatment on infarct 
development following ischaemia/reperfusion 
 
The results presented in Figure 6.1 show the effect of aging on infarct development in 
isolated perfused Langendorff rat hearts. In the 12, 18 and 24 month control groups, 
infarct development (I/R%) was statistically increased in comparison with the 3 month 
control group (p<0.01 for all groups, values in table 6.1). However, there was no 






Figure 6.1: A. Representative heart slices showing Evans blue and TTC staining following I/R 
protocol. Viable tissue is delineated as blue, risk tissue as red and infarction as grey/white. B. 
I/R% of 3, 12, 18 and 24 month Langendorff hearts following I/R protocol. ** p<0.01 vs. 3 
month group, n=3. 
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Table 6.1: Infarct development in the risk zone following ipratropium administration in 





























Figure 6.2: A. Representative heart slices showing Evans blue and TTC staining following I/R 
protocol in the presence of ipratropium (1 x 10-7M) administration. Viable tissue is delineated 
as blue, risk tissue as red and infarction as grey/white. B. I/R% of 3, 12, 18 and 24 month 
Langendorff hearts following I/R protocol and 1 x 10-7 M ipratropium administration at 
reperfusion.* p<0.05 and ** p<0.01 vs. 3 month group, n=3. 
 
Following aging, in the groups treated with ipratropium (1 x 10-7 M), there was an 
apparent age responsive increase in I/R % compared with the 3 month ipratropium 
treatment group. The results are presented in Figure 6.2 show the effect of aging and 
ipratropium administration on infarct development in isolated perfused Langendorff 
rat hearts. With the exception of the 12 month age group, ipratropium administration 
significantly increased I/R% in comparison with the 3 month, ipratropium treated, 
group (*p<0.05, **p<0.01 vs. 3 months, Figure 6.2, values in Table 6.1).  
 


























Figure 6.3: Infarct development in the risk zone following ipratropium (1 x 10-7 M) treatment in 
isolated perfused rat heart from rats of 3, 12, 18 and 24 months of age.Infarct to risk ratio 
following ipratropium administration at the onset of reperfusion. Results are presented as 
infarct/risk (%).* p<0.05 vs. 3 months control, #p<0.05 vs. 3 months ipratropium treated 
group. Results expressed as mean + SEM, n=6. 
 
With the exception of the 12 month age group, ipratropium administration 
significantly increased I/R% in comparison with the respective control (untreated) 
group from the same age group (statistical values represented on Figure 6.3, values in 
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6.3.1.2  Haemodynamic parameters 
 
All haemodynamic parameters were measured and expressed as previously described 
(section 2.3.3), and are presented in Figures 6.5 (LVDP), 6.6 (HR) and 6.7 (CF). There 
were no observed statistical differences in LVDP, HR or CF in comparison with hearts in 
the control group with any treatment group (ipratropium (Ip, 1x10-7 M), CsA (2x10-7 M) 
or Ip + CsA) at any time point throughout the experimental procedure. 
 
6.3.1.3 Left ventricular developed pressure (LVDP) 
 
 
Figure 6.4: Changes in left ventricular developed pressure in isolated perfused rat hearts from 
3, 12, 18 and 24 month old rats subjected to 20 minutes stabilisation, 35 minutes ischaemia 
and 120 minutes reperfusion. Ipratropium (1 x 10-7 M) was administered at the onset of, and 
throughout, reperfusion. Values expressed as mean percentage of the stabilisation period + 






















































































Figure 6.5: Changes in heart rate in isolated perfused rat hearts from 3, 12, 18 and 24 month 
old rats subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium (1 x 10-7 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 3 for 








































































Figure 6.6: Changes in coronary flow in isolated perfused rat hearts from 3, 12, 18 and 24 
month old rats subjected to 20 minutes stabilisation, 35 minutes ischaemia and 120 minutes 
reperfusion. Ipratropium (1 x 10-7 M) was administered at the onset of, and throughout, 
reperfusion. Values expressed as mean percentage of the stabilisation period + SEM, n= 3 for 





































































6.3.2 The role of mPTP opening in aged rat hearts following 
ipratropium ± acetylcholine administration in a model of 
oxidative stress 
 
As previously shown in Chapter 4, administration of acetylcholine (1 x 10-7 M) was 
shown to be capable of partially reversing ipratropium induced myocardial injury 
following I/R injury (as observed in the isolated perfused rat heart model) and 
significantly protecting against the loss of mitochondrial membrane integrity in the 
isolated myocyte model of oxidative stress. This is supported by previous studies 
where acetylcholine has been shown to be cardio-protective, as well as instrumental in 
pre- and post-conditioning, via a mechanism involving activation of the RISK pathway 
and prevention of mPTP opening (Sun et al. 2010a). 
In the present study, the model of oxidative stress was employed to identify whether 
acetylcholine was capable of eliciting protection in this model and also whether 
acetylcholine could protect against ipratropium induced myocardial I/R injury in the 
aged myocardium. In order to address this, 3, 12 and 18 month old male Sprague 
Dawley rats were used. The model of oxidative stress was carried out using 
ipratropium (1 x 10-7 M) ± acetylcholine (1 x 10-7 M) and, as previously described, the 
time taken to depolarisation and hypercontracture were measured via use of confocal 
microscopy. 
Figure 6.7 presents the results, for depolarisation, from the oxidative stress protocol. 
The main observation is that the time to depolarisation in the controls from both the 
12 and 18 month old rats were significantly decreased in comparison with the time to 
depolarisation in the 3 month control (104.8 ± 10.6 s and 98.5 ± 11.8 s, 12 and 18 
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months respectively vs. 201.2 ± 9.9 s 3 months, p<0.01). As observed, in the 3 month 
age group, ipratropium (1 x 10-7 M) significantly decreased the time to depolarisation 
in comparison with the untreated control (147.5 ± 17.5 s, Ip, p<0.01). In comparison 
with this, the time to depolarisation was significantly increased following acetylcholine 
(1 x 10-7 M) administration, in both the presence and absence of ipratropium (276.7 ± 
25.6 s, ACh, and 237.4 ± 9.3 s, Ip + ACh, p<0.05 and p<0.01 respectively). In contrast to 
this, in the 12 and 18 month age groups, there was no significant change in the time to 
depolarisation following any of the drug treatment groups (Ip (1 x 10-7 M), ACh (1 x 10-7 
M) or Ip + ACh (both 1 x 10-7 M)) in comparison with the respective control group. 
However, in 12 and 18 month old rats, all treatment groups showed a significant 
decrease in time to depolarisation in comparison with the respective treatment group 
in 3 month old rats, values in table 6.2. 
 
 Time taken to depolarisation (secs) 
 3 months 12 months 18 months 
Control 201.2 ± 9.9 104.8 ± 10.6 98.5 ± 11.8 
Ipratropium 147.5 ± 17.5 83.6 ± 11.4 93.3 ± 7.4 
Acetylcholine 276.7 ± 25.6 114.0 ± 2.5 107.9 ± 10.0 
Ip + ACh 237.4 ± 9.3 101.8 ± 6.8 102.3 ± 9.3 
 
Table 6.2: Time in seconds for 3, 12 and 18 month rat ventricular myocytes to undergo 
depolarisation following sustained, laser induced, oxidative stress and ipratropium (1 x 10-7 M) 
± acetylcholine (1 x 10-7 M) administration. n=6 animals for all groups, from which between 10-








Figure 6.7: Myocyte model of oxidative stress model conducted in 3, 12 and 18 month old 
Sprague Dawley rat ventricular myocytes. A. Effect of ipratropium (Ip, 1 x 10-7 M) ± ACh, (1 x 
10-7 M) on time to depolarisation and B. Values for time to depolarisation under the conditions 
of sustained oxidative stress. ~ p<0.05, ** and ~~ p<0.01 vs. 3 month control, $$ p<0.01 vs. 3 
month Ip, ^^ p<0.01 vs. 3 month ACh, ## p<0.01 vs. 3 month Ip+ACh. Values expressed as 
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3 months 12 months 18 months 
Control 201.2 ± 9.9 104.8 ± 10.6 ** 98.5 ± 11.8 ** 
Ipratropium 147.5 ± 17.5 ~ 83.6 ± 11.4 $$ 93.3 ± 7.4 $$ 
Acetylcholine 276.7 ± 25.6 ~ 114.0 ± 2.5 ^^ 107.9 ± 10.0 ^^ 
Ip + ACh 237.4 ± 9.3 ~~ 101.8 ± 6.8 ## 102.3 ± 9.3 ## 




As previously shown (Chapter 4), the time to hypercontracture, following ipratropium 
treatment, was significantly less than the control in the 3 month group. The data for 
hypcontracture is presented in Figure 6.8 (B) and Table 6.3. Interestingly, the time to 
hypercontracture in both the 12 and 18 month old group controls were statistically 
indistinct from the 3 month old control (655.4 ± 40.5 s and 613.6 ± 24.1 s, 12 and 18 
months respectively vs. 585.3 ± 33.9 s 3 months). Also, within the 12 and 18 month age 
groups, there was no significance between the groups treated with ipratropium ± 
acetylcholine in comparison with the respective control group. However, both the 
aged (12 and 18 month) ipratropium and acetylcholine treatment groups showed a 
significant increase in time to hypercontracture in comparison with the same 
treatment groups from the 3 month old study. In the 12 month old group, there was a 
significance increase in the time taken to hypercontracture in the group concomitantly 
treated with ipratropium and acetylcholine in comparison with the equivalent 3 month 
old treatment group. However, the 18 month old rats, of the same treatment group, 
were statistically indistinct from both the 3 and 12 month old groups. 
 Time taken to hypercontracture (secs) 
 3 months 12 months 18 months 
Control 585.2 ± 33.9 655.4 ± 40.5 613.6 ± 24.1 
Ipratropium 455.2 ± 15.3 578.6 ± 42.3 563.5 ± 32.6 
Acetylcholine 573.1 ± 23.2 694.6 ± 31.6 693.5 ± 29.7 
Ip + ACh 548.9 ± 11.7 626.6 ± 20.3 576.7 ± 27.8 
 
Table 6.3: Time in seconds for 3, 12 and 18 month rat ventricular myocytes to undergo 
hypercontracture following sustained, laser induced, oxidative stress and ipratropium (1 x 10-7 
M) ± acetylcholine (1 x 10-7 M) administration. n=6 animals for all groups, from which between 








Figure 6.8: Myocyte model of oxidative stress model conducted in 3, 12 and 18 month old 
Sprague Dawley rat ventricular myocytes. A. Effect of ipratropium (Ip, 1 x 10-7 M) ± ACh, (1 x 
10-7 M) on time to hypercontracture and B. Values for time to hypercontracture under the 
conditions of sustained oxidative stress. ~ p<0.05 and ~~ p<0.01 vs. 3 month control, $$ p<0.01 
vs. 3 month Ip, ^^ p<0.01 vs. 3 month ACh, # p<0.05 vs. 3 month Ip+ACh. Values expressed as 
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3 months 12 months 18 months 
Control 585.2 ± 33.9 655.4 ± 40.5 613.6 ± 24.1 
Ipratropium 455.2 ± 15.3  ~~ 578.6 ± 42.3 $$ 563.5 ± 32.6 $$ 
Acetylcholine 573.1 ± 23.2 ~ 694.6 ± 31.6 ^^ 693.5 ± 29.7 ^^ 
Ip + ACh 548.9 ± 11.7 626.6 ± 20.3 # 576.7 ± 27.8 




6.3.3 The role of mPTP opening in aged rat hearts following 
ipratropium ± cyclosporin A administration in a model of 
oxidative stress 
 
It was previously demonstrated in Chapter 5 that CsA is capable of partially reversing 
the observed ipratropium induced myocardial injury, in 3 month adult Sprague Dawley 
rats. CsA is well documented as a cardioprotective agent and links closure of the mPTP 
to preservation of myocyte viability under conditions of oxidative stress, such as during 
myocardial ischaemia/reperfusion (Cohen, Yang and Downey 2008, Crompton 1999, 
Halestrap 2009, Halestrap and Pasdois 2009, Hausenloy, Boston-Griffiths and Yellon 
2011, Hausenloy et al. 2002). However, it has previously been demonstrated that CsA 
is incapable of eliciting cytoprotective effects in the aged myocardium following such 
cellular stresses (Liu et al. 2011).  
The aim of this study was to ascertain whether the action of CsA was still able to 
elongate the times to depolarisation and hypercontracture, indicative of preservation 
of mitochondrial integrity as observed in adult (3 month) rats. Also, to identify whether 
CsA can limit the observed reduction in times for depolarisation and hypercontracture 
(as observed in 3 month rats) due to ipratropium administration in aged rat hearts (12 
and 18 months). 
The data from this study is shown in Figure 6.8. Panel A represents the time for 
depolarisation to occur following the onset of laser induced oxidative stress. In 
comparison with the 3 month control group, the time for depolarisation to occur is 
significantly decreased in both the 12 and 18 month age groups (104.8 ± 10.6 s and 
98.5 ± 11.8 s, 12 and 18 months respectively vs. 201.2 ± 9.9 s 3 months, p<0.01), as 
previously shown in Figure 6.7, A. As previously described ipratropium significantly 
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decreased time to depolarisation in comparison with the untreated control in the 3 
month age group, whereas, CsA was capable of significantly prolonging the time for 
depolarisation (283.1 ± 24.0 s, CsA, p<0.01). The co-administration of ipratropium and 
CsA had an affect which attenuated the reduction in time to depolarisation due to 
ipratropium administration such that it was statistically indistinct from the control 
group (Figure 6.9).  
In the 12 and 18 month groups, there was a significant decrease in time to 
depolarisation (p<0.01 for all groups) in comparison with the respective 3 month 
treatment groups. However, there was no significant change in comparison with the 
control of the same age group observed with any treatment group. There was also no 
significant change between treatment groups within respective age groups (Table 6.4). 
 
 Time taken to depolarisation (secs) 
 3 months 12 months 18 months 
Control 201.2 ± 9.9 104.8 ± 10.6 98.5 ± 11.8 
Ipratropium 147.5 ± 17.5 83.6 ± 11.4 93.3 ± 7.4 
Cyclosporin A 283.1 ± 24.0 98.2 ± 8.8 102.1 ± 10.9 
Ip + CsA 217.0 ± 16.4 92.7 ± 6.1 104.5 ± 9.8 
 
Table 6.4: Time in seconds for 3, 12 and 18 month rat ventricular myocytes to undergo 
depolarisation following sustained, laser induced, oxidative stress and ipratropium (1 x 10-7 M) 
± CsA (2 x 10-7 M) administration. n=6 animals for all groups, from which between 10-15 











Figure 6.9: Myocyte model of oxidative stress model conducted in 3, 12 and 18 month old 
Sprague Dawley rat ventricular myocytes. A. Effect of ipratropium (Ip, 1 x 10-7 M) ± CsA, (2 x 10-
7 M) on time to depolarisation and B. Values for time to depolarisation under the conditions of 
sustained oxidative stress. **and ~~ p<0.01 vs. 3 month control , $$ p<0.01 vs. 3 month Ip, ^^ 
p<0.01 vs. 3 month CsA, ## p<0.01 vs. 3 month Ip+CsA. Values expressed as mean + SEM, n=6 
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3 months 12 months 18 months 
Control 201.2 ± 9.9 104.8 ± 10.6 ** 98.5 ± 11.8 ** 
Ipratropium 147.5 ±  17.5~ 83.6 ± 11.4 $$ 93.3 ± 7.4 $$ 
Cyclosporin A 283.1 ± 24.0 ~ 98.2 ± 8.8 ^  ̂ 102.1 ± 10.9 ^^ 
Ip + CsA 217.0 ± 16.4 ~~ 92.7 ± 6.1 ## 104.5 ± 9.8 ## 




Panel B of Figure 6.10 shows the times taken for hypercontracture to occur in 3, 12 
and 18 month Sprague Dawley ventricular myocytes. Following ipratropium treatment, 
hypercontracture was significantly reduced in 3 month old rats, in comparison with the 
untreated control group (p < 0.01). This was increased (although not significantly) 
following CsA treatment, in comparison with the control and, although CsA appeared 
to abrogate the observed ipratropium induced reduction in time, when co-
administered, this was also not significant. Unexpectedly, the time taken for 
hypercontracture was statistically indistinct from the 3 month control in all treatment 
groups in the 12 and 18 month old myocytes. Also, within the 12 and 18 month age 
groups there was no significant difference between any treatment group. There was, 
however, a significant increase in the time taken for hypercontracture to occur in the 
12 and 18 month groups treated with ipratropium in comparison with the 3 month 
ipratropium group (p < 0.01) (Figure 6.10, Table 6.5).  
 
 Time taken to hypercontracture (secs) 
 3 months 12 months 18 months 
Control 585.2 ± 33.9 655.4 ± 40.5 613.6 ± 24.1 
Ipratropium 455.2 ± 15.3 578.6 ± 42.3 563.5 ± 32.6 
Cyclosporin A 638.9 ± 41.0 633.7 ± 43.2 611.8 ± 40.6 
Ip + CsA 599.0 ± 23.8 600.0 ± 41.9 583.0 ± 17.4 
 
Table 6.5: Time in seconds for 3, 12 and 18 month rat ventricular myocytes to undergo 
hypercontracture following sustained, laser induced, oxidative stress and ipratropium (1 x 10-7 
M) ± CsA (2 x 10-7 M) administration. n=6 animals for all groups, from which between 10-15 









Figure 6.10: Myocyte model of oxidative stress model conducted in 3, 12 and 18 month old 
Sprague Dawley rat ventricular myocytes. A. Effect of ipratropium (Ip, 1 x 10-7 M) ± CsA, (2 x 10-
7 M) on time to hypercontracture and B. Values for time to hypercontracture under the 
conditions of sustained oxidative stress. **and ~~ p<0.01 vs. 3 month control , $$ p<0.01 vs. 3 
month Ip, ^^ p<0.01 vs. 3 month CsA, ## p<0.01 vs. 3 month Ip+CsA. Values expressed as mean 
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3 months 12 months 18 months 
Control 585.2 ± 33.9 655.4 ± 40.5 613.6 ± 24.1 
Ipratropium 455.2. ± 15.3 ~~ 578.6 ± 42.3 $$ 563.5 ± 32.6 $$ 
Cyclosporin A 638.9 ± 41.0 633.7 ± 43.2 611.8 ± 40.6 
Ip + CsA 599.0 ± 23.8 600.0 ± 41.9 583.0 ± 17.4 




6.3.4 Ipratropium bromide induced myocardial injury in aged rat 
heart is associated with downregulation of phospho-Akt  
 
It was previously reported in Chapter 4,  that increased expression of phospho-Akt 
following ipratropium (1 x 10-7 M) administration were associated with ipratropium 
induced myocardial injury, following 5, 15 and 120 minutes of reperfusion. Due to the 
identification that ipratropium administration appears to further exacerbate 
myocardial I/R injury in aged rats (12, 18 and 24 months), the present study aimed to 
identify whether this exacerbation of injury was associated with changes in Akt levels. 
Hearts were harvested 15 minutes after the onset of reperfusion where ipratropium (1 
x 10-7 M) was administered as reperfusion was initiated. Western blot analysis was 
used to determine the expression levels of phospho-Akt as a percentage of total Akt in 
the homogenised heart samples.  
As shown in Figure 6.11, A, in all four age groups, hearts subjected to 35 minutes 
ischaemia and ipratropium (1 x 10-7 M) administration at the onset of reperfusion 
showed a statistically significant increase in p-Akt in comparison with control I/R hearts 
for the corresponding age group (Fig. 6.11, B, p<0.01 for all groups).  
Interestingly, there was no significant difference in phospho-Akt levels in comparison 
with the 3 month I/R control in the I/R control groups in any of the other age groups. 
However, in contrast to this, there was what appeared to be an age-dependent 
reduction in phospho-Akt levels compared with the 3 month group in the groups 
exposed to I/R protocol and ipratropium (1 x 10-7 M) administration (321.0 ± 9.4% (3 
months) vs. 218.6 ± 22.3% (12 months), 152.7 ± 20.2% (18 months) and 110.8 ± 20.3% 






Figure 6.11: The effect of ipratropium (1 x 10-7 M) treatment on the levels of phosphorylated 
Akt following 35 minutes regional ischaemia and 15 minutes reperfusion in hearts taken from 
3, 12, 18 and 24 month old male Sprague Dawley rats. A. Shows corresponding representative 
blots for GAPDH, p-Akt and total Akt for all groups and graphical representation of mean + 
SEM of p-Akt/Akt as a percentage of the 3 month control. B. Numerical values for all groups. 
** p<0.01 vs. 3 month ipratropium treated group. Statistical difference between ipratropium 
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6.3.5 Ipratropium bromide induced myocardial injury in aged rat 
heart is associated with downregulation of phospho-Erk 1/2 
 
In chapter 4, following 5, 15 and 120 minutes reperfusion, ipratropium administration 
was associated with a statistical increase in levels of phospho-Erk1/2. In this study, 3, 
12, 18 and 24 month old Sprague Dawley rat hearts were subjected to 35 minutes 
regional ischaemia and 15 minutes reperfusion, in the absence and presence of 
ipratropium (1 x10-7 M) at reperfusion, and harvested for Western blot analysis (as 
previously described). These studies were conducted in order to elucidate whether 
there was involvement of Erk 1/2 in the observed exacerbation of ipratropium induced 
myocardial injury in the aged myocardium. 
There was no observed statistical difference in levels of phosphorylation of Erk 
between the 3, 12 or 18 month control groups (values in Figure 6.12 B). However, in 
the 24 month group, levels of phospho Erk were significantly less than in the 3 month 
control group (100.0 ± 0.0%, 3 months vs 57.7 ± 12.5%, 24 months, p<0.01). 
As previously observed, the administration of ipratropium significantly increased Erk 
phosphorylation in comparison with the untreated control in the 3 month group (100.0 
± 0.0%, control vs. 180.9 ± 10.7%, Ip, p<0.01). In both the 12 and 18 month groups, the 
administration of ipratropium significantly increased the level of phospho-Erk in 
comparison with the respective untreated control of the same age group (values in 
figure 6.12 B, both p<0.01). In the 24 month age group, despite a small increase in Erk 
phosphorylation in comparison with the control, the difference between the two 
groups was not significant. 
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Interestingly, the levels of Erk phosphorylation in the ipratropium treated groups 
appeared to decline in an age dependent manner. In particular, in the 18 and 24 
month groups, the levels of phospho-Erk were significantly less than in the 3 month 






















Figure 6.12: The effect of ipratropium (1 x 10-7 M) treatment on the levels of phosphorylated 
Erk1/2 following 35 minutes regional ischaemia and 15 minutes reperfusion in hearts taken 
from 3, 12, 18 and 24 month old male Sprague Dawley rats. A. Shows corresponding 
representative blots for GAPDH, p-Erk1/2 and total Erk1/2 for all groups and graphical 
representation of mean + SEM of p-Erk1/2/Erk1/2 as a percentage of the 3 month control. B. 
Numerical values for all groups. * p<0.05 and ** p<0.01 vs. 3 month ipratropium treated 
group. Statistical difference between ipratropium treated groups and respective control 
depicted on graph. n=3 for all groups.    
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6.3.6 Ipratropium bromide induced myocardial injury in aged rat 
heart is associated with an increase in phosphorylation of JNK 
 
In chapter 4, following 5, 15 and 120 minutes reperfusion, ipratropium administration 
was associated with a statistical decrease in levels of phospho-JNK, following 15 
minutes reperfusion. In this study, 3, 12, 18 and 24 month old Sprague Dawley rat 
hearts were subjected to 35 minutes regional ischaemia and 15 minutes reperfusion, in 
the absence and presence of ipratropium (1 x10-7 M) at reperfusion, and harvested for 
Western blot analysis (as previously described). These studies were conducted in order 
to elucidate whether there was involvement of JNK in the observed exacerbation of 
ipratropium induced myocardial injury in the aged myocardium. 
In the 12, 18 and 24 month untreated control groups, there were significantly higher 
levels of phospho-JNK in comparison with the 3 month control group (p<0.01 vs. 3 
month control for all groups, values in Figure 6.13 B).  In the ipratropium treatment 
groups, there was also a significant increase in comparison with the 3 month group 
with all of the other ipratropium treatment groups *p<0.01 vs. 3 month ipratropium 
group for all groups, values in Figure 6.13 B). 
Interestingly, with the exception of the 3 month group, there was no statistical 










Figure 6.13: The effect of ipratropium (1 x 10-7 M) treatment on the levels of phosphorylated 
JNK following 35 minutes regional ischaemia and 15 minutes reperfusion in hearts taken from 
3, 12, 18 and 24 month old male Sprague Dawley rats. A. Shows corresponding representative 
blots for GAPDH, p-JNK and total JNK for all groups and graphical representation of mean + 
SEM of p-JNK/JNK as a percentage of the 3 month control. B. Numerical values for all groups. 
** p<0.01 vs. 3 month control group, $$ p<0.01 vs. 3 month ipratropium treatment group. 
Statistical difference between respective control depicted on graph. n=3 for all groups.   
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6.4  Chapter Discussion 
 
Globally, by the year 2050, the number of individuals who fall into the “elderly” 
population (aged 60 or above) is projected to be 1.5 billion. As previously described, 
aging not only represents an increase in the risk of myocardial syndromes, but also 
enhances susceptibility to adverse clinical outcomes. In the context of myocardial I/R, 
aging has been shown as a critical determinant in the exacerbation of I/R injury 
(Lesnefsky et al. 1994, Lucas and Szweda 1998). Within the heart, changes in cellular 
metabolism in senescent myocytes leads to alterations of myocardial metabolism, 
mitochondrial function (Jian et al. 2011), increases in ROS and deficiencies in Ca2+ 
signalling. The contribution of these changes in the context of I/R leads to deregulation 
of downstream cellular survival pathways (Korzick and Lancaster 2013, Tani et al. 
1999).  
In addition to this, COPD is, on average, diagnosed at 67 years of age. However, 
despite the frequent co-morbidity of COPD with concurrent IHD and the knowledge 
that MI accounts for a major cause of death in COPD patients, as well as the previous 
mentioned alterations in senescent myocytes, there are not currently different 
therapies for elderly COPD patients. It has also been observed that, in older patients, 
left ventricular function is compromised, which represents a further risk factor for the 
development of IHD (Gardin and Lauer 2004). The aim of the present study was to 
identify the effects of ipratropium on myocardial injury following I/R, in the hearts of 
aged (12, 18 and 24 month) rats. 
The major finding of the work presented in this chapter is that, within the aged rat 
groups (12, 18 and 24 months), myocardial injury following simulated I/R is 
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significantly exacerbated in comparison with the 3 month, adult rat, groups. This was 
observed as a significant increase in I/R% in the Langendorff isolated perfused heart 
model (12, 18 and 24 months vs. 3 month group), as well as a significant decrease in 
time to depolarisation, indicative of loss of mitochondrial integrity, in the cardiac 
myocyte model of oxidative stress (12 and 18 months vs. 3 month group). These 
observations support a growing body of research which shows that aging itself 
exacerbates I/R injury (Poulose and Raju 2014). Coupled with this, it has also been 
demonstrated that protection afforded by ischaemic pre-conditioning is lost in the 
aged myocardium (van den Munckhof et al. 2013). Under naïve conditions, there is a 
reduction in myocyte mitochondrial activity, as well as a reduction in the number of 
mitochondria. This implies there is a reduced oxidative phosphorylation (attributed to 
decreased complex III and IV activity), therefore contributing to a baseline increase in 
oxidative stress, even in the absence of myocardial injury (Boengler, Schulz and Heusch 
2009).  
In contribution to this, Ca2+ handling is deregulated in the aged myocardium, due to 
age associated increases in NCX activity as well as a reduction in SERCA expression 
(Janczewski, Spurgeon and Lakatta 2002). This promotes endogenous Ca2+ overloading 
in the absence of disease which, following I/R, is further exacerbated. 
Primarily, the mechanism of mPTP opening has been shown as a determinant for 
myocyte fate at the onset of reperfusion, following an ischaemic insult (Halestrap 
2009). In conjunction with increases in intracellular Ca2+ and ROS generation, the 
reduction in mitochondrial membrane integrity following mPTP opening promotes 
myocyte loss by both apoptosis and necrosis (Halestrap 2009). ROS induced injury 
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following I/R is thoroughly documented, as is the contribution of increases in Ca2+ 
(Chen et al. 2006, Chen et al. 2011). Within the senescent myocardium, the underlying 
elevated ROS and Ca2+ levels, are further exacerbated during I/R, which therefore 
promotes mPTP opening at reperfusion to an extent which is greater than that in the 
young myocardium. This therefore leads to further infarct development due to higher 
levels of apoptosis and necrosis, as observed in the Langendorff studies. The myocyte 
model of oxidative stress used in this work also supports the literature as there was a 
significant reduction in time to depolarisation following sustained oxidative stress, 
implying that the mitochondria are less resilient in comparison with those in the 3 
month group. This has been attributed to underlying increases in ROS and Ca2+ in the 
aged cardiac myocytes. 
Interestingly, there was no aged-related significant difference in hypercontracture 
observed in comparison with the 3 month group. In chapters 4 and 5, it was observed 
that, despite large differences following different pharmacological treatments in the 
time to depolarisation, the variation in time to hypercontracture between groups was 
much less. It is postulated that this is due to the time taken for elevated Ca2+ levels to 
reduce following I/R or oxidative stress. This is dependent on the restoration of NCX 
and IP3R function which requires reactivation of the Na+-K+-pumps by ATP, thereby 
slowly restoring the Na+ gradient prior to the NCX being able to extrude the excess 
cytosolic Ca2+ (Zaugg, Schaub and Foex 2004, Murphy and Steenbergen 2008). 
However, irrespective of the severity of ischaemic injury, the time frame for this does 
not particularly vary. A possible explanation for the results presented here is that, 
within the aged myocardium, although resting levels of Ca2+ are significantly higher 
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than in the young heart, the time frame for the restoration of baseline Ca2+ levels, 
following re-establishment of NCX and IP3R function, remains indifferent from that in 
the adult (3 month) group.  
In the Langendorff model, there was a further increase in I/R% in comparison with the 
respective untreated control in the aged myocardium (significant in the 18 and 24 
month groups). This is in accordance with the data from the 3 month group whereby 
ipratropium was observed to exacerbate myocardial injury following I/R (Chapter 3). 
Myocardial injury in the aged myocardium was already observed to be statistically 
exacerbated, as described above. In the 3 month group, the exacerbation of I/R% 
following ipratropium administration was attributed to blockage of endogenous ACh 
signalling, therefore preventing activation of pro-survival kinases such as (PI3K)-Akt 
and Erk1/2 (components of the RISK pathway). In the case of the aged study, it is 
understood that muscarinic receptors within the myocardium decrease with age 
(Brodde et al. 1998, Lo et al. 2001). It is therefore possible that the competitive action 
of ipratropium at the muscarinic receptors in the aged myocardium is, therefore, 
sufficient to further diminish downstream, protective signalling cascades from 
endogenous ACh, thereby contributing to a further exacerbation of myocardial injury 
in this context.  
It is plausible that the exacerbation of infarct development following ipratropium 
injury in the aged myocardium is also due to disruption of RISK signalling, which, once 
activated, is linked to closure of the mPTP, therefore maintaining mitochondrial 
function and salvage of cardiac myocytes. However, in the aged myocardium, 
protection via mechanisms which prevent mPTP opening appear to be lost (Liu et al. 
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2011b). This is primarily due to the increased susceptibility for mPTP opening due to 
elevated levels of ROS and Ca2+ (Liu et al. 2011b).  
Further to this, it has also been demonstrated that mPTP opening promotes myocyte 
loss, on the whole, by primary necrosis with apoptotic death only slightly contributing 
(Kung, Konstantinidis and Kitsis 2011). However, within the aged myocardium, it has 
been demonstrated that, following an ischaemic insult, the contribution of necrosis to 
myocardial injury is indistinct from that observed in younger rats, however, the 
increase in apoptosis is greatly increased (Kajstura et al. 1996). This has been 
accompanied by age associated increases in essential components of the intrinsic 
apoptotic cascade, such as Bcl-2, Bax, caspase-3 and cytochrome c (Liu et al. 2002, 
Phaneuf and Leeuwenburgh 2002, Liu et al. 2011b) at both the cellular and molecular 
level as mRNA levels of Bax are disproportionately increased in comparison with Bcl-2 
(Liu et al. 2002).  
The role for the mPTP in ipratropium induced myocardial injury in the aged heart was 
studied via the model of oxidative stress (Figures 6.8 – 10). As already described, there 
was a significant reduction in time to depolarisation in the control aged groups in 
comparison with the respective 3 month group. In comparison with the respective 
treatment groups, in both the 12 and 18 month groups, all drug treatment groups (Ip, 
ACh, CsA and Ip ± ACh or CsA) showed a significant (p<0.01 for all groups) decrease in 
the time taken for depolarisation to occur in comparison with the respective, 3 month, 
treatment group. However, within the 12 and 18 month groups, there was no 
significant change in depolarisation observed between any of the treatment groups 
within the same age group. 
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As previously described, following aging, ROS and Ca2+ levels are increased, leading to 
an increased susceptibility for the mPTP to open at the onset of reperfusion. In the 
study where ipratropium and ACh were investigated, it is possible that the inability for 
ACh to protect is due to the down-regulation of cardiac mAChR receptors. This may 
mean that activation of components of the RISK signalling cascade are not as potently 
activated following muscarinic stimulation as in young (3 month) rats. Due to the 
intrinsic link that RISK pathway activation prevents mPTP opening, this data implies 
that this limitation of pro-survival muscarinic signalling may be sufficient to prevent 
preservation of mitochondrial membrane integrity through the delay of mPTP opening. 
Further to this, opening of KATP channels have been shown to play a role in 
acetylcholine mediated pre-conditioning due to inhibition of mPTP opening (Qian et al. 
1996, Hausenloy et al. 2002). However, in the aged myocardium, a reduction in KATP 
channels has been shown (Ranki et al. 2002) and also, isoflurane (an anaesthetic 
known to induce cardio-protection via KATP) is significantly less effective following aging 
(Mio et al. 2008). It is therefore possible that the impaired function of KATP channels, 
due to aging, is able to “over-ride” the protective properties of ACh, thereby abolishing 
the protective effect of ACh on the mPTP.  
In the 3 month group, ipratropium accelerates mPTP opening. However, in this study, 
further contribution to the decrease in time to depolarisation following ipratropium 
administration does not occur. As with ACh, it could be that the age-associated 
reduction of mAChRs in the aged myocardium means that ipratropium is unable to 
exert further injury via disruption of the mitochondria through muscarinic signalling.  
300 
 
In the context of the CsA studies, it was also observed that CsA was unable to protect 
against the prevention of mPTP opening in the aged (12 and 18 month) groups, 
whereas it was observed in chapter 5 that CsA could potently protect against mPTP 
opening as well as ipratropium mediated myocardial injury.  
Cyclosporin A (CsA) inhibits mPTP opening via binding to cyclophilin-D, which therefore 
elicits CsA mediated cardioprotection (Xie and Yu 2007, Halestrap and Richardson 
2014). This has been widely documented and observed, as significant decreases in 
infarct size as well as modulation of critical mediators of I/R injury, following CsA 
administration. In the context of the aged myocardium, CsA is incapable of reducing 
infarct size. In conjunction with this, NAD+ loss following mPTP opening was not 
different in the aged hearts following I/R with or without CsA administration (Liu et al. 
2011b). Given that the cardioprotective effects of CsA can be inhibited by elevations of 
Ca2+, it is possible that the inability for CsA to protect in the aged myocardium involves 
a similar mechanism as Ca2+ levels are significantly higher following I/R in aged hearts 
in comparison with young hearts.  
It is proposed that CsA protects against mPTP opening via a mechanism which inhibits 
cyclophilin D from associating with the ANT (Halestrap 2009), as such, it is possible that 
the observed defects within the mitochondria and increases in oxidative damage due 
to aging are sufficient that the mitochondria are less resilient to oxidative stress, such 
that the interaction of CsA with cyclophilin D is unable to protect (Liu et al. 2011b). 
There is a multitude of evidence to suggest a down-regulation of GPCR expression as a 
consequence of aging. From an intracellular signalling perspective, the limitation of 
cytoprotective, GPCR mediated, signalling is either due to a reduction in receptors of 
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loss of sensitivity to agonist binding (Peart et al. 2014). The correlation of the 
expression of mAChRs with age is of primary interest. As already stated, mAChR 
expression has been shown to decrease with age. 
In this study, levels of the pro-survival kinases Akt and Erk1/2, as well as the stress 
induced kinase JNK, were ascertained in 3, 12, 18 and 24 month rats following 35 
minutes regional ischaemia and 15 minutes reperfusion. This is due to the primary 
involvement of Akt and Erk1/2 in pro-survival signalling cascades following I/R as well 
as the known association of JNK activation following cellular stresses (including I/R). All 
three kinases are also known effectors of downstream signalling following muscarinic 
receptor activation by acetylcholine. Further to this, significant differences in levels of 
Akt, Erk1/2 and JNK phosphorylation were previously observed in 3 month rats 
following I/R and ipratropium administration.  
The involvement of Akt and Erk signalling in the aged myocardium has been shown as 
an important determinant in sevoflurane mediated post-conditioning (Li et al, 2013). It 
has also been demonstrated that, within the murine and human myocardium, there is 
a repressed tolerance to ischaemia which appears to be due to age-related differences 
in cyto-protective, kinase signalling (Peart et al. 2014). The data presented here 
support this as Akt and Erk1/2 are both activated at lower levels (even in the absence 
of ipratropium) following I/R in the aged tissues compared with the three month 
controls. It is also interesting that JNK, a stress induced kinase, appears to have a role 
in the myocardial injury recorded in this study. However, previously (Chapters 4 and 5) 
it appearsed as though JNK was not instrumental in mediating ipratropium induced 
myocardial injury. It is therefore likely thar JNK is activated at higher levels within the 
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aged myocardium, as previously described (Xu et al. 2014), which contributes to 
myocardial injury, even in the absence of a cardio-toxic agent, such as ipratropium.    
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Chapter 7 General Discussion 
 
7.1  Summary of Findings  
 
Ipratropium bromide has been administered as a treatment for COPD and emergency 
adjunct therapy for asthma since 1987 (Restrepo 2007). The primary aim of this work 
was to identify whether there was a cellular basis for the observed increased risk of 
adverse cardiovascular outcomes in the setting of underlying heart conditions, 
following ipratropium administration, as outlined in the meta-analysis conducted by 
Singh and colleagues (Singh et al. 2008). Specifically, this was investigated in the 
context of ischaemia/reperfusion injury in order to ascertain whether, in a non-clinical 
ex vivo heart model, injury following regional ischaemia and reperfusion was 
exacerbated due to ipratropium administration.  
The rationale behind the use of this model was that many patients who receive 
ipratropium may also be at risk of myocardial infarction if they have underlying IHD 
(Huiart, Ernst and Suissa 2005, Maclay, McAllister and Macnee 2007, Macnee, Maclay 
and McAllister 2008). The co-morbidity of IHD with COPD remains the biggest risk 
factor for death by myocardial infarction (MI) in COPD patients (Zielinski et al. 1997). 
There is an increasing wealth of clinical studies which indicate that anti-muscarinic 
treatments (such as ipratropium) are responsible for an increased risk of both 
occurrence and severity of adverse cardiovascular events (Singh et al. 2008, Singh et al. 
2013). As such, this work aimed to identify whether this was due to ipratropium 
interacting with cellular signalling pathways involved in the clinical manifestation of 
MI. In a non-clinical, although clinically relevant, study, this was addressed by using in 
vitro rat myocardial models of simulated ischaemia and reperfusion.  
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From this respect, this work has identified that under normoxic conditions ipratropium 
does not appear to influence the cellular function of cardiac myocytes, with the 
exception that at 1 x 10-6 M and 1 x 10-7 M ipratropium, following administration for 60 
minutes, LVDP showed significant increases in comparison with the untreated controls 
and heart rate was significantly increased (also following 60 minutes exposure to 
ipratropium) in the group treated with 1 x 10-6 M ipratropium. This is in accordance 
with previous work which has shown ipratropium to possess positive inotropic and 
chronotropic effects (Windom 1990). This is potentially due to an impairment of the 
NCX and, therefore, mediated via Ca2+ influx, as previously shown in the context of 
cardiotoxicity where physostigmine (an AChE inhibitor) potentiated negative inotropic 
and chronotropic responses within rat atria, but this was antagonised with the addition 
of atropine (Mazumder et al. 1997). 
Interestingly, in the studies where hearts were subjected to the I/R protocol, 
ipratropium administration did not appear to have any haemodynamic effect, although 
there was observed exacerbation of infarct development in comparison with the 
untreated control hearts subjected to the same protocol. It is speculated here that the 
absence of haemodynamic effects in these studies is as a result of overall cardiac 
dysfunction following ipratropium induced injury and, therefore, haemodynamic 
effects could not be observed in this study.  
The release of ACh from the vagus nerve, and subsequent binding to MAChRs in the 
myocardium, stimulates parasympathetic actions leading to GPCR led decreases of 
cAMP and activation of KACh channels (Shultz et al. 2008). Therefore, endogenously, 
ACh reduces the rate of conduction from the sinoatrial node leading to negative 
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chronotropy (Nathanson 2008). In contrast to this, in vivo and clinical use of muscarinic 
antagonists prevent the action of ACh and attenuate the vagal nerve stimulation, 
therefore leading to increases in both heart rate and conduction velocity (Singh et al. 
2013). In patients with underlying heart conditions, this can promote arrhythmias and 
tachycardia. From a clinical perspective, pro-arrhythmic and pro-ischaemic effects due 
to anti-muscarinic treatments have been observed in patients with underlying IHD 
(Singh et al. 2013).  It is possible that the inotropic and chronotropic effects may 
contribute to contractile dysfunction, which could represent a further risk factor for 
the development of MI and IHD. Contractile dysfunction is a major hallmark for the 
development of many cardiovascular disorders, including conditions involving 
ischaemic events such as MI and IHD. It is considered that abnormal levels of Ca2+ 
influence not only the contraction of the heart, but also can contribute to 
mitochondrial Ca2+ overload, therefore also initiating mitochondrial damage and 
oxidative stress (Goldhaber 2001). In addition to this, ipratropium has been shown to 
stimulate eryptosis (programmed cell death in erythrocytes with mechanistic 
similarities to apoptosis) via increases in Ca2+ (Shaik et al. 2012). In combination, it is 
therefore possible that ipratropium elicits myocardial damage following I/R through a 
similar mechanism which stimulates apoptosis via increases in Ca2+. As it is known that 
the protective properties of ACh are partly due to cholinergic signalling which 
regulates Ca2+ levels (Russo et al. 2014), it is plausible that muscarinic antagonists 
could promote myocardial injury through mechanisms which cause de-regulation of 
the same cellular machinery, in this case, Ca2+ regulation and signalling. 
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Within this work it was identified, by use of the MTT assay and flow-cytometry, that 
ipratropium decreases overall myocyte viability, including both apoptosis and necrosis, 
which were observed following ipratropium administration. This supports the notion 
that myocyte death after the initiation of reperfusion occurs through concomitant 
apoptosis and necrosis (Buja and Weerasinghe 2010, Bishopric et al. 2001) and implies 
that ipratropium exerts its cardio-toxic effect during reperfusion rather than before. 
The remainder of this work therefore concentrated on cellular processes which occur 
during reperfusion in order to try to identify a signalling mechanism for ipratropium 
induced myocardial injury. 
 
7.1.1 Mechanism of protection by Acetylcholine 
 
In order to further characterise the mechanism by which ipratropium elicits myocardial 
damage following an ischaemic insult, studies were conducted with ACh and CsA as 
both agents are known to be cardio-protective, as has been demonstrated in rat, 
mouse and human cell lines. In particular, ACh is the endogenous agonist of muscarinic 
receptors (Caulfield and Birdsall 1998).  
With use of an ACh assay, it was identified that endogenous ACh was present in the 
experimental models used. This was necessary as an antagonist does not exhibit 
efficacy following receptor binding and, therefore, without endogenous ACh present, it 
is likely that the detrimental effects observed due to ipratropium administration were 
off-target and not due to disruption of muscarinic signalling. 
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In the context of cardio-protection, ACh has shown to exert protective effects in 
various animal models, including rat and mouse following an ischaemic insult (Buys et 
al. 2003, De Sarno et al. 2003, De Sarno et al. 2005, Styles, Zhu and Li 2005). In 
particular, this is proposed to be via the M3 muscarinic receptor subtype present in the 
heart (Budd et al. 2003, Li et al. 2011, Resende and Adhikari 2009).  
Following simulated I/R, ACh was shown to statistically abrogate infarction due to I/R 
alone, therefore supporting previous work (Sun et al. 2013). ACh was also able to 
significantly increase the time for depolarisation to occur in the model of oxidative 
stress, thereby also supporting previous investigations which have shown that ACh 
elicits its cardio-protective effects via mechanisms which involve the RISK pathway 
linked to the preservation of mitochondrial integrity due to promoting closure of the 
mPTP (Sun et al. 2010a).  
In the presence of ipratropium, ACh was able to significantly attenuate the observed 
myocardial damage, this implies that ipratropium is acting at the muscarinic receptors 
and that blockade of endogenous ACh by ipratropium is sufficient to limit downstream 
signalling which leads to loss of the protective mechanisms which are normally elicited 
by ACh. These observations also support other work where it has been shown that ACh 
mediated cyto-protection can be abolished by muscarinic antagonists (Lim et al. 2007). 
In this study ipratropium (a non-selective muscarinic antagonist) was used and so it is 
not possible to identify whether the ipratropium induced injury is due to a specific 
action on one subtype of muscarinic receptor, or whether it is a general action on all 
the subtypes in the heart. By population, M2 receptors are the most densely 
distributed of all muscarinic receptors in the myocardium, however the role of M3 
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receptors in cardio-protection has been more extensively studied in comparison with 
the other subtypes (Pan et al. 2012, Wang et al. 2012, Zhao et al. 2010). It actually 
appears as though M2 receptors play a minor role in protective signalling following I/R 
and, therefore it is proposed in this work that it is the antagonist action of ipratropium 
on the M3 receptors which is responsible for the observed myocardial injury. In order 
to fully elucidate this, further work with selective antagonists and, where possible, 
agonists, for specific subtypes of muscarinic receptors would need to be carried out.  
 
7.1.2 Mechanism of protection by CsA 
 
CsA is known to protect from the mitochondria via a mechanism which prevents 
opening of the mPTP and was therefore used to help clarify whether ipratropium 
induced injury has mitochondrial involvement. It is now well established that opening 
of the mPTP within the first few minutes of reperfusion is a pivotal event in the 
development of infarction and cardiac myocyte loss following an ischaemic event. 
Throughout prolonged ischaemia, Ca2+ levels steadily rise, mitochondrial [Pi] is high 
and levels of ATP are significantly reduced due to limitation of oxidative 
phosphorylation. These events condition the mPTP such that the oxidative stress and 
further Ca2+ accumulation, as well as increases in pH following ischaemia induced 
acidosis, which occur as a consequence of reperfusion, promote pore formation 
(Halestrap and Richardson 2014). Upon mPTP opening, cytosolic solutes rapidly move 
into the mitochondria causing swelling and, eventual rupture, of the outer 
mitochondrial membrane. This then promotes cardiac myocyte death due to both 
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apoptosis (following release of mitochondrial pro-apoptotic factors) as well as necrosis 
(due to inhibition of ATP formation).  
In addition to this, protective strategies which target the mPTP have therefore become 
attractive since the elucidation of the detrimental role of mPTP opening at the onset of 
reperfusion (Cohen, Yang and Downey 2008, Crompton 1999, Halestrap 2009, 
Halestrap and Pasdois 2009, Hausenloy, Boston-Griffiths and Yellon 2011, Hausenloy et 
al. 2002). In this work, 2 x 10-7 M CsA was used as this concentration has previously 
been shown to potently protect against oxidative stress induced myocardial damage 
due to its ability to associate with CypD and, therefore, restricts mPTP opening. 
Although in the model used in this work opening of the mPTP was not directly 
measured, the model used allowed depolarisation and hypercontracture to be 
measured which are indicative of mPTP opening and myocte rigor due to loss of ATP, 
respectively (Yellon and Hausenloy 2007). Within this work, it has been demonstrated 
that ipratropium significantly reduced the time to depolarisation, therefore indicating 
that ipratropium treatment renders myocytes less resilient to oxidative stress and, at 
least in part, that ipratropium exerts its detrimental effects on the myocardium due to 
an action on the mPTP. CsA was shown to provide significant protection against the 
ipratropium induced injury thereby further supporting that ipratropium induced 





7.1.3 Signalling proteins 
 
Within this work it was ascertained that in the model of I/R used, ipratropium 
administration during reperfusion significantly increased levels of p-Akt and pErk1/2. 
Co-administration of ACh with ipratropium statistically abrogated the observed 
increase in p-Akt observed with ipratropium alone, however did not significantly 
abrogate p-Erk1/2 levels at all time points. Interestingly, CsA administration caused 
significant reductions in p-Akt and p-Erk1/2 levels in comparison with the untreated 
controls and was unable to significantly abrogate the ipratropium induced increases in 
p-Akt and p-Erk1/2. It is generally considered that increases in Akt and Erk1/2 activity 
are protective cellular mechanisms against various cellular insults, including I/R injury 
(Miyamoto, Murphy and Brown 2009). However, constitutive over activation of Akt has 
been shown as detrimental in various animal models including rat, (Nagoshi et al. 
2005, O'Neill and Abel 2005) and also, previous studies have shown doxorubicin 
induced elevation of p-Akt and p-Erk1/2 in conjunction with cardiovascular injury 
(Gharanei et al. 2013). This was attributed to an intrinsic survival mechanism whereby 
myocytes up-regulate these proteins in order to counteract the toxic effects of 
doxorubicin. There is evidence that, in part, doxorubicin has anti-muscarinic properties 
(Sasaki et al. 2010). As such, it is postulated here that the increases in Akt and Erk1/2 
activation following ipratropium treatment may be attributed to a similar mechanism 
as that of doxorubicin.  
However, although the study which used wortmannin in conjunction with ipratropium 
showed entire ablation of p-Akt levels, this was not associated with a decrease in 
infarct size as observed with ipratropium treatment alone. This implies that although 
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there is a cellular mechanism which increases Akt phosphorylation following 
ipratropium administration, this is not a determining factor for an increase in 
ipratropium induced injury and may simply be a consequence of ipratropium 
administration but not a requisite for injury. In order to further elucidate this, UO126 
should be used in conjunction with ipratropium to ascertain whether inhibiting Erk1/2 
activation influences the levels of injury observed as Erk1/2 is able to be activated due 
to cross-talk following activation of Akt in the signalling cascade.  
There is a wealth of evidence which suggests that, despite the well reported role of Akt 
as a protective kinase (Sussman et al. 2011), paradoxically, chronic Akt activation has 
been shown to fail to reduce infarction following I/R and has been demonstrated to 
actually increase infarct size in an isolated heart model of I/R in the mouse (Nagoshi et 
al. 2005, O’Neill and Abel 2005). Exacerbated levels of Akt phosphorylation have also 
been identified in patients with heart failure (Nagoshi et al. 2005).Interestingly, in this 
context, although PI3K inhibition is generally shown to abolish the protective effects of 
Akt, it also appears that inhibition of PI3K is capable of further exacerbating myocardial 
injury due to chronic Akt activation (Nagoshi et al. 2005). These data imply that PI3K is 
necessary for the regulation and promotion of cadioprotection due to Akt signalling 
and, therefore that protective or detrimental cellular mechanism may be dependent 
on PI3K rather than the levels of phosphorylated Akt (Sussman et al. 2010). This 
indirectly supports the current study where it appeared from the wortmannin studies 
that Akt activation is not a requisite for ipratropium induced myocardial injury. In 
order to more fully clarify these mechanisms, studies designed to specifically look at 
PI3K would be necessary. 
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Despite the above postulation, there has been previous work which promotes the 
notion that drug induced cardiotoxicity is associated with increases in Akt (Deres et al. 
2005, Merten et al. 2006, Ichihara et al. 2007, Liu et al., 2008a, Gharanei et al., 2013). 
In particular, these studies have been in the context of doxorubicin associated 
myocardial injury, which have shown Akt phosphorylation to be up-regulated by up to 
250% in comparison with control groups (Merten et al. 2006).  As well as abrogation of 
Akt activation due to pre- or co-administration of a cardioprotective agent, such as 
CsA, with doxorubicin being associated with reduction in infarct size and 
improvements in haemodynamic function (Deres et al. 2005, Gharanei et al. 2014).  
The promotion of ROS due to doxorubicin administration is postulated as promoting 
the activation of Akt and, in the context of this study it is proposed that the 
mechanistic similarities of ipratropium and doxorubicin, due to shared anti-muscarinic 
actions (Sasaki et al. 2010) are of relevance and that ipratropium may also be inducing 
Akt through a similar mechanism to that of doxorubicin. However, it has also been 
proposed that it is not the anticholinergic properties of doxorubicin which are 
responsible for ROS generation (Sasaki et al. 2010). In addition, there is a 
contemporary notion which suggests that muscarinic antagonists hold potential as 
anti-cancer therapies. Although the mechanisms remain unknown and are difficult to 
unravel due to the diverse phenotypes and genotypes of tumour cells, it is suggested 
that Akt and MAPK signalling as well as increases in ROS (as associated with I/R and 
doxorubicin induced myocardial injury) may play a role in the observed anti-cancer 
effect (Russo et al. 2014). Therefore it is currently difficult to ascertain whether there 
is a shared mechanism between ipratropium and doxorubicin induced cardio-toxicity. 
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It is also important to note that, following I/R, increases in Akt phosphorylation, 
despite being associated with increases in myocardial damage following doxorubicin 
treatment (Gharenai et al. 2014), may actually represent an endogenous protective 
mechanism to counteract against doxorubicin induced apoptosis (Taniyama and Walsh 
2002, Ichihara et al. 2007).  However this remains a matter of great debate as 
promotion of Akt activation has also been shown to protect against myocardial injury 
both in this context and, also, due to exogenous administration of Ach which has been 
shown to promote survival and salvage of myocardial tissue by Akt and Erk 1/2 
activation (Taniyama and Walsh 2002, Wiklund et al. 2012). Erk1/2 may be a 
downstream kinase of Akt which is frequently associated with cardio-protection due to 
it’s role in RISK signalling and, in the context of muscarinic signaling, has shown to elicit 
cardio-protective mechanisms (Hausenloy and Yellon 2004). It is proposed here that 
the observed increases of Erk1/2 following ipratropium administration are due to 
increases in Akt which, therefore lead to subsequent elevation of downstream Erk1/2 
phosphorylation.  
    
In this study, with the exception of a decrease following ipratropium administration at 
the 15 minute reperfusion time point, there were no observed differences in levels of 
JNK activation following ipratropium administration in the three month rats. Although 
JNK is not a direct downstream messenger of muscarinic signalling, it has a well 
defined role in the initiation of apoptosis as necrosis following I/R injury (Xu et al. 
2014). It therefore appears as though downstream transcription of pro-apoptotic 





7.1.4 Differences in aged hearts 
 
Within the aged studies (Chapter 6), it was identified that ipratropium induced 
significant increases in myocardial injury in the 12 and 18 month age groups in 
comparison with the 3 month old studies (Chapters 3, 4 and 5). However, it is also 
necessary to note that the control levels of injury due to I/R or oxidative stress alone, 
were also more severe. This implies that the aged myocardium is less resilient to 
injury, which supports previous work which shows protection from pre-conditioning 
and survival-signalling kinase pathways are lost following aging, leading to increased 
susceptibility to myocardial injury (van den Munckhof et al., 2013, Peart et al. 2014, 
Poulose and Raju, 2014). From a signalling perspective, it was also observed that there 
were significant increases in p-Akt and p-Erk1/2 following ipratropium administration 
in comparison with the respective untreated control of the same age group. However, 
it was observed that there was an age-related decrease in overall activation of these 
proteins which correlated with increasing age of the animals used. This supports 
previous work that shows that both Akt and Erk1/2 are activated at lower levels in the 
aged myocardium (Li et al. 2013, Peart et al. 2014) but, also, as the injury was more 
severe in these age groups in comparison with the 3 month studies, further supports 
that differences in Akt and Erk1/2 activation following ipratropium administration is an 
interesting consequence but not a necessary event for ipratropium induced injury to 
occur. Further to this, it has been demonstrated that GPCRs are under expressed and 
that downstream signalling is limited and less effective in the senescent myocardium 
(Willems et al. 2005). It is therefore likely that there is limitation on the protective 
mechanisms available following I/R injury and, in particular, an inability for the 
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myocardium to further salvage tissue following the extra insult of a cardio-toxic agent, 
such as ipratropium. 
From the context of the experiments carried out using the model of oxidative stress, 
both of the aged groups (12 and 18 months) showed significant decreases in the time 
for depolarisation to occur in comparison with the 3 month groups. There was also no 
significant attenuation of injury (as observed in the three month groups) following 
administration of CsA or ACh. It is postulated here that this is due to age related 
differences in the ischaemic tolerance of the myocardium (Liu et al. 2002). There is 
increasing evidence to promote the “free radical theory of aging” (Boengler et al. 
2009). This pertains to the mitochondria where, during aging, mitochondria are 
exposed to higher levels of ROS and, therefore enhanced oxidative stress, even under 
healthy conditions (Fernandez-Sanz et al 2015). Following I/R, these levels of oxidative 
stress are further enhanced and, as mitochondria in senescent cells are already 
swollen due to increased basal levels of ROS, this renders mitochondria less resilient to 
further oxidative stress, which is supported in this study as a significant reduction in 
time to depolarisation in the aged (12 and 18 month) studies, in comparison with the 3 
month studies. 
The inability of CsA or ACh to protect against a reduction in the time to depolarisation 
following sustained oxidative stress was expected as previous studies have also 
observed that there are age related differences in how CsA protects (Liu et al. 2011b). 
As ACh has been linked to the RISK pathway and mPTP, it is therefore likely that the 
inability for CsA to protect is due to a mechanism which links protective muscarinic 
signalling mechanisms to the mPTP and, from this respect, provides further evidence 
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that the pathways for CsA and ACh mediated cardio-protection are linked. However, in 
order to fully elucidate the events observed in the oxidative stress model, a potent 
uncoupler of oxidative stress, such as FCCP, would need to be employed as the present 
results cannot provide information as to whether ipratropium exacerbates 
depolarisation in this model or if, due to senescence, the myocytes are less resilient to 
oxidative stress and therefore there is no pharmacological intervention which can 
either protect against injury or exacerbate the observed injury. 
In contrast to the work conducted in three month rats, in the aged rats, there was a 
significant increase in p-JNK levels following I/R as well as the groups where 
ipratropium was administered. JNK is a stress-induced kinase and is known to be 
endogenously activated at higher levels in senescent cells in comparison with 
comparative cells from younger age groups, irrespective of disease state (Shang et al. 
2010). It is therefore postulated here that underlying, age related, increases in JNK 
activation may be partially responsible for the increase in I/R injury observed in the 
aged groups, however as there were no discernible differences in JNK activation 
following ipratropium administration (with the exception of the 15 minute reperfusion 
group in 3 month rats), it appears as though JNK does not play a role in ipratropium 
induced injury in the myocardium of either young (3 month) or aged (12 and 18 
month) rat hearts following regional ischaemia and reperfusion.  
It is also important to note that the pharmacokinetics of ipratropium have not been 
studied in elderly patients, despite this being the age group to which they are most 
commonly prescribed. Therefore, the aged study in this work is of particular 
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importance as, to our knowledge, it is the only study to have addressed the 
cardiovascular safety of ipratropium in a model of aging. 
 
7.2 Study Limitations and future work 
 
The aim of this study was to identify whether there was a basis for the clinical 
observations that pharmacological use of ipratropium promotes the occurrence and 
severity of adverse cardiovascular outcomes in patients with COPD. From a 
physiological perspective, this study has been successful as it has been identified that 
ipratropium is capable of exacerbating myocardial injury following simulated I/R and, 
in particular, that this effect appears to be restricted to reperfusion. This indicates that 
the presence of ipratropium during reperfusion interferes with signalling cascades and 
cellular events which occur during reperfusion (for example opening of the mPTP and 
proteins involved in the RISK pathway). However, within the scope of this study it has 
not been possible to fully elucidate the exact mechanism by which ipratropium exerts 
the observed cardio-toxic effects. 
The primary limitation of this study is that as ipratropium is a non-selective antagonist, 
it has not been possible to identify whether there is an action on a specific subtype of 
muscarinic receptor. It has been shown that the myocardium contains M1, M2 and M3 
subtypes (Abrams et al. 2006). The use of specific muscarinic antagonists such as 
Telenzepine dihydrochloride (M1), AF-DX 116 (M2) and DAU 5884 hydrochloride (M3) 
could assist in ascertaining whether there is a specific nature to the ipratropium 
induced injury. Although in previous work it has been speculated that it is likely due to 
the action on M3 receptors as M3 receptors appear responsible for the anti-apoptotic 
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properties of muscarinic activation (Pan et al. 2012, Wang et al. 2012, Hang et al. 
2013), preliminary studies using the selective M1 and M3 antagonist, tiotropium 
bromide, did not indicate an exacerbation of injury (data not shown in this thesis). 
Although, this is in contrast to previously published clinical data which implies that 
tiotropium elicits higher levels of myocardial damage than ipratropium. However, the 
available data from the present in vitro study implies that it may be limitation of 
protective downstream signalling from the M2 receptors which is responsible for the 
observed ipratropium induced injury. However, this remains unanswered and so 
further studies to classify which receptors are involved should be carried out. 
Despite the ability of ACh to attenuate the ipratropium induced myocardial injury, 
there is insufficient evidence in this work to claim that the action of ipratropium is 
definitively due to a specific action at muscarinic receptors. In order to address this 
issue, further work with the use of acetylcholinesterase (AChE) would need to be 
carried out. As through this study endogenous levels of ACh were identified, it is 
currently postulated that ipratropium (as a competitive antagonist for acetylcholine at 
muscarinic receptors) essentially out-competes the endogenous ACh and, as such 
limits the downstream muscarinic signalling, thereby causing injury. The use of AChE 
would remove any ACh present and therefore, if administered in conjunction with 
ipratropium, it would be possible to ascertain whether ipratropium was still able to 
elicit injury. If this were the case, it would imply that ipratropium induced myocardial 




In order to more fully identify the cellular events which occur, it would also be useful 
to carry out studies where connexin-43 (Cx-43) as well as the NCX are explored in the 
context of I/R and ipratropium administration. This is because it has been shown that 
ischaemia impairs the association of Cx-43 and muscarinic receptors which limits 
protective signalling and causes a cascade of injury due to contraction band necrosis 
(CBN) (Shintani-Ishida, Unuma and Yoshida 2009). Acetylcholine has shown a role in 
preserving these interactions (Yue et al. 2006) and, therefore, it may be that 
ipratropium limits this and promotes CBN. This would support the current study as 
myocyte loss due to ipratropium administration was identified as a consequence of 
both apoptosis and necrosis. Identification of involvement of the NCX would also help 
to clarify as within the cardiovascular system, it has been shown the M3 activation by 
ACh decreases expression of the NCX-1 antiporter, which assists in the reduction of 
Ca2+ overload during reperfusion (Wang et al. 2012). As Ca2+ overload is a determining 
event in the opening of the mPTP, it is therefore possible that interaction of 
ipratropium at the M3 receptors may conversely limit this reduction in cytosolic Ca
2+ 
due to prevention of downstream down-regulation of NCX-1. This could potentially 
provide novel information which may help identify the role of the mPTP in ipratropium 
induced myocardial injury. 
The final limitation of this study is that although clinically relevant models were used 
throughout, it was not possible to use an in vivo model and, in particular an in vivo 
model of COPD. Systemically, the interactions of ipratropium with other organs also 
need to be explored and, in particular, patients with any form of renal complications 
are excluded from clinical trials prior to drug release onto the market. Elderly patients 
320 
 
are also excluded, which, given the average age for a COPD diagnosis is 67 years (Goff 
et al. 2007) and that cellular signalling in the senescent myocardium is altered from 
that of young patients, implies that the effect of ipratropium induced myocardial injury 
has not been fully identified in the primary age groups to which this drug is prescribed. 
 
7.3 Overall Conclusions 
 
To conclude, the data presented here have identified for the first time that 
ipratropium is capable of eliciting myocardial injury following regional ischaemia and 
reperfusion. It is postulated here that it is the effect of ipratropium on signalling 
mechanisms which occur during reperfusion which are responsible for the observed 
injury. The observation that ACh is able to partially abrogate ipratropium induced 
injury implies that the effect is due to disruption in downstream, protective, 
cholinergic pathways which have been previously shown to protect the myocardium 
following an ischaemic insult (Resende 2007). In addition to this, CsA was also able to 
prevent some of the ipratropium induced injury which indicates that, at least in part, 
ipratropium induced myocyte loss is due to necrosis and apoptosis through a 
mechanism which involved the mPTP. The involvement of the pro-survival kinases Akt 
and Erk1/2 needs to be further characterised, however in this study, the increases 
observed following ipratropium treatment are attributed to an endogenous survival 
mechanism, activated to oppose the ipratropium induced injury, however, especially in 
the case of Akt, this may serve to exacerbate injury as constitutive over-action of Akt is 
detrimental to cellular survival. Despite these observations, the use of wortmannin 
entirely blocked the activation of Akt following ipratropium administration; however 
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this did not abrogate the observed increase in infarct development. Therefore it is 
postulated that although Akt, and subsequent downstream Erk1/2, activation may be a 
consequence of ipratropium administration, these proteins alone are not sufficient for 
injury to occur and ipratropium induced myocardial injury is not dependent on this 
signalling cascade. Interestingly, there were few observed differences in JNK 
phosphorylation in the 3 month rats, however there were significant increases in all 
groups in the aged studies. This is attributed to age-related differences in stress 
induced proteins (such as JNK) which may contribute to an increase in myocardial 
injury following ischaemia/reperfusion, even in the absence of ipratropium. The aged 
study provided further, novel information, which indicates that, in the elderly 
population, exacerbation of myocardial injury due to ipratropium is more severe. From 
a clinical perspective, it is necessary for practitioners to prescribe ipratropium, and 
other anti-cholinergic agents, with caution in patients who suffer from IHD or may be 
at risk of cardiovascular complications, especially given that in pre-clinical trials the 
elderly population are excluded. 
According to Boehringer-Ingelheim, the manufacturer of ipratropium nasal spray 
(marketed as Atrovent®), the systemic bioavailability of ipratropium following oral 
administration is limited as ipratropium is unable to readily absorb across mucosal 
membranes. As such, following administration it would be postulated that 
concentrations of ipratropium in the blood would be zero, however this is not the case 
and plasma values which range between 5 x 10-8 – 1 x 10-7 M have been reported 
following a single, inhaled dose of Atrovent® (Singh et al. 2008). It is likely that this is 
due to around 90% of inhaled drugs being swallowed due to improper inhaler use. To 
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compound this issue, inhalers are also one of the most frequently abused medications 
with patients frequently deviating from their dose and administering the medication 
more often than advised. It is therefore likely that our observations from this work are 
clinically relevant with respect to both the concentrations used and the exacerbation 
of injury observed. 
In the future, it is of paramount importance that the effect of muscarinic antagonists 
are fully characterised in disease models, particularly those of MI and COPD, as well as 
in healthy individuals prior to their release onto the market. In particular, clinically 
relevant models of elderly patients should be fully explored as differences in cellular 
signalling in senescent cells appear to play a major role in the ipratropium mediated 
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